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Abstract 
Hao Wei, Mechanisms of microparticle release from human platelets 
 
Platelets release a variety of extracellular vesicles, including platelet-derived microparticles 
that expose phosphatidylserine on their surface. This thesis aims to resolve the mechanisms 
by which pro-thrombotic microparticles are released from platelets, which have not been 
well-characterised. Experimental methods used include flow cytometry, Western blotting, 
fluorescence-based microplate assays, confocal microscopy and electron microscopy. 
 
Intact cholesterol-rich lipid rafts were found to be required for the calpain-dependent 
release of microparticles from activated platelets. Microparticle release was prevented 
when cholesterol was depleted or sequestered from the platelet membrane. Membrane 
blebbing and scission in this process were independent of influx of hydrophilic ions or the 
endosomal sorting complex required for transport. 
 
It was found that microparticles were also released from platelets undergoing apoptosis, 
which would progress to secondary necrosis in vitro as they were not cleared. Microparticle 
release in apoptotic platelets was dependent on Ca2+ entry, intracellular Ca2+ mobilisation 
and caspase activity, but it was largely independent of calpain. During apoptosis, caspases 
downregulated microparticle release from platelets in response to pro-coagulant stimuli. 
This may limit the pro-thrombotic consequences by providing a period of reduced capacity 
for platelet activation.  
 
2-Aminoethoxydiphenyl borate (2-APB), a non-specific modulator of ion channels, was found 
to inhibit microparticle release from both activated and apoptotic platelets. In activated 
platelets, the effect of 2-APB was not related to inhibition of plasma membrane ion channels 
or calpain activity. In apoptotic platelets, the effect of 2-APB might be associated with 
inhibition of Ca2+ entry, although the specific target remained unclear. Future studies in 
identifying the target of 2-APB might provide new insights into how microparticles are 
released from platelets. Moreover, 2-APB may provide a scaffold for developing a 
pharmacological inhibitor of microparticle release. 
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Chapter 1 Introduction 
1.1. Platelets 
Platelets are small anucleate cells in the mammalian blood circulation. In a healthy adult 
human, there are between 150 to 400 million platelets per millilitre of blood, generated from 
megakaryocytes in the bone marrow. The exact mechanism of how platelets are produced 
from megakaryocytes is still unclear. An early in vitro study showed that platelets were 
initially assembled and formed at one end of the megakaryocytes, before the whole cell was 
disintegrated to generate numerous proplatelets (Italiano et al., 1999). However, more 
recent studies showed that megakaryocytes extend long protrusions, mediated by dynein, 
into sinusoidal blood vessels in the bone marrow. Pro-platelets are then released from these 
protrusions under shear stress (Junt et al., 2007; Bender et al., 2015). Whatever the 
mechanism might be in vivo, a mature inactivated platelet in the blood has a biconvex 
discoid structure, with a diameter between 1 to 3μm (Paulus, 1975). Usually a platelet has a 
lifespan of around 10 days. Aged platelets are cleared by phagocytosis by macrophages in 
the spleen or Kupffer cells in the liver (Quach et al., 2018). 
 
1.1.1. Platelets in haemostasis 
Platelets are key players in haemostasis. By stopping bleeding at injury sites on the 
endothelium, platelets help to prevent outflow of blood and influx of bacteria into the blood 
at the same time. During the haemostatic event, platelets undergo three major processes: 
adhesion to a blood vessel, secretion of pro-coagulatory factors and aggregation to block the 
injury site. 
 
1.1.1.1. Adhesion of platelets to blood vessels 
Damage to blood vessels exposes the sub-endothelial matrix, which is made up mostly of 
collagen, to blood components. Derived from endothelial cells, megakaryocytes or platelets, 
von Willebrand factors (vWFs) in the blood circulation can anchor onto the collagen matrix. 
Platelets can be tethered to immobilised vWFs via the vWF receptor glycoprotein Ib (GPIb) 
on the platelet membrane. In this way, platelets from flowing blood are effectively linked to 
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the exposed collagen (Yun et al., 2016). This does not require platelet activation. However, 
upon binding to vWF, GPIb triggers a weak signalling pathway that leads to activation of 
integrins and secretion of platelet granules. In addition, the vWF-GPIb interaction slows the 
platelet, allowing other receptors to interact with collagen. A key receptor is membrane 
glycoprotein VI (GPVI), which binds collagen directly without vWF (Sarratt et al., 2005). Upon 
binding to collagen, GPVI triggers a strong signalling pathway that activates integrins αIIbβ3 
(major) and α2β1 (minor), which bind to vWF and collagen respectively. Platelets lacking GPVI 
cannot activate integrins during adhesion to collagen and consequently fail to stably adhere 
to soluble collagen (Nieswandt et al., 2001). Outside-in signalling from activated integrins 
further promotes platelet adhesion, leading to stable arrest of the platelet on the exposed 
collagen matrix. 
 
The importance of platelet adhesion in haemostasis is shown by defects in platelet adhesion 
that lead to bleeding disorders. For example, deficiency or dysfunction of the GPIb complex 
causes the rare Bernard-Soulier syndrome (Berndt and Andrews, 2011). Defective or missing 
vWFs cause von Willebrand disease (Lillicrap, 2013). 
 
1.1.1.2. Platelet activation and secretion of pro-coagulatory factors 
When platelets are bound to the sub-endothelial matrix, primary interactions between 
surface receptors and their ligands lead to platelet activation. The platelets rapidly shoot out 
long processes called filopodia. The activation signals, along with shear stress, lead to release 
of α-granules and dense granules from platelets via the soluble N-ethylmaleimide sensitive 
factor attachment protein receptor (SNARE)-mediated exocytosis machinery (Berndt et al., 
2014; Golebiewska et al., 2015). The α-granules contain over 300 proteins and peptides, 
many of which are essential to platelet function. These include vWF, multimerin, integrin 
αIIbβ3 and P-selectin (Whiteheart, 2011). P-selectin helps to recruit neutrophils by binding to 
its receptor P-selectin glycoprotein ligand 1 (PSGL1) on the surface of neutrophils (Diacovo et 
al., 1996). Dense granules contain many physiological activators of platelets including ADP, 
ATP and Ca2+ (Rao, 2013). Dense granules also contain serotonin (5-HT) that leads to 
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constriction of vessels, which helps to slow down the flow of blood towards the injury site 
(Watts et al., 2012). In addition to these pre-packaged factors, activated platelets produce 
thromboxane A2 (TXA2) from arachidonic acid through the actions of cyclooxygenase 1 (COX1) 
and thromboxane synthase (Warner et al., 2011). 
 
Secreted platelet activators bind to GPCRs on platelet membranes. ADP binds purinergic 
P2Y12 (Gi) and P2Y1 (Gq), while TXA2 binds to TPα (Gq). In addition, thrombin, the final 
common protease of the coagulation cascade, activates protease-activator receptors PAR1 
(Gq) and PAR4 (Gq) by proteolytic cleavage of their N-terminal domains. The Gq-linked 
pathway leads to activation of phospholipase C (PLC), which converts PIP2 to diacylglycerol 
(DAG) and inositol triphosphate (IP3). IP3 acts as a second messenger that triggers Ca2+ 
release from the endoplasmic reticulum, which in turn activates CalDAG-GEF1 that promotes 
GDP-GTP exchange from Rap1b-GDP to Rap1b-GTP (Cifuni et al., 2008). The Gi-linked 
pathway downstream of P2Y12 inhibits RASA3, which is a GTPase-activating protein that 
converts Rap1b-GTP to Rap1b-GDP (Stefanini et al., 2015). Therefore, Gq- and Gi-linked 
pathways downstream of surface GPCRs converge at Rap1b-GTP, which in turn leads to 
activation of talin. Talin, via its headgroup, binds to and activates integrin αIIbβ3 by triggering 
a conformational change (Petrich, 2009). This is sometimes called “inside-out signalling”.  
 
1.1.1.3. Platelet aggregation and blood coagulation 
Activated integrin αIIbβ3 binds fibrinogen with high affinity. Since each fibrinogen molecule 
can bind to two activated integrin αIIbβ3 molecules, it can cross-link two activated platelets. 
Integrin αIIbβ3 activation therefore underlies platelet aggregation. In general, these secretion 
events amplify the activation process and the inside-out signalling events associated with 
integrin αIIbβ3, recruiting more platelets for aggregation (Bennett, 2005). In this way, a 
non-stable primary haemostatic plug is formed that blocks the injury site. Integrin αIIbβ3 can 
also deliver outside-in signals that enhance platelet activation, granule secretion and 
cytoskeletal rearrangement, which further facilitate the primary haemostatic plug and 
thrombus formation (Durrant et al., 2017). 
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In addition to their central roles in forming the primary plug, platelets also contribute to the 
coagulation pathway. Coagulation is initially triggered by the exposure of tissue factor (TF), 
normally in the vessel wall but revealed to plasma coagulation factors by vessel injury. TF 
activates factor VII that, together with activated factor V, forms the extrinsic tenase complex. 
This requires a negatively-charged phospholipid surface both to accelerate the formation of 
activated factor X, and also to protect activated factor X from tissue factor pathway inhibitor 
(TFPI). The negatively-charged phospholipid surface is provided by a subpopulation of 
activated platelets that expose phosphatidylserine (PS) on their outer surface. By providing a 
negatively-charged surface to which γ-carboxyglutamic acid (GLA) domain-containing 
coagulation factors bind, PS markedly potentiates production of thrombin at the site of 
vascular injury (Hoffman and Monroe, 2001). Thrombin is a serine protease that cleaves 
plasma fibrinogen to form fibrin, which is cross-linked into a mesh (Swieringa et al., 2018). In 
this way, platelets facilitate generation of the cross-linked fibrin clot, which seals the injury 
site until tissues are repaired. In summary, platelets have essential functions in all three 
major steps of haemostasis: vasoconstriction, primary haemostasis (temporary blockage by 
the platelet plug) and blood coagulation (formation of the fibrin clot). 
 
1.1.2. Platelets in thrombosis and vessel occlusion  
Haemostasis maintains vascular integrity and blood flow, but pathological factors can disrupt 
its regulation, which can lead to uncontrolled clot formation, thrombosis and vessel 
occlusion in either arteries or veins. Arterial thrombosis in coronary arteries is the major 
trigger of acute coronary syndrome, which includes myocardial infarction and unstable 
angina pectoris, while venous thrombosis might lead to thromboembolism or pulmonary 
embolism. Activated platelets have essential roles in these thrombotic events (McFadyen et 
al., 2018)  
 
The vascular endothelium continuously prevents platelet activation by releasing inhibitory 
factors. These include endonucleotidases that degrade ADP, thrombomodulin that 
inactivates thrombin, and prostacyclin that suppresses most known platelet activation 
5 
 
processes (Versteeg et al., 2013). This endothelium-mediated suppression is impaired not 
only at sites of vascular injury, but also at eroded or ruptured atherosclerotic plaques 
(Jackson, 2011). Many atherosclerotic plaques are rich in TF, so plaque rupture triggers the 
coagulation cascade. In addition, collagen is present in atherosclerotic plaques (Shekhonin et 
al., 1985), so platelets can be activated and aggregate at the plaques in the same way as they 
do at vascular injury sites. Activated platelets release secondary mediators (e.g. ADP, 5-HT, 
TXA2) that recruit circulating platelets to the growing thrombus, which in turn leads to 
activation of more platelets and ultimately formation of a three-dimensional fibrin clot that 
occludes the arteries (van der Meijden and Heemskerk, 2018). 
 
Compared to arterial thrombosis that occurs under high shear stress around ruptured 
plaques, venous thrombosis occurs under low shear flow and mostly around intact 
endothelial walls. The exact trigger for venous thrombosis is still under debate, but it usually 
initiates with inflammation and activation of the endothelium. Activated endothelium 
expresses adhesion molecules on the surface (e.g. selectin) to capture platelets and 
leukocytes. Attached leukocytes and platelets become activated and in turn initiate the 
coagulation process, which leads to fibrin deposition and clot formation (Mackman, 2012). 
Unlike the arterial “white clot” that is composed mainly of fibrin and platelets, the venous 
“red clot” encapsulates tightly packed erythrocytes at its core that are resistant to fibrinolysis 
under low shear flow, with activated platelets attached to fibrin at the periphery (Cines et al., 
2014). Since platelet adhesion is not mediated by collagen, venous thrombi are not tightly 
anchored to the endothelium. They can easily dislodge to cause embolism and hence distant 
vessel occlusive diseases (Koupenova et al., 2017). 
 
1.1.3. Pharmacology of anti-platelet drugs 
Anti-platelet drugs are the cornerstone therapy for patients with acute coronary syndromes 
or stable coronary arterial diseases, and for those undergoing revascularisation procedures 
such as percutaneous coronary intervention (PCI) (Yousuf and Bhatt, 2011). This is because 
platelets are essential to forming a thrombus under the high shear conditions of a ruptured 
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atherosclerotic plaque and localising coagulation to this injury site. Currently four main 
classes of anti-platelet drugs are used either alone or in combination for clinical purposes. 
These include COX1 inhibitors (aspirin), P2Y12 inhibitors (cangrelor, clopidogrel, prasugrel and 
ticagrelor), PAR1 antagonists (vorapaxar) and integrin αIIbβ3 inhibitors (abciximab, 
eptifibatide and tirofiban) (Figure 1.1). These drugs have proven successful in reducing 
morbidity and mortality associated with arterial thrombosis. However, inhibition of platelet 
function is inherently linked to bleeding risks, which lead to adverse cardiovascular outcomes 
and sometimes mortality. 
 
1.1.3.1. Aspirin 
Aspirin, the oldest anti-platelet drug, irreversibly inactivates the COX1 enzyme. COX1 
mediates production of prostaglandin H2 (PGH2) from arachidonic acid, which is released 
from membrane phospholipids by phospholipase A2 (PLA2) upon activation of platelets. PGH2 
is transformed by TXA2 synthase into TXA2, which is an agonist for the TPα receptor. Patients 
with a rare loss-of-function mutation in the TBXA2R gene, which encodes the TPα receptor, 
experience mild bleeding symptoms (Mundell and Mumford, 2018). By blocking TXA2 
production, aspirin inhibits TPα-mediated platelet activation and aggregation. Aspirin’s 
bleeding risk is correlated with both its anti-platelet effect and its inhibition of prostaglandin 
production that has protective effects on the gastrointestinal tract (Warner et al., 2011). 
 
1.1.3.2. P2Y12 antagonists 
The purinergic P2Y12 receptor mediates sustained activation of integrin αIIbβ3 in response to 
ADP stimulation. While ADP is a natural agonist for P2Y12, ATP and many triphosphate 
analogues are natural antagonists of this receptor (Storey, 2001). Given the central roles of 
P2Y12 in ADP-dependent secretion, platelet aggregation and procoagulant activities, 
inhibition of P2Y12 carries major bleeding risks. Prolonged tail bleeding time was recorded in 
both P2Y12-knockout mice and wild-type mice treated with high doses of P2Y12 inhibitors 
(Andre et al., 2003; Liu et al., 2012). P2Y12 gene mutations have been linked to bleeding in 
human subjects (Scavone et al., 2017). For example, a patient with rare congenital P2Y12 
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deficiency caused by a point mutation in the translation initiation codon showed impaired 
platelet aggregation in response to ADP, and he had experienced mild bleeding tendency 
since childhood (Shiraga et al., 2005). 
 
Thienopyridine pro-drugs irreversibly inhibit P2Y12. Clopidogrel’s active metabolite partitions 
P2Y12 oligomers out of lipid rafts (Savi et al., 2006), which may contribute to its actions. Its 
efficacy for secondary prevention was confirmed in the PCI-CURE trial. Results from 
PCI-CURE showed that post-PCI patients using aspirin should be given clopidogrel at the 
same time (Mehta et al., 2001), which laid the foundation for today’s dual anti-platelet 
therapy (DAPT) – aspirin plus clopidogrel (Mauri et al., 2014). Metabolism of clopidogrel is 
highly variable, with common polymorphisms in CYP2C19 reducing the formation of its 
active metabolite (Holmes et al., 2011). Unlike clopidogrel, the first step of prasugrel 
metabolism is by esterases, so it has a faster onset of action and is not affected by 
polymorphisms in CYP2C19 (Ancrenaz et al., 2010). In the TRITON-TIMI 38 trial, prasugrel 
showed significant superiority over clopidogrel for post-PCI patients in reducing 
cardiovascular events but increased bleeding (Wiviott et al., 2007). However, this may reflect 
consistency of effect of prasugrel over clopidogrel rather than greater efficacy. 
 
P2Y12 can also be reversibly inhibited by nucleotide derivatives. Ticagrelor is an ADP 
derivative and cangrelor is an ATP analogue. In the PLATO trial, ticagrelor was better than 
clopidogrel at preventing infarction and cardiovascular death without increasing bleeding 
risks (Wallentin et al., 2009). In the CHAMPION-PHOENIX trial, cangrelor used with 
subsequent DAPT showed clear benefits for preventing death in post-PCI patients (Bhatt et 
al., 2013). In addition, cangrelor, delivered by intravenous infusion, does not require 
metabolism and it has a very rapid onset of action about 5 to 10 minutes (Ferreiro et al., 
2009). Therefore, cangrelor is more suitable for acute clinical situations and P2Y12 inhibition 
in in vitro experimental settings. 
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1.1.3.3. Vorapaxar and PAR inhibition 
There are two thrombin receptors on the platelet surface, the high affinity PAR1 and the low 
affinity PAR4 (Covic et al., 2000). Vorapaxar is an oral PAR1-selective antagonist. Based on 
results from TRACER and TRA-2P TIMI-50 trials, vorapaxar showed clear benefits in reducing 
ischaemic events when used together with DAPT, but the bleeding risk was so high that 
TRACER was prematurely terminated (Morrow et al., 2012; Tricoci et al., 2012). Vorapaxar 
has now been approved for treating cardiovascular events in patients with a history of 
myocardial infarction, but it is contra-indicated in patients with major bleeding histories. 
Vorapaxar’s high bleeding risk might derive from disrupting protein C-mediated activation of 
PAR1, which is biased towards β-arrestin pathways that prevent endothelial apoptosis 
(Mosnier et al., 2012). 
 
Novel PAR inhibitors are being developed as potential therapies. A new PAR1 antagonist class, 
the parmodulins, are antagonists biased towards Gq-mediated pathways and they do not 
inhibit β-arrestin pathways. Theoretically, they inhibit platelet aggregation without inducing 
endothelial damage (Aisiku et al., 2015). On the other hand, a new PAR4 antagonist 
BMS-986120 has demonstrated substantial anti-thrombotic activities and its bleeding risks 
were lower than vorapaxar in animal models (Wong et al., 2017). Clinical efficacy of 
parmodulins or BMS-986120 still awaits thorough investigations. 
 
1.1.3.4. Integrin αIIbβ3 inhibitors and others 
Currently three integrin αIIbβ3 inhibitors are in clinical use: a monoclonal antibody abciximab, 
a cyclic heptapeptide eptifibatide, and a non-peptide small molecule tirofiban. They are all 
ligand mimetic molecules that prevent fibrinogen from binding to activated platelets. Due to 
their high propensity to cause bleeding, integrin inhibitors are limited to patients with high 
thrombotic risks and low bleeding risks (Bosch et al., 2013). Potential novel anti-platelet 
therapies include GPIb or vWF inhibitors (ARC1779, caplacizumab) that disrupt the GPIb-vWF 
axis and a GPVI inhibitor (Revacept) that blocks collagen-mediated activation (Gachet, 2015). 
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Although they are effective in preventing platelet activation, anti-platelet drugs are limited 
by bleeding risks and highly variable efficacy in reducing cardiovascular events. Therefore, 
there is scope for developing new classes of drugs based on further understanding other 
aspects of platelets in thrombosis, e.g. the release of pro-coagulant microparticles from 
activated platelets. 
 
 
 
Figure 1.1: Anti-platelet drugs and their mechanisms of action  
Light grey boxes for the anti- platelet drugs, dark grey boxes for receptors targeted by these 
drugs, red arrows for binding and/or activation, and black arrows for inhibition. 
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1.2. Microparticles  
Extracellular vesicle (EV) is a generic term for cell-derived particles that are delimited by a 
lipid bilayer without a functional nucleus. All cells have the ability to produce EVs in response 
to activation, oxidative stress or tissue hypoxia. According to the International Society for 
Extracellular Vesicles, no consensus has been reached for the nomenclature of EVs that are 
of different sizes, origin or composition (Théry et al., 2018). This thesis adopts the standard 
of classifying EVs into three categories: exosomes, microparticles and apoptotic bodies 
(Turturici et al., 2014). Exosomes are the smallest EVs (30 to 100nm in diameter), while 
microparticles (also known as ectosomes) are bigger in size (100nm to 1μm in diameter). 
Apoptotic bodies are large membrane blebs up to 5μm in diameter that are produced 
exclusively during apoptotic cell disassembly (Poon et al., 2014; Hauser et al., 2017). 
 
1.2.1. Definition of microparticles 
Microparticles are a heterogeneous population of small vesicles ranging from 0.1 to 1μm in 
size that are derived from plasma membrane of cells (Morel et al., 2008). The presence of 
microparticles has been reported in a variety of body fluids, which include peripheral blood, 
urine, saliva, semen, synovial fluid, cerebrospinal fluid and bile (Freyssinet and Toti, 2010). 
Sources of microparticles in the blood circulation include platelets, leukocytes, erythrocytes, 
monocytes, endothelial cells and smooth muscle cells (Flaumenhaft et al., 2009). Initially 
identified as “platelet dust” that are released by activated platelets in human blood (Wolf, 
1967), platelet-derived microparticles (PMPs) represent approximately 70 to 90% of all 
microparticles in the blood. They play essential roles in platelet function and various disease 
conditions (Żmigrodzka et al., 2016). 
 
Microparticles are formed by direct membrane deformation and blebbing during cell 
activation (Morel et al., 2011). They are generally identified by phosphatidylserine (PS) on 
the surface, although it has been suggested that some microparticles are PS-negative 
(Latham et al., 2015). Similar to microparticles, apoptotic bodies are generated by 
membrane blebbing. They can be distinguished based on their larger sizes and components 
that are distinctive of apoptosis such as nuclear fragments (Akers et al., 2013).  
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Exosomes are a specific subtype of relatively homogenous secreted vesicles that are 
composed of spherical fragments of lipid bilayers from inner cell compartments (Vlassov et 
al., 2012). Exosome biogenesis starts with endocytosis. Early endosomes mature into 
multivesicular bodies (MVBs) in the cytoplasm, during which the endosomal membrane 
invaginates to form intraluminal vesicles (Bobrie et al., 2011). MVBs can be directed to 
lysosomes for degradation or transported to the vicinity of plasma membrane for exosome 
release (Urbanelli et al., 2013). Upon fusion of MVBs with the cell surface, exosomes are 
secreted into extracellular fluids in bursts. Several protein-protein interactions have been 
suggested to reduce the energy barriers in this process, among which the SNARE proteins 
facilitate membrane fusion (Hessvik and Llorente, 2018). Tetraspanins have important roles 
in exosome biogenesis, cargo selection, targeting and function. Two subtypes of the 
tetraspanin family, CD63 and CD81, are used as classical markers of exosomes (Andreu and 
Yáñez-Mó, 2014), although CD63 and CD81 have also been detected on the surface of 
microparticles secreted from certain cell lines (Crescitelli et al., 2013). In addition, exosomes 
are generally considered to expose little if any PS (Heijnen et al., 1999), but a recent study 
showed that exosomes might also expose PS (De Paoli et al., 2018).  
 
1.2.2. Composition of microparticles 
Microparticles are composed of spherical phospholipid bilayer structures that enclose 
cytosolic components such as enzymes, cytoskeletal proteins and RNAs from their parent 
cells, yet they lack a nucleus and thus synthetic capacity. Membrane markers are commonly 
used to identify the cell of origin, including CD41 for platelets, CD235 for erythrocytes, CD31 
for endothelial cells, CD45 for leukocytes and CD14 for monocytes (Burnier et al., 2009). In 
particular, PMPs contain more than 40 glycoproteins (GPs) characteristic of platelets, 
including integrin αIIbβ3 (CD41), integrin β1 (CD29) and P-selectin (CD62P). Mostly, these 
proteins act as adhesion molecules that initiate stimulation of recipient cells or EV 
internalisation by these cells (Żmigrodzka et al., 2016).  
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Microparticles may contain RNAs in their luminal space. Microparticles derived from 
endothelial progenitor cells carry coding mRNAs associated with the PI3K/AKT signalling 
pathway, which triggers angiogenesis in endothelial cells (Deregibus et al., 2007). Non-coding 
miRNAs and siRNAs have been reported in microparticles derived from embryonic stem cells, 
at least in vitro (Yuan et al., 2009). By comparison, there is no indication that DNA is present 
in microparticles, while exosomes and apoptotic bodies may contain traces of DNA 
(Kawamura et al., 2017). 
 
Membrane lipids are the least studied components of microparticles. Some studies 
suggested that microparticles show a similar lipid composition as the plasma membrane, 
while others found specific enrichment or depletion of cholesterol, ceramide or 
sphingomyelin, leading to conclusions that microparticles are shed from specific regions of 
the plasma membrane (Pollet et al., 2018). Despite their differences in the cell of origin or 
the pathophysiological context, almost all microparticles expose PS at the outer membrane 
leaflet, which makes PS the standard marker for microparticle identification (Morel et al., 
2011). However, one electron microscopy study showed that a large proportion of blood- 
borne EVs between 30nm to 1μm in diameter did not expose PS (Arraud et al., 2014). 
Whether the majority of these PS-negative EVs are exosomes or microparticles, or should be 
described as a separate category, remains to be resolved. 
 
1.2.3. Functions of microparticles 
Microparticles promote coagulation by providing a catalytic surface for the assembly of 
proteins in the coagulation cascade, which can be attributed to the presence of PS on their 
surface. Clotting proteins bind to PS thanks to the electrostatic interactions between the 
phosphate groups in the phospholipids and the tightly-bound calcium ions in the GLA 
domains in these proteins (Tavoosi et al., 2011). Proteins that contain a GLA domain include 
factors VII, IX and X, and pro-thrombin. For example, surfaces of PMPs exhibit 50-100 times 
higher pro-coagulant activities compared to activated platelets (Sinauridze et al., 2007).  
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Microparticles, especially those derived from monocytes, may harbour active TF. TF has a 
high affinity for coagulation factors VII and VIIa, and the TF-factor VIIa complex activates 
factors IX and X to initiate the extrinsic pathway of blood coagulation (Mackman et al., 2007). 
It was suggested that rapid accumulation of TF-exposing microparticles had important roles 
in thrombus formation (Lechner and Weltermann, 2008). Microparticles positive for both PS 
and TFs that are derived from tumour cells can potentially serve as biomarkers for identifying 
risks of venous thrombosis in cancer patients (Owens and Mackman, 2011). 
 
Apart from providing pro-coagulant surfaces, microparticles can act as mediators for trans- 
cellular signal delivery. Microparticles carrying membrane receptors, cytosolic proteins and 
RNAs from their parent cells stimulate target cells, which then transform and communicate 
with the micro-environment in a way programmed by these contents of microparticles 
(Ratajczak et al., 2006). By delivering CD154, PMPs can stimulate B-cells to produce 
antigen-specific IgG (Sprague et al., 2008). Due to the expression of CD62P on their surface, 
PMPs can recruit and allow aggregation of leukocytes that express PSGL1 under flow 
conditions (Forlow et al., 2000). When PMPs were engulfed by lung cancer cell lines, they 
stimulated cell proliferation, induced mRNA expression for the pro-invasive protein matrix 
metalloproteinase-9 and upregulated adhesion to endothelial cells (Janowska-Wieczorek et 
al., 2005).  
 
Given the multi-faceted roles of microparticles, it is not surprising that elevated microparticle 
levels in the blood circulation have been reported in patients with hypertension (Preston et 
al., 2003), atherosclerosis (Wang et al., 2016), acute coronary syndromes (Mavroudis et al., 
2017), myocardial infarction (Jung et al., 2012), heart failure (Berezin et al., 2015), type II 
diabetes (Li et al., 2016), obesity (Murakami et al., 2007), tumour progression and metastasis 
(Goubran et al., 2015). These associations make blood-borne microparticles attractive clinical 
targets and potential biomarkers of disease progression (Zhou et al., 2015). 
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1.2.4. How are platelet-derived microparticles released? 
The mechanisms that lead to microparticle release from platelets are poorly understood. 
This is remarkable given their apparent contribution to many cardiovascular diseases and the 
details in which other platelet processes, such as granule secretion and aggregation, are 
understood. Microparticle release from platelets is dependent on an increase in cytosolic 
Ca2+. Activation of platelets by a Ca2+ ionophore resulted in PMP release, and it was 
abolished when Ca2+ influx was inhibited (Heemskerk et al., 2002). Physiological routes for 
Ca2+ entry into platelets include purinergic P2X1 receptors, the sodium-calcium exchanger 
(NCX), store-operated channels and transient receptor potential channels (Mahaut-Smith, 
2012). It is not clear which of these channels or transporters mediate Ca2+ influx that 
ultimately leads to PMP release and whether this depends on the specific stimulus used. 
 
An elevated level of intracellular Ca2+ activates calpain, a Ca2+-dependent thiol protease. 
Activated calpain is responsible for the proteolytic cleavage of prominent cytoskeleton- 
associated proteins including filamin-1, gelsolin, myosin and talin (Fox et al., 1990), which in 
turn allows the plasma membrane to detach from the cortical actin cytoskeleton and bleb 
outwards. Inhibition of calpain reduced the degree of PMP release from platelets activated 
with thrombin, collagen or Ca2+ ionophore (Yano et al., 1993). Incubation of platelets with 
cytochalasin D, an agent that caps actin filaments and prevents their polymerisation, 
resulted in slow PMP release in the absence of calpain activation (Cauwenberghs et al., 
2006). PMP release might also involve caspases and Rho-kinases, as described in nucleate 
cells (Sapet et al., 2006; Böing et al., 2013). Although caspase 3 is activated in apoptotic 
platelets that expose PS, it is not clear whether it has any role in platelet activation or PMP 
release (Kile, 2014). Activated Rho-kinases could alter the cytoskeleton and result in cellular 
contraction as well as membrane blebbing in platelets undergoing either apoptotic or 
pro-coagulant changes (Coleman et al., 2001; Paul et al., 2003).  
 
Downstream of Ca2+ signalling, formation of microparticles also requires the loss of lipid 
asymmetry between the inner and outer leaflets of plasma membrane (Zwaal et al., 2005). 
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At resting state, the inner leaflet is enriched in PS, PIP2 and phosphatidylethanolamine (PE), 
whereas phosphatidylcholine (PC) and sphingomyelin are predominantly distributed at the 
outer leaflet (Vance and Tasseva, 2013). This asymmetry is maintained by ATP-dependent 
transporters for inward (flip) and outward (flop) lipid translocation. In many human cells, 
P4-ATPase ATP11A and ATP11C act as the PS flippase (Andersen et al., 2016). When cells are 
activated, a rise in the intracellular Ca2+ concentration leads to inhibition of flippase activity. 
It is not enough to rapidly abolish lipid asymmetry, since uncatalysed lipid translocation is 
generally slow. In the meantime, scramblases whose activities are dependent on Ca2+ and 
independent of ATP might be activated to transport negatively-charged lipids including PS to 
the outer membrane leaflet (Bevers and Williamson, 2010). In addition, proximity of anionic 
phospholipids including PS might induce membrane curvature (Xu et al., 2013; Hirama et al., 
2017). In this way, PS exposure is a necessary part of PMP release as well as a major 
contributor to its pathological effects. 
 
In platelets, the Ca2+-dependent scramblase has been identified as transmembrane protein 
16F (TMEM16F). A point mutation at a splicer-acceptor site of the TMEM16F gene was 
identified in one patient with Scott syndrome, a rare bleeding disorder (Suzuki et al., 2010). 
TMEM16F-deficient platelets from Scott syndrome patients showed defects in PS exposure 
and PMP release in vitro, amongst other pro-coagulant activities, in response to physiological 
agonists (Mattheij et al., 2016) or a Ca2+ ionophore (Zwaal et al., 2004). Stimulated platelets 
from TMEM16F-null mice exhibited significantly lower levels of PS exposure, PMP release 
and in vivo thrombus formation compared to wild type (Fujii et al., 2015). 
 
1.2.5. Hypothesis for the mechanism of microparticle release from platelets 
Little is known beyond the calpain-dependent pathway or loss of lipid asymmetry regarding 
how microparticles are released from human platelets. Our working hypothesis is that it can 
be broken down into several stages.  
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Firstly, calpain-dependent breakdown dislodges cytoskeletal proteins from the membrane, 
which induces blebbing and sometimes membrane expansion (Miyoshi et al., 1996; Dewitt et 
al., 2013). Yet blebbing might also be facilitated by local increases in hydrostatic pressure 
through influx of hydrophilic ions followed by water. It causes the cytoplasm to flow towards 
those unsupported regions of the membrane where the cytoskeleton has been dislodged 
(Gauthier et al., 2012).   
 
Secondly, blebbing often occurs in local regions of the plasma membrane, so there might be 
a specific mechanism (e.g. lipid rafts) to compartmentalise the relevant signalling complexes. 
For example, localisation of Ca2+ channels in lipid rafts might localise Ca2+ entry and 
subsequent calpain activity to these regions. 
 
Lastly, the outward bleb needs to be pinched off. This process can be spontaneously driven 
by relaxation of elastic energy at a strongly curved point on the membrane (Kozlov et al., 
2010), or it could be facilitated by a specialised scission mechanism (Figure 1.2). 
 
 
Figure 1.2: Hypothesis for the mechanism of microparticle release from platelets 
(1) Increased hydrostatic pressure to induce outward membrane blebbing; (2) Lipid rafts to 
localise signalling events; (3) Membrane scission to pinch off membrane blebs. 
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1.3. Influx of ions at the platelet membrane 
When microparticles are formed at the platelet membrane, outward blebbing might require 
local increases in pressure, possibly in the form of increased hydrostatic pressure. It could be 
provided by influx of Na+ and Cl- followed by water.  
 
Ion influx is important for many platelet functions. Na+ entry was shown upon activation of 
platelets by ADP (Feinberg et al., 1977), thrombin (Greenberg-Sepersky and Simons, 1984) 
and collagen (Roberts et al., 2004). It appears to have essential roles in triggering or 
amplifying Ca2+ signals. Store-operated calcium entry (SOCE) in platelets was inhibited when 
extracellular Na+ was absent or when Na+ entry was blocked by specific inhibitors (Harper et 
al., 2010). Na+ entry via TRPC3 and TRPC6, followed by activation of NCX, contributes to the 
increase in cytosolic Ca2+ that ultimately triggers PS exposure when stimulated by thrombin 
plus collagen (Harper et al., 2013). In the presence of Cl- channel blockers, PS exposure was 
reduced in response to physiological agonists but not to Ca2+ ionophores, so Cl- influx may be 
required for membrane hyperpolarisation in stimulated platelets, which in turn is required 
for sustained downstream Ca2+ signalling events (Harper and Poole, 2013). The identity of 
the Cl- channel is still under debate, but some suggested that the scramblase TMEM16F 
could function as a Ca2+-activated Cl- channel (Yang et al., 2012; Liu et al., 2015). 
 
Apart from Ca2+ signalling and PS exposure, ion influx mediates “ballooning” in platelets. 
Observable under light microscopy, balloons are large PS-exposing membrane sacks (1 to 
6μm in diameter) filled with small debris and devoid of organelles or the open canalicular 
system (Podoplelova et al., 2016). Balloon formation was significantly attenuated when 
platelets were incubated in medium lacking Na+ or Cl-, or when extracellular osmolality was 
increased by sucrose (Agbani et al., 2015). Water molecules might enter platelets through 
the aquaporin-1 channel, which was reported to be expressed in both murine and human 
platelets (Agbani et al., 2018). Swelling morphological changes was absent in platelets from 
TMEM16F-deficient mice or a patient of the rare Scott syndrome (Mattheij et al., 2016), so 
TMEM16F might mediate PS exposure or Cl- entry, or both, during balloon formation. 
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It is not clear whether coordinated ion and water entry is needed for blebbing in PMP 
release, which is similar yet distinct from ballooning. The first phase of ballooning is 
associated with blebbing and bleb retraction before the swelling becomes irreversible 
(Agbani et al., 2015). However, membrane blebbing analogous to this process in cancerous 
cells appears reversible and independent of fluid entry (Fackler and Grosse, 2008). When 
ballooning was impaired by inhibiting Na+ or Cl- entry or blocking aquaporin-1, there was a 
reduction in the number of PMPs released from platelets (Agbani et al., 2017, 2018). This 
reduction in PMP count was based on measuring Annexin V fluorescence in microscopy 
images. Since microparticles are difficult to detect under light microscopy due to their small 
sizes, the results would be more convincing if they can be reproduced using an additional 
and more objective method, e.g. flow cytometry or nanoparticle tracking analysis (Théry et 
al., 2018). 
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1.4. Lipid rafts 
Lipid rafts are heterogeneous, dynamic (in terms of lateral mobility) and microscopic 
(>300nm) domains on the plasma membrane that are enriched in saturated phospholipids, 
sphingolipids, glycolipids and cholesterol (Pike, 2006). These domains are formed transiently 
on the membrane by the collective behaviours of raft-associated lipids and proteins that 
interact preferentially with one another (Simons and Vaz, 2004). Enrichment of hydrophobic 
lipids and proteins endows lipid raft domains with increased lipid packing (or order) and 
decreased fluidity. Lipid rafts are present in both the inner and outer leaflets of an 
asymmetrical cell membrane, and they are potentially coupled across leaflets (Raghupathy et 
al., 2015). Functionally, lipid rafts act as platforms for the regulation of various cellular 
processes via selective accumulation of lipidated proteins and glycosyl phosphatidylinositol 
(GPI)-anchored proteins, thereby facilitating interactions between these proteins (Lingwood 
and Simons, 2010). This makes lipid rafts potential hubs for localised signalling cascades. 
 
1.4.1. Studying lipid rafts 
Early studies focused on isolation of lipid raft domains from the cell membrane. When 
detergents are applied, cellular membranes separate into two distinct fractions: detergent- 
soluble membranes (DSMs) and detergent-resistant membranes (DRMs) (Yu et al., 1973). 
Since DRMs are enriched in cholesterol, sphingolipids and GPI-anchored proteins, they 
became the paradigm in probing lipid raft compositions (Brown and Rose, 1992). However, 
DRMs cannot reflect the native lipid raft composition and organisation in living cells due to 
the non-physiological nature of how DRMs are extracted (Lichtenberg et al., 2005). 
 
In parallel with differential solubilisation, artificial model membranes were developed to 
study principles behind raft formation. Membranes composed of miscellaneous lipids can be 
separated into two distinct phases: a relatively packed liquid-ordered (Lo) phase enriched in 
saturated lipids and cholesterol, and a relatively fluid liquid-disordered (Ld) phase enriched in 
unsaturated lipids (Kaiser et al., 2009). Nonetheless, it is technically difficult to integrate 
proteins into systems of model membranes, which limits the scope of Lo phase in modelling 
lipid rafts (Sezgin et al., 2012). 
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Microscopy has been used regularly for studying localisation, structure and composition of 
lipid rafts, although this is limited by the spatial resolution of the technique used. 
Morphologically, lipids rafts can be identified by caveolae that contain caveolin-1 protein 
(Parton et al., 2006). Detected by confocal microscopy, co-localisation of putative lipid raft 
markers (e.g. cholera toxin B) with certain molecules has been used as evidence that these 
molecules are associated with lipid rafts (Gupta and DeFranco, 2003). The resolution of 
confocal microscopy limits its use in direct assays of lipid raft structure and composition, 
especially in small cells such as platelets. Recently, PALM, STED and NSOM super-resolution 
microscopy techniques help to visualise lipid-mediated protein clustering; whereas SPT, iSCAT 
and FRET are powerful tools for measuring the real-time dynamics of lipid diffusion at 
nanometre scale (Sezgin et al., 2017). Most of these methods are dependent on fluorescent 
markers. As lipid behaviours are determined by molecular packing yet fluorophores are 
similar in size as the lipid molecules, fluorescent labels inevitably alter the native behaviour 
of lipids and perturb lipid raft functions (Sezgin and Schwille, 2011), which might 
compromise conclusions derived from fluorescence-based microscopy studies. 
 
To study lipid raft functions, cells are treated with drugs or enzymes that interfere with 
cholesterol levels to disrupt lipid raft structure and function. Given its specificity and rapid 
onset of action, a cholesterol-depleting agent methyl-β-cyclodextrin (MβCD) is widely used. 
However, MβCD has off-target effects beyond cholesterol depletion, including inhibition of 
cholesterol-independent lateral diffusion of membrane proteins, increase in membrane 
permeability to ions and acute cytotoxicity (Mahammad and Parmryd, 2015). In addition, 
statins are used in combination with cholesterol-free medium over long incubation time (up 
to 24 hours) to inhibit cholesterol synthesis via the mevalonate pathway (Goodwin et al., 
2005). It is not suitable for platelet studies in vitro because HMG-CoA reductase, the 
intracellular target of statins (Istvan and Deisenhofer, 2001), is not expressed in human 
platelets.  
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Ceramide confers a spontaneous curvature to the plasma membrane because of its 
cone-shaped structure, which might mediate membrane blebbing or invagination (Verderio 
et al., 2018). Drugs that interfere with sphingolipid synthesis (myriocin) or stability (tricyclic 
anti-depressants) have been used to disrupt lipid rafts (Miller et al., 2015; Zhao et al., 2015), 
but not in platelets so far. These drugs are limited by their off-target effects, because 
inhibiting sphingolipid metabolism or ceramide generation inevitably alters membrane 
properties.  
 
1.4.2. Functions of lipid rafts 
The primary function of lipid rafts is to facilitate and regulate specific protein-protein 
interactions as a catalytic platform, via selective accumulation and segregation of lipidated or 
GPI-anchored proteins at the plasma membrane. In addition, close proximity with raft lipids 
such as cholesterol and sphingolipids may induce conformational changes in lipid raft- 
associated proteins and thus affect their activities (Laganowsky et al., 2014). 
 
The first cellular pathway discovered to be associated with lipid rafts is IgE-mediated 
signalling in mucosal mast cells. Under resting conditions, high affinity IgE receptors FcεRI, 
T-cell receptors and B-cell receptors were all found in DSMs. These key immune receptors all 
translocate to DRMs upon activation (Field et al., 1995). This notion was further supported 
when proteins of the signal transduction machineries downstream of these receptors were 
found to be enriched in DRMs (Filipp et al., 2004). Many immune-associated proteins at the 
cell surface such as DAF, CD14, CD59 and Thy-1 are GPI-anchored (Saha et al., 2016). Since 
then, lipid rafts have been implicated in the coordination of numerous signalling pathways in 
immunity, cancer, cell growth, neural development, diabetes and cardiovascular diseases 
(Sezgin et al., 2017). 
 
Lipid rafts have been suggested to mediate budding of HIV viruses, which is similar in 
topology to microparticle release. A comparative lipidomics study found that cholesterol, 
sphingolipids and saturated lipids were more prevalent than unsaturated lipids in the HIV-1 
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viral envelope (Lorizate et al., 2013). Viral receptors and viral fusion proteins in general are 
preferentially partitioned into lipid raft domains on the cell surface (Teissier and Pécheur, 
2007). Moreover, binding of the HIV Gag protein, a step necessary for virus assembly and 
budding, favours cholesterol-rich membrane domains with close packing of lipids, although it 
is not clear how Gag protein senses membrane domains that are of different lipid 
compositions (Dick et al., 2012). 
 
1.4.3. Lipid rafts, platelets and microparticle release 
Lipid raft domains are present on the platelet membrane. The first evidence came from 
discovery of cholesterol-rich DRMs from resting platelets (Dorahy et al., 1996). Reversible 
phase separation and lipid domain formation was observed under microscopy when platelets 
were activated by thrombin plus collagen, and it was abrogated when cholesterol was 
depleted by MβCD (Gousset et al., 2002).  
 
Functions of many platelet receptors are linked to lipid rafts. Lipid rafts are required in 
Gi-linked signalling events downstream of the P2Y12 receptor in response to stimulation by 
ADP (Quinton et al., 2005). GPVI, the major collagen receptor, is recruited to lipid rafts upon 
stimulation (Locke et al., 2002; Bodin et al., 2003), and lipid rafts regulate activation of 
platelets by GPVI agonists (Quinter et al., 2007).  
 
The role of lipid rafts in microparticle release has been shown in several cell types. 
Cholesterol depletion from THP-1 monocyte membranes impaired the release of TF-bearing 
microparticles (Del Conde et al., 2005), while loading THP-1 monocytes with cholesterol 
induced PS exposure on the surface and increased microparticle release (Liu et al., 2007). 
Lipid rafts also control the composition of the monocyte-derived microparticles by allowing 
incorporation of TF, PSGL1 and β1 integrins (Rothmeier et al., 2015). Disruption of lipid rafts 
by MβCD or nystatin blocked microparticle release from endothelial cells in response to 
stimulation with angiotensin II (Burger et al., 2011). Microparticles released from 
erythrocytes either under storage or treated with a Ca2+ ionophore are enriched in the lipid 
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raft marker stomatin (Salzer et al., 2002, 2008). Total cholesterol content on the erythrocyte 
membrane decreased following the release of cholesterol-enriched vesicles (Santos et al., 
2005). These studies show that lipid rafts are a conserved feature of microparticle release 
from cardiovascular cells. However, roles of lipid rafts in signalling including those relevant to 
Ca2+ channels are well-established (Pani and Singh, 2009). It is not always clear whether lipid 
rafts are involved in microparticle release itself, or in the generation of the Ca2+ signal that 
triggers microparticle release. 
 
No previous study has directly linked lipid rafts to PMP release, yet lipid rafts have been 
connected to platelet membrane deformation. Upon interaction with fibrinogen or 
stimulation of thrombin receptors, cholesterol is redistributed to the tips of filopodia and the 
leading edges of spreading platelets (Heijnen et al., 2003), while cholesterol depletion 
impedes formation of these plasma membrane extensions (Larive et al., 2010). In addition, 
lipid rafts in platelets are sites of high PI metabolism (Bodin et al., 2001). Activated calpain 
has been shown to cleave raft-associated PIP kinases. This would lead to decreased PIP2 
levels in lipid rafts and may locally disrupt adhesion of cytoskeleton to the membrane, which 
favours membrane blebbing and vesicle release (Chichili and Rodgers, 2009). Finally, 
phospholipid content of PMPs vary slightly depending on the stimuli, but the cholesterol 
content in PMPs tends to be higher than that on platelet surfaces, secreted granules and 
intracellular membranes (Biró et al., 2005). 
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1.5. Membrane scission 
After budding from the plasma membrane, blebs for PMPs need to be pinched off, and it 
requires a membrane scission mechanism. Generally the scission process starts with 
formation of a neck on a budding vesicle, followed by constriction of the membrane neck 
until it reaches a critical diameter estimated to be within 1 to 5nm. Scission occurs 
spontaneously when the force put on the membrane is great enough to cause constriction 
beyond this critical threshold (Campelo and Malhotra, 2012). Three major mechanisms have 
been reported under different circumstances to facilitate membrane scission in cells, namely 
dynamin-mediated constriction, Arf1-mediated lipid insertion and ESCRT-mediated 
scaffolding (Figure 1.3). They all manipulate lipid-lipid interactions within biological 
membranes to alter curvature of the phospholipid membrane bilayer. 
 
1.5.1. Dynamin-mediated constriction 
Dynamins are large GTPases involved in many processes including budding of transport 
vesicles, division of organelles, cytokinesis and pathogen resistance (Praefcke and McMahon, 
2004). They can assemble into a helical coat, a ring-like structure, at necks of budding 
vesicles (Takei et al., 1995). Assembly of dynamin triggers its inherent GTPase activity and 
subsequent conformational changes constrict the necks below the critical diameter (Faelber 
et al., 2012). Spontaneous scission occurs at the interface between the dynamin ring and 
uncoated membrane, because increases in local membrane elastic energy due to curvature is 
the greatest at this location and the energy barrier for scission is minimised (Morlot et al., 
2012). This protein machinery has been widely reported to mediate membrane scission and 
fusion during clathrin-mediated endocytosis (De Camilli et al., 1995; Mettlen et al., 2009). 
There is no evidence yet that dynamin mediates outward scission or ectocytosis, so it is 
unlikely to be involved in microparticle release from platelets. 
 
1.5.2. ARF1-mediated lipid insertion 
ADP-ribosylation factor 1 (Arf1) proteins are small GTPases that regulate membrane 
functions. Binding of GTP to Arf1 releases an N-terminal amphipathic α-helix from the 
protein core so that its hydrophobic residues can interact with membrane phospholipids 
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(Antonny et al., 1997). Insertion of this amphipathic helix into lipids causes a stacking effect 
leading to expansion of the outer membrane leaflet. In this way, membrane curvature is 
induced locally at sites of Arf1-GTP binding until constriction goes beyond the critical 
threshold (Beck et al., 2008). Although Arf1 has been reported in the platelet proteome 
(Thon et al., 2008; Haudek et al., 2009), it has not been implicated in any platelet function or 
EV release from any type of cells. 
 
1.5.3. ESCRT-mediated scaffolding 
The endosomal sorting complex required for transport (ESCRT) comprises a system for 
membrane budding and severing membrane necks from their inner surface (Hurley, 2015). 
The conserved membrane neck-directed activities of ESCRT are involved in a huge variety of 
biological processes. These include budding of HIV-1 viruses from infected cells (Gan and 
Gould, 2011), cytokinetic abscission checkpoint control (Carlton et al., 2012), surveillance of 
nuclear pore complex assembly (Webster et al., 2014), secretion of vesicles that carry 
Hedgehog signals during Drosophila wing development (Matusek et al., 2014), budding and 
shedding of small wounds during repair of injured cell membrane (Jimenez and Perez, 2017), 
and sealing of newly formed nuclear envelopes (Vietri et al., 2015).  
 
1.5.3.1. Structure of ESCRT protein complexes 
The ESCRTs were identified as five hetero-oligomeric sub-complexes called ESCRT-0, -I, -II, –
III, and vacuolar protein sorting 4 (VPS4) (Katzmann et al., 2001; Babst et al., 2002; Saksena 
et al., 2007). Despite its name, ESCRT-0 is not a core component of the membrane budding 
and scission machinery. ESCRT-I and -II and apoptosis linked gene 2-interacting protein X 
(ALIX) are directly involved in membrane budding. They function as two branches that feed 
into ESCRT-III, or commonly referred to as charged multivesicular body proteins (CHMPs). 
ESCRT-III, in concert with VPS4, carries out scission of budding necks (Hurley and Hanson, 
2010). Of these two branches, the ALIX-dependent pathway is more important for certain 
ESCRT functions such as EV biogenesis, virus budding and plasma membrane wound repair 
(Campsteijn et al., 2016). Also, damaged membrane segments are shed from the plasma 
membrane in the same manner as in budding of microparticles (Jimenez et al., 2014). 
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1.5.3.2. Mechanism of ESCRT-mediated scission 
The ALIX pathway initiates with apoptosis-linked gene 2 (ALG2). ALG2 is activated by Ca2+ 
binding and it recruits ALIX to the plasma membrane (Maki et al., 2016), which in turn binds 
and recruits CHMP4 subunits of the ESCRT-III pathway (Scheffer et al., 2014). CHMP4B is the 
major binding partner of ALIX among the CHMP4 isoforms (McCullough et al., 2008). 
Downstream of ALIX, knockdown of CHMP4 and VPS4 genes blocked biogenesis of syndecan 
exosomes (Baietti et al., 2012). Upon binding to ALIX, CHMP4B self-assembles at the 
N-helical hairpin domain into 5nm circular polymers that are attached to the plasma 
membrane. 
 
Once assembled and attached to a membrane, CHMP4B filaments have an intrinsic tendency 
to curve and they form conical spirals known as ESCRT-III rings. By imposing their intrinsic 
geometry onto the tightly-attached membrane structures, ESCRT-III rings are able to deform 
and distort the membrane, pushing membrane domains to bud (Hanson et al., 2008). 
Subsequently, constriction of the ESCRT-III spiral ring by Vps4 ATPase at the budding neck 
leads to membrane scission (Adell et al., 2014). As a result, vesicles are pinched off and 
released from the cell. 
 
Figure 1.3: Mechanisms that facilitate membrane scission 
(1) ESCRT-mediated protein scaffolding on the inside of membrane bud (e.g. membrane 
repair); (2) Constriction of membrane by dynamin rings on the outside of membrane bud 
(e.g. clathrin-mediated endocytosis); (3) Arf1-mediated lipid insertion at the neck of 
membrane bud (e.g. budding of vesicles of at the Golgi complex en route to the endoplasmic 
reticulum). 
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1.6. Apoptosis 
Apoptosis or programmed cell death occurs during cell development, maturation and aging 
as a homeostatic mechanism to maintain cell populations in tissues. Unlike necrotic cells that 
swell until the plasma membrane ruptures, apoptotic cells shrink and the integrity of the 
plasma membrane is intact (Kerr et al., 1972). Apoptosis is mediated by a group of enzymes 
called caspases, for cysteine-aspartyl proteases (Alnemri et al., 1996). Activated caspases 
execute apoptosis and apoptotic cells present on their surface “eat me” signals that recruit 
macrophages for engulfment. In this way, dying cells can be cleared before intracellular 
contents are spilled out onto surrounding cells, preventing inflammation (Elmore, 2007).  
 
1.6.1. Intrinsic and extrinsic apoptosis pathways 
Apoptosis proceeds via two convergent pathways in human cells: intrinsic and extrinsic 
(Figure 1.4). The intrinsic apoptosis pathway is regulated by Bcl-2 family proteins, which 
include pro-survival Bcl-2 proteins, pro-death triggers BH3-only proteins and functionally 
redundant pro-death effectors BAK and BAX (Lindsten et al., 2000; Czabotar et al., 2014). In 
healthy cells, Bcl-2 proteins prevent apoptosis by sequestering and inhibiting BAK and BAX 
proteins. In response to cellular stress, cytotoxic insults or developmental cues, BH3-only 
members are upregulated. They bind to and inhibit Bcl-2 proteins, thereby relieving the 
inhibition on BAK and BAX. Activated BAK and BAX oligomerise or dimerise to form pores at 
the outer mitochondrial membrane, through which cytochrome c is released into the cytosol. 
Cytochrome c, along with Apaf1, forms apoptosome, which is a heptameric scaffolding 
complex that cleaves pro-caspase 9 into active caspase 9. Activated caspase 9 cleaves 
pro-caspase 3 into active caspase 3, which is the major cell death effector (Baig et al., 2016) . 
 
The extrinsic apoptosis pathway is triggered by death factors of the tumour necrosis factor 
(TNF) superfamily including Fas ligands, TNFα and TRAIL. Binding of death ligands to their 
specific receptors causes oligomerisation of death domains on the intracellular side of 
plasma membrane. These death domains recruit pro-caspase 8 and other proteins to form a 
death-inducing signalling complex that facilitates cleavage of pro-caspase 8 into active 
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caspase 8. There are two pathways downstream of active caspase 8. In type I cells (e.g. 
lymphocytes), caspase 8 by itself is sufficient to cleave pro-caspase 3. In type II cells (e.g. 
hepatocytes), caspase 8 cleaves BID, a BH3-only protein. Cleaved BID (tBID) directly activates 
BAK and BAX, which induces cytochrome c release and eventually activation of caspase 3 in 
the same way as in the intrinsic pathway (Nagata, 2018).  
 
Intrinsic and extrinsic apoptosis pathways converge at the caspase cascade. A recent 
enzymology study showed that different caspases have distinct substrate specificities (Julien 
et al., 2016). In total, caspases cleave more than 1,300 substrates at more than 1,700 sites in 
human cells (Crawford et al., 2013). For example, inhibitor of caspase-activated DNase is 
cleaved and DNase is released to cause apoptotic DNA fragmentation that further invokes 
p53 signalling (Larsen and Sørensen, 2017). ROCK1 is cleaved to induce apoptotic membrane 
blebbing (Zhang et al., 2018). Involvement of caspases in cell death has been extensively 
verified, as most proteolytic cleavages and downstream apoptotic features are ablated in the 
presence of pan-caspase inhibitors such as Q-VD-OPh or Z-VAD-FMK. 
 
1.6.2. Apoptosis in platelets 
Apoptosis in platelets is regulated by Bcl-extra-large (Bcl-xL), a member of the pro-survival 
Bcl-2 protein family. Gene disruption or pharmacological inhibition of Bcl-xL reduced platelet 
lifespan and caused thrombocytopenia in a dose-dependent manner, while simultaneous 
deletion of BAK and BAX genes prolonged platelet lifespan and caused thrombocytosis in 
murine models (Mason et al., 2007). Although megakaryocytes possess both functional BAK- 
or BAX-mediated intrinsic and Fas ligand-induced extrinsic pathways, apoptosis in platelets 
proceeds only through the intrinsic pathway (McArthur et al., 2018). Death receptors have 
not been reported on the surface of platelets, and roles of caspase 8 or the extrinsic 
apoptosis pathway remain elusive.  
 
There is no consensus regarding how apoptosis is triggered in platelets in the circulation. 
First put forward was the “molecular clock” model stating that Bcl-xL was gradually degraded 
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over time and Bcl-xL levels declined relative to BAK and BAX (Dowling et al., 2010). However, 
Western blot analysis detected no changes in the amount of Bcl-xL proteins in platelets with 
significantly different age profiles (Kile, 2014), so it is likely that BH3-only proteins (e.g. BID, 
BIM, BAD) act as active mediators of apoptosis in platelets. There was a small extension in 
the lifespan of platelets from BAD-/- mice (Kelly et al., 2010). BAD has also been reported to 
be directly inhibited by PKA. Downregulation of PKA relieved its inhibition and allowed BAD 
to initiate platelet apoptosis by sequestering Bcl-xL (Zhao et al., 2017). In this way, apoptosis 
could be linked to Gi-coupled receptors such as P2Y12 or chemokine receptor type 7 (CXCR7) 
on the platelet surface, but definitive genetic evidence is lacking. 
 
1.6.3. BH3-mimetic drugs 
BH3-mimetic drugs tightly bind to the surface groove of pro-survival Bcl-2 proteins. By 
inhibiting Bcl-2 functions, BH3-mimetic drugs can induce apoptosis in cells independently of 
BH3-only proteins. ABT-737, the first BH3-mimetic drug ever developed, has low nanomolar 
affinity for Bcl-2, Bcl-xL and Bcl-w, but it has negligible affinity for Mcl-2 or Bcl-B (Park et al., 
2006). ABT-737 has become a useful tool for investigating cellular apoptosis, and it has led to 
increased understanding of the signalling events that take place (Billard, 2013). For example, 
the use of ABT-737 for in vitro platelet studies offered insights into intracellular Ca2+ 
dynamics, caspase activity and morphological changes associated with the intrinsic apoptosis 
pathway (Vogler et al., 2011). 
 
The orally available ABT-263 (navitoclax) was the first BH3-mimetic drug to enter clinical 
trials. It has an affinity profile similar to that of ABT-737 (Tse et al., 2008). Despite its efficacy 
in killing tumour cells with high Bcl-2 activity, ABT-263 provoked acute thrombocytopenia, 
because it inhibited Bcl-xL and induced platelet apoptosis in the blood circulation (Roberts et 
al., 2012). 
 
The selective Bcl-2 inhibitor ABT-199 (venetoclax) spares platelets. It engages with the p4 
hydrophobic pocket that differs in Bcl-2 (Arg103) and Bcl-xL (Glu96) (Cang et al., 2015). 
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ABT-199 has now been approved to treat relapsed or refractory chronic lymphocytic 
leukaemia with 17p deletion. Since the Bcl-2-associated intrinsic pathway acts downstream 
of p53, it was not surprising that the efficacy of ABT-199 was independent of p53 status 
(Anderson et al., 2016). In preclinical studies, ABT-199 has been shown to sensitise tumour 
cells to other therapies, so it has potential to enter clinical trials in combination with many 
other known anti-cancer agents (Adams and Cory, 2018).    
 
Figure 1.4: Signal transductions in apoptosis pathways 
Red arrows are for activation and black arrows are for inhibition. BH3-mimetic drugs, e.g. 
ABT-737 and ABT-263 (navitoclax), induce apoptosis in platelets by inhibiting Bcl-xL, a 
member of the pro-survival Bcl-2 family. 
 
1.6.4. Hallmark of apoptosis: PS exposure 
Apoptotic cells expose PS on their surface in a caspase-dependent manner (Martin et al., 
1995). Fluorescently labelled Annexin V, which specifically binds to PS (and PE) in an 
extracellular Ca2+-dependent manner, has been the standard practice for detecting cellular 
apoptosis in vitro (Vermes et al., 1995). There are two recognition sites for caspase 3 in the 
cytoplasmic region of the PS flippase ATP11A (Segawa et al., 2014). Apart from flippase 
inhibition, a scramblase needs to be activated so that PS can be transported to the outer 
membrane leaflet (Bevers and Williamson, 2010). Although intracellular Ca2+ concentration 
increases during apoptosis, the Ca2+-dependent scramblase TMEM16F is not indispensable 
for apoptotic PS exposure. TMEM16F-null platelets from a Scott syndrome patient still 
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exposed PS when apoptosis was induced by BH3-mimetics in vitro (van Kruchten et al., 2013). 
It agrees with an earlier hypothesis that activation-induced and apoptosis-induced PS 
exposure are regulated by two distinct pathways in platelets (Schoenwaelder et al., 2009).  
 
XK-related protein 8 (XKR8) has been suggested as the Ca2+-independent PS scramblase. 
When cells undergo apoptosis, caspase 3 cleaves XKR8 at its C-terminal tail. The truncated 
XKR8 undergoes dimerisation with its chaperones basigin or neuroplastin. The dimerised 
complex works as a non-specific scramblase that bi-directionally translocates phospholipids 
across membrane leaflets, so that PS can be exposed on the surface (Suzuki et al., 2016). 
However, there has been no evidence reporting the presence of XKR8 in human platelets. In 
addition, it remains to be established if there is cross-talk between the two PS mobilisation 
pathways in platelets. It is technically difficult to confirm whether highly activated platelets 
undergo apoptosis to enhance pro-coagulant activities such as PS exposure. More specifically, 
it is unclear whether physiological agonists can induce BAK- or BAX-mediated platelet death, 
partly because a potent and specific inhibitor for BAK or BAX is still lacking. 
 
PS exposure is a necessary and sufficient “eat me” signal for cell clearance. Masking PS by 
pre-incubating apoptotic cells with Annexin V blocked clearance (Krahling et al., 1999). When 
flippase activity was inhibited, constitutive PS expression caused phagocytosis of living cells 
(Segawa et al., 2014). After apoptotic cells are engulfed by macrophages, they are 
transported along the cytoskeleton to the lysosome for degradation (Nishi et al., 2014). 
 
1.6.5. Secondary necrosis  
If apoptotic cells are not cleared rapidly by macrophage phagocytosis, they undergo 
secondary necrosis. Secondary necrotic cells feature plasma membrane swelling and cell lysis. 
Intracellular contents are released, so there might be pro-inflammatory or immunogenic 
consequences (Sachet et al., 2017). Recently, gasdermin E (also called deafness, autosomal 
dominant 5; DFNA5) was identified as a central regulator of apoptotic cell disassembly and 
progression to secondary necrosis. Downstream of mitochondrial damage, cytochrome c 
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release and the Apaf1 apoptosome pathway, DFNA5 is cleaved by caspase 3 at Asp270. The 
cleaved N-terminal fragments of DFNA5 self-assemble into oligomer rings that penetrate the 
plasma membrane from the inside. In this way, membrane permeability is increased, which 
causes swelling and induces secondary necrosis (Rogers et al., 2017). 
 
It is difficult to distinguish necrotic from apoptotic platelets in experiments. Fluorescently 
labelled Annexin V can be used to detect PS exposed on the surface of apoptotic platelets, 
but Annexin V can also stain necrotic platelets because it can access the inner membrane 
leaflet through the ruptured plasma membrane. Necrotic cells are commonly identified by 
co-staining with propidium iodide, a fluorescent DNA-intercalating agent, that cannot cross 
the membrane of apoptotic cells (Crowley et al., 2016), but it is not applicable for anucleate 
platelets. In addition, some suggested that Annexin A1 was externalised only on necrotic 
cells (Blume et al., 2009), yet others reported that Annexin A1 began to be exposed at the 
early stages of apoptosis similar to the timing of PS exposure (Weyd et al., 2013). 
 
The greatest extent of PS exposure is seen after 1 to 3 hours of treating platelets with BH3- 
mimetic drugs, so signalling studies often investigate these later time points (Schoenwaelder 
et al., 2011; Vogler et al., 2011; Rukoyatkina et al., 2013). It seems likely that an apoptotic 
platelet would be cleared within this time under normal circumstances, but the scavengers 
of apoptotic cells are not present in vitro and hence the apoptotic platelets will not be 
rapidly cleared. It is possible that secondary necrosis is initiated at these later time points. If 
necrosis does ensue, it then becomes necessary to review whether the classic apoptotic 
features reported in platelets so far should instead be associated with secondary necrosis. 
 
 
 
 
 
 
 
33 
 
1.7. 2-Aminoethoxydiphenyl borate 
The drug 2-aminoethoxydiphenyl borate (2-APB) was initially developed as a cheap and fast- 
onset membrane-penetrable antagonist for intracellular phosphoinositide (PI) signalling. The 
first report of 2-APB showed that it inhibited IP3-induced Ca2+ release in platelets in a 
concentration-dependent manner (Maruyama et al., 1997). Later, 2-APB was found to 
suppress Ca2+ signals in a variety of cells including neurons, neutrophils, cardiac myocytes 
and endothelial cells. Many of these studies used 2-APB to demonstrate involvement of IP3 
receptors without considering its additional effects (Bootman et al., 2002). Since then, 2-APB 
has been established as non-specific inhibitor of multiple Ca2+ channels not limited to IP3 
receptors. Rather than Ca2+ release, the principal antagonistic effect of 2-APB is on Ca2+ entry. 
 
1.7.1. 2-APB inhibits store-operated calcium entry 
2-APB inhibits store-operated calcium entry (SOCE), a process by which depletion of Ca2+ 
from the ER activates Ca2+ influx across the plasma membrane. SOCE helps to maintain a 
relatively constant Ca2+ concentration in the ER, which underlies protein synthesis, folding 
and IP3-induced Ca2+ signalling (Putney et al., 2017). In platelets, SOCE can be induced by 
physiological agonists such as thrombin (Harper and Poole, 2011), or by pharmacological 
agents such as thapsigargin that inhibits SERCA pumps and depletes ER luminal Ca2+ (Sage et 
al., 2011). The inhibitory effect of 2-APB on SOCE does not involve IP3R, but is likely to be a 
direct effect on SOCE in platelets (Diver et al., 2001). This is also seen in other cells. For 
example, in primary hepatocytes, 2-APB caused a concentration-dependent inhibition of Ca2+ 
influx without blocking IP3-induced Ca2+ release (Gregory et al., 2001). In addition, Ca2+ entry 
triggered by thapsigargin was still inhibited by 2-APB in IP3R knockout cells (Iwasaki et al., 
2001), further supporting the conclusion that 2-APB directly blocks SOCE. 
 
SOCE is mediated by two protein families: stromal interacting molecules (STIM) as the Ca2+ 
sensors in the ER and Orai as the pore-forming subunits in the plasma membrane. When Ca2+ 
is depleted from ER, Ca2+ dissociates from STIM, which triggers self-association and migration 
of STIM to the closely apposed ER-plasma membrane junctions. At these junctions, STIM 
oligomers interact with and activate Orai-formed channels to allow Ca2+ influx (Hogan and 
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Rao, 2015). When used at relatively high concentrations (e.g. 50μM), the inhibitory effect of 
2-APB on SOCE is multi-faceted. It rapidly blocks the Orai1 pore within 90 seconds, before its 
direct inhibition on STIM1 develops within several minutes. 2-APB locks STIM1 in its auto- 
inhibitory resting state, thereby inhibiting formation of STIM1 oligomers. 2-APB also weakens 
interactions between STIM1 and the N-terminal region of Orai1, so it indirectly affects 
functional coupling between STIM1 and Orai1 (Wei et al., 2016). 
 
Although generally denoted as an inhibitor of SOCE, 2-APB has bimodal actions. Whilst it 
inhibits Ca2+ influx at high concentrations of 25 to 100μM, 2-APB enhances SOCE at a lower 
range of 1 to 20μM (Putney, 2010). In a recent study, 2-APB (5μM) was found to increase the 
pore size of STIM1-activated Orai1 channels, which then conduct Ca2+ and Na+ (Xu et al., 
2016). On the other hand, Orai2 is relatively insensitive and Orai3 is strongly activated by 
2-APB even at high concentrations. 2-APB (75μM) increased the pore size of Orai3 channels 
by more than 40% independently of STIM1 (Schindl et al., 2008). Orai1 is the predominant 
member of Orai family in human platelets. Expression levels of Orai2 and Orai3 are 
significantly lower (Braun et al., 2009), so the stimulatory effect of 2-APB on Orai3 is likely to 
be negligible for platelet studies.  
 
1.7.2. Other targets of 2-APB 
2-APB inhibits canonical-type TRP channels (TRPCs). Subtypes of TRPC reportedly inhibited by 
2-APB include TRPC1 (Delmas et al., 2002), TRPC3 (Trebak et al., 2002), TRPC5 (Xu et al., 2005), 
TRPC6 and TRPC7 (Lievremont et al., 2005). Among these subtypes, TRPC1, 3 and 6 are 
expressed in human platelets. The role of TRPC1 remains to be clarified. Although early 
reports implicated TRPC1 as a channel for SOCE (Rosado et al., 2002; Brownlow et al., 2004), 
platelets from TRPC1-knockout mice showed fully intact SOCE compared to wild type 
(Varga-Szabo et al., 2008). By contrast, TRPC3 and TRPC6 have well-established roles in 
store-independent calcium entry, also known as non-capacitative calcium entry (NCCE), which 
can be triggered in platelets by the diacylglycerol analogue, 1-Oleoyl-2-Acetyl-sn-Glycerol 
(OAG) (Berna-Erro et al., 2016). 
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Functions of TRPCs are sometimes coupled to sodium-calcium exchanger (NCX). For example, 
Na+ entry via TRPC3 and TRPC6, followed by reverse activation of NCX, mediates an increase 
in cytosolic Ca2+ that ultimately triggers platelet PS exposure in response to thrombin plus 
collagen (Harper et al., 2013). 
 
2-APB affects functions of vanilloid-type TRP channels (TRPVs). Whilst it inhibits TRPV6 
(Voets et al., 2001; Singh et al., 2018), 2-APB is a common activator of TRPV1, 2 and 3 
channels (Colton and Zhu, 2007). TRPV1 is the only TRPV subtype expressed in human 
platelets, and Ca2+ influx through TRPV1 can be triggered specifically by capsaicin (Sage et al., 
2014). Functionally, TRPV1 is involved in agonist-induced 5-HT secretion from platelets, 
which is further associated with dense granule secretion and Ca2+ release during platelet 
activation (Harper et al., 2009). 
 
2-APB inhibits connexin hemichannels. Opposing hemichannels dock onto each other and 
form gap junctions that allow direct exchange of small molecules between cytoplasm of 
adjacent cells (Laird and Lampe, 2018). Usually gated by Ca2+ (Lopez et al., 2016), connexins 
act as non-specific anion channels (Fiori et al., 2012). 2-APB was shown to inhibit 
inter-cellular transfer of molecules at both high (100μM) and low (10μM) concentrations 
(Griffith et al., 2005; Neijssen et al., 2005). Instead of altering single channel conductance, 
2-APB inhibits gap junctions by rapidly reducing the number of channels remaining in the 
open state. Potency of 2-APB inhibition varies depending on specific connexin subunits (Bai 
et al., 2006). Roles of subunits Cx37 and Cx40 have been studied extensively in platelets 
using specific gap junction inhibitors and genetic knockout mice. They have important roles 
in fibrinogen binding, granule secretion, platelet aggregation, thrombus formation and 
stability, and clot retraction (Vaiyapuri et al., 2012, 2013). 
 
2-APB may also inhibit pannexins (Willebrords et al., 2017). Pannexins are topologically 
analogous to connexins, although there is no sequence homology (Sosinsky et al., 2011). 
Pannexin subunits form plasma membrane hexameric ion channels, through which cytosolic 
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contents, e.g. ATP, are released to the extracellular space (Boassa et al., 2007). They can also 
act as Ca2+-permeable gap junctions that propagate Ca2+ waves between cells (Vanden 
Abeele et al., 2006; Ishikawa et al., 2011). Pannexin subunit 1 (Panx1), but not Panx2 or 
Panx3, is expressed in human platelets. Inhibition of platelet Panx1 reduced Ca2+ influx and 
ATP release in response to various agonists (Taylor et al., 2014). It is thus hypothesised that 
ATP release through Panx1 leads to autocrine or paracrine activation of the ligand-gated P2X1, 
which then mediates Ca2+ influx and ultimately platelet aggregation and thrombus formation 
(Molica et al., 2015, 2017). 
 
1.7.3. Structure of 2-APB 
Divergent and non-specific effects of 2-APB may derive from its structural complications. A 
2-APB molecule consists of three parts: an aminoethyl chain, a boron-oxygen core and two 
phenyl rings. The boron atom can interact with N or O atoms in amino acids (Mc Cormack et 
al., 1997). The amine chain can conduct intra- and inter-molecular nucleophilic attack on 
boron, so 2-APB can also exist as ring-form monomers or dimers (van Rossum et al., 2000). 
 
Several studies focused on the structure of 2-APB. When 2-APB was replaced by two 
analogues without an aminoethyl chain or B-O core, inhibition of platelet SOCE or activation 
of keratinocyte TPRV3 was not affected (Dobrydneva and Blackmore, 2001; Chung et al., 
2005), so the biphenyl moiety could be the pharmacophore for these functions. Later, it was 
found that the phenyl rings were not essential in inhibiting SOCE, yet there was a clear 
correlation between the number of phenyl rings in the molecule and its ability to inhibit 
SOCE (Zhou et al., 2007; Dellis et al., 2011). More recently, custom-synthesised analogues 
enabled refined structure-function analysis of how 2-APB potentiates and inhibits SOCE in 
Jurkat T cells (Djillani et al., 2014, 2015). 
 
Most 2-APB structural studies relied on analogues. Chemical structures of commercially 
available analogues are listed below. Compared to 2-APB, PBA is a small molecule that only 
retains the B-O core attached to one phenyl group. In DP3A, the B-O core is replaced by a 
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phosphate group. DPHD lacks the boron atom and has two methyl groups attached to the 
secondary amine. Diphenylborinic acid is not stable (Finch and Gardner, 1966), while DMBA 
provides a more stable structure where two phenyl rings are replaced by mesitylene rings. In 
DPBA, the terminal amine chain is replaced by another diphenylborinic group. DPTHF lacks 
the boron atom, yet it has a five-membered ring containing an oxygen atom, which is similar 
to the ring form of 2-APB monomer (Figure 1.5) 
 
 
Figure 1.5: Structures of 2-APB and its analogues 
2-APB: 2-aminoethoxydiphenyl borate; PBA: phenylborinic acid;  
DP3A: 3-(diphenylphosphino)-1-propylamine; DPHD: diphenhydramine;  
DMBA: dimesitylborinic acid; DPBA: diphenylborinic anhydride;  
DPTHF: 2, 2-diphenyl tetrahydrofuran.  
These structures were drawn in ChemDraw. 
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1.8. Aim of study 
This thesis aims to understand how microparticles are released from human platelets. In the 
literature, there is no consensus on the method of detecting microparticles or other types of 
extracellular vesicles. To start with, an assay needed to be developed for the detection of 
platelet-derived microparticles. 
 
Secondly, it was investigated how microparticles are released from activated human platelets. 
Little is known beyond the calpain-dependent pathway or loss of lipid asymmetry. A few 
hypotheses for this process were studied. These include influx of hydrophilic ions as a 
mechanism for membrane blebbing, lipid rafts as a platform for localised signalling and 
endosomal sorting complex required for transport as a system for membrane scission. 
 
Thirdly, it was investigated whether and how microparticles are released from apoptotic 
human platelets. In terms of platelet apoptosis, little is known beyond the intrinsic apoptotic 
pathway and caspase-mediated phosphatidylserine exposure. Regulatory mechanisms of 
platelet apoptosis, secondary necrosis, and the relevant microparticle release were studied 
and then compared with its counterpart in activated platelets. 
 
Finally, 2-aminoethoxydiphenyl borate (2-APB) was found to inhibit microparticle release 
from platelets in response to either pro-coagulant stimulation or induction of apoptosis. 
These two pathways for microparticle release have not been fully resolved. Studying the 
mechanisms behind inhibition by 2-APB, and possibly identifying its target, could bring 
insights into how microparticles are released from activated and apoptotic platelets. 
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Chapter 2 Materials and methods 
2.1. Isolation of platelets from whole blood and preparation of washed platelets 
Healthy, drug-free volunteers had given written, informed consent in accordance with the 
Declaration of Helsinki. Use of human blood for these experiments was approved by the 
Human Biology Research Ethics Committee, University of Cambridge, United Kingdom. Blood 
was drawn by venepuncture into vacuettes (Greiner) with sodium citrate (3.8% v/v in dH2O) 
used as an anti-coagulant. Whole blood was gently mixed 7:1 with pre-warmed (30ºC) acid 
citrate dextrose (ACD; 85mM tri-sodium citrate, 71mM citric acid, 111mM D-glucose).  
 
Centrifuged at 200g for 10 minutes without brake at room temperature, whole blood was 
separated into platelet-rich plasma (PRP) on top and red blood cells (RBCs) at the bottom. 
PRP was diluted 1:1 with pre-warmed (30ºC) HEPES-buffered saline (HBS; 135mM NaCl, 
10mM HEPES, 3mM KCl, 1mM MgCl2, 0.34mM NaH2PO4, pH 7.4) containing 0.9mg/ml 
D-glucose. Diluted PRP was supplemented with 100nM prostaglandin E1 (PGE1) and 0.02U/ml 
apyrase (Grade VII), and centrifuged at 600g for 10 minutes with brake at room temperature. 
The pellet was resuspended in HBS as washed platelets, counted using a Coulter counter 
(Beckman Coulter), and adjusted to the appropriate concentrations for specific experiments. 
Platelets were rested at 30ºC for 30 minutes prior to stimulation or treatment with inhibitors. 
Calcium chloride (2mM) was added immediately prior to stimulation (Figure 2.1). 
 
Several reagents were used to prevent platelet activation in the process of isolation from 
whole blood. Both sodium citrate and ACD act as anti-coagulants by the action of citrate ion, 
which chelates free ionised calcium and thus makes Ca2+ unavailable to the coagulation 
system. Apyrase is a highly active enzyme that catalyses hydrolysis of ATP and ADP into AMP. 
By breaking down ADP, it prevents activation of platelets via the purinergic receptors P2Y1, 
P2Y12 and P2X1 (Mans et al., 1998). This also prevents desensitisation of these receptors 
during platelet activation. PGE1 stimulates adenylyl cyclase (AC) activity and increases cyclic 
AMP (cAMP) concentrations, which inhibits the Ca2+ mobilisation and platelet aggregation 
induced by P2Y1 receptor activation (Kreutz et al., 2013). 
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Figure 2.1: Preparation of washed platelets 
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2.2. Flow cytometry 
Platelets (5 × 107 per ml) were rested at 30ºC for 30 minutes, followed by treatment with 
agonists or inhibitors, as described in Chapters 3 to 6. Samples (10μl) were then stained with 
the appropriate dyes or conjugated antibodies (40μl in total) for 3 minutes (Table 2.1), fixed 
by paraformaldehyde (PFA; 1%; 250μl) and diluted by half in HBS. In most experiments, 
platelets were stained with Annexin V FITC to detect exposed phosphatidylserine (PS) and 
with anti-human CD41a PE-Cy7 to distinguish platelet-derived events (Figure 2.2A). CaCl2 
(2mM) was present during staining even if not present during stimulation. 
 
Samples were acquired using a BD Accuri C6 flow cytometer at medium speed: flow rate 35μl 
per minute and core size 16μm. Forward scatter (FSC) and side scatter (SSC) of light were set 
in logarithmic scales, and the ﬂuorescence channels were set in logarithmic gain. The 1μm 
gate was set in FSC using 1μm silicon dioxide beads (1 in 100,000). Event acquisition was 
triggered by the PE-Cy7 fluorescence of anti-human CD41a on channel FL3. The PS-binding 
protein, Annexin V (AnxV), was conjugated to FITC, so its fluorescence was reflected on 
channel FL1. Platelets were defined as events larger than 1μm positive for CD41a, whereas 
platelet-derived microparticles (PMPs) were defined as events smaller than 1μm positive for 
both CD41a and Annexin V (Figure 2.2A). Microparticle count was expressed as microparticle 
per platelet (PMP/PLT). This approach allowed comparison between individual experiments, 
as more platelets would inherently produce more PMPs. 
 
Table 2.1: Conjugated antibodies or fluorescent dyes used for flow cytometry. 
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A more refined analysis of PMP release and platelet activation was enabled by fluorescently 
labelled markers. In CD41a +ve events smaller than 1μm, stimulation of platelets with A23187 
was accompanied by an increase in the count of AnxV-positive events, i.e. PMPs (Figure 2.2B). 
Platelets expose PS on the surface when they are activated, so Annexin V can be used as an 
index for platelet activation. Resting platelets were AnxV-negative. When stimulated by 
A23187, platelets became activated and AnxV-positive (Figure 2.2C). PS exposure was 
expressed as percentage of events positive for AnxV binding in the platelet population. 
 
Figure 2.2: Detecting platelets and PMPs with flow cytometry 
(A) Platelets are 1 to 3μm in diameter and they express CD41a molecules on their surface. 
CD41a can be detected by binding of a fluorescently-conjugated anti-human CD41a antibody. 
PMPs are 0.1 to 1μm in diameter, and they express CD41a and PS on their surface. PS can be 
detected by binding of fluorescently conjugated Annexin V molecules. The number of events 
counted by flow cytometry was an underestimate of the total number of microparticles, as 
only the largest EVs were predominantly acquired. (B) A23187-induced microparticle release 
(red) compared to resting state (black) reflected on FL1. All events in this plot are <1μm and 
positive for CD41a. (C) A23187-induced activation of platelets and PS exposure on surface of 
platelets (red) compared to resting state (black) reflected on FL1. All events in this plot 
are >1μm and positive for CD41a. 
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2.3. Confocal microscopy of filipin-stained platelets 
Fresh stocks of 50mM methyl-β-cyclodextrin (MβCD) in HBS and 50mM alpha-cyclodextrin 
(αCD) in HBS were prepared before each experiment. Platelets were diluted 4:1 or 1:1 with 
50mM cyclodextrin to achieve a final concentration of 10mM or 25mM, or HBS was added 
alone as vehicle, followed by incubation at 30ºC for 30 minutes.  
 
Platelets (5 × 107 per ml) treated with αCD, MβCD or vehicle were fixed with 1% PFA, washed 
by centrifugation (600g, 10 minutes) and resuspended in 250μl phosphate buffered saline 
(PBS). Fixed platelets were then adhered to coverslips coated with 10μg/ml poly-L-Lysine 
overnight at 4ºC. After one gentle wash with PBS, platelets attached to coverslips were stained 
with 50μg/ml filipin in PBS containing 33% (v/v) fetal calf serum (FCS) for 2 hours at room 
temperature in the dark. Coverslips were washed gently again with PBS, before being 
mounted onto glass plates using Fluoromount-G (Figure 2.3). 
 
Images were taken using a Leica SP5 confocal microscope, objective 63x oil, 405nm excitation 
and 411nm - 505nm emission. For quantitative analysis of platelets stained with filipin, images 
were obtained under identical conditions: smart gain 1142.0V, smart offset 0.6%, pinhole 
90.00μm and 405nm laser 15%. Average intensity of fluorescence per platelet was measured 
and calculated using Fiji (Schindelin et al., 2012). 
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Figure 2.3: Fluorescence imaging of filipin-stained platelets by confocal microscopy 
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2.4. Western blotting 
2.4.1. Cell culture for positive controls 
HeLa cells were maintained as monolayer cultures grown at 37ºC in a moist atmosphere 
containing 5% CO2 in 75cm cell culture flasks. The growth medium was Dulbecco’s Modified 
Eagle Medium (DMEM) with 4.5g/L D-glucose, supplemented with FCS (10% v/v) and 
penicillin-streptomycin (1% v/v). HeLa cells were passaged every three days with a split ratio 
of 1:4. After reaching 90% confluency, HeLa cells were harvested by treating with 0.5mM 
EDTA and trypsin. Washed once with PBS, HeLa cell suspension was centrifuged (600g, 5 
minutes, room temperature) to obtain pellets, which were then lysed for Western blot. 
 
2.4.2. Collection of cell lysates 
Western blot was performed on washed platelets (5 × 108 per ml), HeLa cells harvested from 
cell culture and human umbilical vein endothelial cells (HUVECs) gifted by Dr Bonita Apta. Cell 
pellets were lysed with radioimmune-precipitation assay (RIPA) lysis buffer (100mM Tris, 2% 
Triton X-100, 0.2% sodium dodecyl sulphate, 1% sodium deoxycholate, 300mM NaCl, pH 8.0) 
containing a protease inhibitor cocktail (PIC; 1% v/v) and 100mM dithiothreitol (DTT). Lysed 
pellets were incubated at 4ºC for 30 minutes with agitation by vortex, followed by 
centrifugation at 17,000g for 10 minutes to pellet membrane proteins. The supernatant was 
collected as cell lysate. 
 
2.4.3. Protein assay 
Bovine serum albumin (BSA) standards were prepared from 1.4 to 0mg/ml as serial dilution in 
dH2O. Bradford reagent (250μl) was added to BSA standards (5μl) at each concentration and 
diluted samples of cell lysates (5μl), prior to incubation with gentle agitation for 10 minutes at 
room temperature. Protein absorbance was measured at 595nm by a Clariostar Microplate 
Reader (BMG Labtech). Standard curve of absorbance versus protein concentration was 
plotted by linear regression. Concentrations of proteins were calculated from the standard 
curve. 
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2.4.4. Gel electrophoresis and protein transfer 
Cell lysates containing 20μg protein were electrophoresed on 6 to 16% polyacrylamide gels 
(Table 2.2) at 200V in the running buffer (19mM glycine, 25mM Tris, 0.1% SDS). Proteins were 
transferred from gels onto 0.45μm polyvinylidene difluoride (PVDF) membranes at 4ºC for 1 
hour at 100V in the transfer buffer (19mM glycine, 25mM Tris, 20% v/v methanol).  
 
Table 2.2: Formula for poly-acrylamide gels. The percentage of separating gels was selected 
according to the size of the protein of interest. Stacking gel was layered on top of separating 
gel. Into the wells of stacking gels, PageRuler protein ladder (5μl) was loaded to the first lane. 
The remaining lanes (20μl per well) were loaded with cell lysates (20μg protein per well) 
mixed 3:1 with NuPAGE LDS loading buffer. 
 
2.4.5. Treatment with antibody and membrane development 
Membranes were blocked with non-fat powdered milk or BSA (5% w/v) in Tris-buffered 
saline-Tween (TBS-T; 137mM NaCl, 20mM Tris, 0.1% Tween-20, pH 7.6) for 1 hour at room 
temperature, incubated overnight at 4ºC with the appropriate primary antibody (Table 2.3), 
and washed three times with TBS-T. To detect the primary antibody, membranes were 
incubated for 1 hour at room temperature with horseradish peroxidase (HRP)-conjugated anti- 
rabbit IgG (7074, Cell Signaling Technology; CST) or anti-mouse IgG (7076, CST), again washed 
three times with TBS-T. To visualise the blot, membranes were incubated for 5 minutes with 
SuperSignal Chemiluminescent Substrate and developed using OptiMax X-ray film processor 
(Protec Medizintechnik) or GeneGnome XRQ (Syngene Bio Imaging). Quantification of blots, 
when required, was performed using Fiji (Schindelin et al., 2012). 
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Table 2.3: Antibodies used for Western blotting and their optimal dilutions. Membranes were 
incubated with primary antibodies at 4ºC overnight and secondary antibodies at room 
temperature for 1 hour. 
 
2.5. Fluorescence measurements by microplate reader 
For measuring cytosolic Ca2+ concentration, PRP was loaded with 500nM Cal520 by 
incubation with Cal520 AM for 10 minutes. Washed platelets (5 x 107 per ml) were added 
into black 96-well plates for 150μl per well. Cal520 was excited at 492nm and fluorescence 
emission was detected at 520nm on FLUOstar Omega (BMG Labtech). Fluorescence was 
normalised to the initial fluorescence intensity of unstimulated vehicle control (F/F0). Area 
under curve (AUC) for the Ca2+ trace above basal was calculated. 
 
For measuring cytosolic pH, PRP was loaded with 1μg/ml 2’, 7’-Bis-(2-Carboxyethyl)-5-(and-6) 
-Carboxyfluorescein (BCECF) by incubation with BCECF AM for 30 minutes. Washed platelets 
(5 x 107 per ml) were added into black 96-well plates for 150μl per well. BCECF was excited at 
485nm and fluorescence emission was detected at 520nm on FLUOstar Omega (BMG 
Labtech). Fluorescence was normalised to the initial fluorescence intensity of untreated 
control (F/F0).  
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2.6. Transmission electron microscopy 
Suspensions of platelets and microparticles were centrifuged to pellet platelets at 600g for 
10 minutes at room temperature. Microparticle-rich supernatant was absorbed onto glow- 
discharged carbon film-coated 400 mesh copper grids for 3 minutes, washed twice with 
distilled water, allowed to dry at room temperature, and negatively-stained with uranyl 
acetate  (3% w/v in dH2O) for 30 seconds. Imaging was performed using a Tecnai G2 
transmission electron microscope at the Cambridge Advanced Imaging Centre (Figure 2.4). 
 
Figure 2.4: Sample preparations for transmission electron microscopy 
 
2.7. Data Analysis 
Data were reported as mean +/- standard error of mean (SEM) from at least 5 independent 
experiments, unless otherwise specified for preliminary experiments. Data were compared 
by t-test, Mann-Whitney U test, one-way or two-way ANOVA, followed by Tukey’s or 
Dunnett’s multiple comparisons test, as appropriate. Concentration-response curves were 
fitted using a four-parameter logistical equation and compared by extra-sum-of-squares F 
test, where appropriate, in GraphPad Prism v6. 
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2.8. Sources of reagents 
 
Chemical, Drug or Solution Supplier Code 
2-APB Cayman Chemicals 64970 
A23187 Sigma Aldrich C7522 
ABT-199 Selleck Chemicals S8048 
ABT-263 Selleck Chemicals S1001 
ABT-737 Selleck Chemicals S1002 
Acrylamide Severn Biotech 20-2100-05 
ADP Sigma Aldrich A2714 
Alpha cyclodextrin Sigma Aldrich C4642 
Amitriptyline Sigma Aldrich A8404 
Ammonium chloride Sigma Aldrich A4514 
Amphotericin B Sigma Aldrich A9528 
APS Honeywell Fluka 248614 
Apyrase, grade VII Sigma Aldrich A6535 
Aspirin Sigma Aldrich A5376 
AT101 Selleck Chemicals S2812 
BAM7 Selleck Chemicals S7105 
BAPTA AM Invitrogen B1205 
BCECF AM Invitrogen B3051 
Bradford reagent Sigma Aldrich B6916 
BSA Sigma Aldrich A7906 
Cal520 AM AAT Bioquest 21130 
Calcium chloride Sigma Aldrich 21115 
Calpeptin Sigma Aldrich C8999 
Cangrelor Selleck Chemicals S3737 
Carbenoxolone Sigma Aldrich C4790 
Choline chloride Sigma Aldrich C1879 
CID-1067700 Cayman Chemicals 15194 
Citric acid Sigma Aldrich C1909 
CMAC, t-BOC-Leu-Met Thermo Fisher A6520 
Complement C5b, 6 CompTech A122 
Cyclosporin A LKT Labs C9611 
D-glucose Fisher Scientific G/0500/53 
Digitonin Calbiochem 300410 
Diphenhydramine Sigma Aldrich D3630 
DMBA Sigma Aldrich 473782 
DMEM Sigma Aldrich D6406 
DMSO Sigma Aldrich D2650 
DP3A Sigma Aldrich 43163 
DPBA Sigma Aldrich 358835 
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Chemical, Drug or Solution Supplier Code 
DPTHF Sigma Aldrich S408271 
DTT Sigma Aldrich D9779 
E64 Sigma Aldrich E3132 
EDTA Sigma Aldrich E8008 
FCS Sigma Aldrich F2442 
Filipin Sigma Aldrich F9765 
Gap27 Tocris 1476 
Glycine Sigma Aldrich G7126 
GSK429286 Tocris 3726 
GW4869 Cayman Chemicals 13127 
HA14-1 Selleck Chemicals S1071 
HCl Fisher Scientific H/1200/PB08 
HEPES Sigma Aldrich H3375 
High Range Protein Ladder Thermo Fisher 26625 
Histone H4 New England Biolabs M2504S 
KCl Sigma Aldrich P3911 
KH2PO4 Fisher Scientific P/4800/53 
Mdivi-1 Sigma Aldrich M0199 
Methyl beta cyclodextrin Sigma Aldrich M7439 
MgCl2 Sigma Aldrich M2670 
NaCl Sigma Aldrich S7653 
NaH2PO4 Acros 207802500 
NaOH Alfa Aesar J63736 
NMDG Acros 126845000 
NuPAGE LDS sample buffer (4X) Thermo Fisher NP0008 
Nystatin Sigma Aldrich N6261 
OAG Sigma Aldrich O6754 
10Panx Tocris 3348 
PBA Sigma Aldrich 78181 
PBS tablet Sigma Aldrich P4417 
Penicillin-Streptomycin Sigma Aldrich P4333 
Pepstatin A Sigma Aldrich P5318 
PFA, 4% in PBS Alfa Aesar J61899 
PGE1 Santa Cruz sc-201223 
Poly-L-lysine Sigma Aldrich P6282 
Pre-stained Protein Ladder Thermo Fisher 26619 
Probenecid, water soluble Thermo Fisher P36400 
Protease Inhibitor Cocktail Sigma Aldrich P2714 
Quinine hydrochloride Sigma Aldrich Q1125 
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Table 2.4: Sources of all chemicals, drugs and solutions. 
 
 
 
 
 
 
 
 
 
Chemical, Drug or Solution Supplier Code 
Q-VD-OPh Sigma Aldrich SML0063 
R5421 EndoTherm ENG071 
Sabutoclax Selleck Chemicals S8061 
SAR7334 Tocris 5831 
SDS Fisher Scientific S/5200/53 
SFLLRN (TRAP6 amide) Bachem H-2936 
SN-6 Tocris 2184 
Sodium deoxycholate Sigma Aldrich D6750 
Sodium propionate Alfa Aesar A17440 
Streptolysin O Sigma Aldrich S5265 
Western Blot Stripping buffer Thermo Fisher 46430 
SuperSignal Chemiluminescent Substrate Thermo Fisher 34077 
Synta66 Sigma Aldrich SML1949 
TEMED Sigma Aldrich T9281 
TEA chloride Sigma Aldrich T2265 
Thrombin Sigma Aldrich T7513 
TMA chloride Sigma Aldrich T19526 
Tris base Sigma Aldrich T1503 
Tris HCl Sigma Aldrich T3253 
Tri-sodium citrate Sigma Aldrich 71405 
Triton X-100 Sigma Aldrich T9284 
Trypsin Gibco 25200-056 
TW-37 Selleck Chemicals S1121 
Tween-20 Santa Cruz sc-29113 
Y27632 Sigma Aldrich Y0503 
Zymosan A Sigma Aldrich Z4250 
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Chapter 3 Detection of platelet-derived microparticles 
3.1. Aim of study 
About 75% of laboratories apply flow cytometry to detect small vesicles in experimental and 
clinical samples, but the method varies greatly depending on specific subjects (Lacroix et al., 
2010). In this chapter, an assay was developed and optimised for detecting platelet-derived 
microparticles by flow cytometry.  
 
3.2. Calibration beads 
The 1μm standard is set by calibration beads, which requires optimisation due to the nature 
of flow cytometry. When a laser beam is directed at a particle or an aggregate of particles, it 
changes direction and scatters. Forward scattered light provides estimation about the size, 
while side scattered light provides information about the internal structure, i.e. granularity 
(Kim and Ligler, 2010). Refractive indices (RI) determine the scatter profiles of different cells 
and particles. Although calibrated at 1μm, polystyrene beads (RI = 1.598) show larger FSC 
values than silicon dioxide beads (RI = 1.459) in a flow cytometer (Figure 3.1A-B). Silicon 
dioxide beads are a better option for PMP studies, because the RI is closer to that of blood- 
borne EVs (RI = 1.398), though it may still be an overestimate (Gardiner et al., 2014). It 
contradicts the conventional microparticle counting method where the 1μm gate is set by 
polystyrene beads (Chandler et al., 2011; Nielsen et al., 2014; Kong et al., 2015). 
 
The use of silicon dioxide beads was further justified by real-time acquisition of PMP release. 
Platelets are larger than 1μm at resting state. Upon addition of the stimulus A23187, 
platelets appear to shrink and produce smaller vesicles. This “shrinking” may be a reduction 
in size or a change in refractive index. Some “shrunken” platelets were grouped as <1μm 
when polystyrene beads were used, and they would be mistaken as PMPs (Figure 3.1C). On 
the contrary, shrunken platelets were still grouped as >1μm when silicon dioxide beads were 
used (Figure 3.1D). Consequently, using 1μm polystyrene beads would lead to a false 
increase in the PMP count, which was expressed as PMP per platelet. 
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Figure 3.1: Optimisation of calibration beads 
(A-B) Flow cytometry density plots of calibration beads with size reflected on forward scatter 
(FSC). (A) 1μm polystyrene beads (original density 10%; diluted in HBS 100,000 times). (B) 
1μm silicon dioxide beads (original density 5%; diluted in HBS 100,000 times). Three spots of 
high density were seen. The lowest (with FSC-A between 1 x 104 and 2 x 104) represents 
single beads, whereas those with higher FSC-A represent more than one bead together. (C-D) 
Washed platelets (5 x 106 per ml) were stimulated with 10μM A23187 as indicated by the 
black arrows. Events were recorded in real time with size set by 1μm polystyrene beads in (C), 
and 1μm silicon dioxide beads in (D). These plots are scaled on time vs. FSC-A. These plots 
are representative of data from 5 different donors. 
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3.3. Fluorescence triggering 
It is common practice in flow cytometry to use a trigger to identify and differentiate events 
of interest from debris and machine noise. Also known as the discriminator, the trigger is 
traditionally based on a FSC threshold (Boeck, 2001). However, light scattering is not the only 
option when a trigger is needed. There are situations where fluorescence might be a more 
reliable trigger, such as sorting minor sub-populations of cells (McCoy et al., 1991), detecting 
rare events (Rehse et al., 1995) and studying cell-derived EVs in the plasma (Arraud et al., 
2016). Both platelets and PMPs stain positive for anti-human CD41a PE-Cy7, so PE-Cy7 
fluorescence on channel FL3 can be used as the trigger to distinguish platelets and PMPs 
from background. 
 
Size- and fluorescence-based triggers were compared. Platelets samples (unstimulated and 
A23187-stimulated) were triggered on size (FSC-H > 5,000) or PE-Cy7 fluorescence (FL3-H > 
2,000), so events lower than a certain FSC or FL3 value were not detected. When an 
unstimulated sample was triggered on FL3 threshold, a high proportion of events were in 
the >1μm area (i.e. platelets) and few were in the <1μm area (i.e. PMPs). In contrast, a large 
number of events negative for CD41a fluorescence were detected in the <1μm area (i.e. 
debris or machine noise) when the same unstimulated sample was triggered on FSC 
threshold. It was similar for A23187-stimulated platelets, as more PMPs could be detected 
with less debris in the background when the same sample was triggered on FL3 rather than 
FSC threshold (Figure 3.2). Therefore, triggering on anti-human CD41a PE-Cy7 fluorescence 
on channel FL3 was a more suitable option for detecting platelets and PMPs. 
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3.4. Swarm detection 
When poly-disperse samples are presented to a flow cytometer, a count can be generated by 
one large particle or a collection of small particles (i.e. swarm). Swarm detection occurs if the 
power of light scattered by small particles that are simultaneously present in the laser beam 
exceeds the detection limit (van der Pol et al., 2012). If every detected event represents one 
particle, the count determined by flow cytometry would be equal to the real count. A linear 
relationship can be obtained between the acquired count and the dilution factor on a 
logarithmic scale. In other words, a 1/2 dilution of the sample would result in a 50% 
reduction in particle count. However, neither the microparticle count nor the platelet count 
was halved when a representative sample of activated platelets and PMPs was diluted by half. 
The count determined by flow cytometer was an underestimation, and it produced a 
non-linear relationship on logarithmic scale. This slope turned linear and parallel to the 
theoretical line when the sample was diluted from 1/2 to 1/4 or 1/8 (Figure 3.3). Therefore, 
under our conditions, platelet samples needed to be diluted at least in half before 
acquisition on the flow cytometer to prevent swarm detection. In this way, a more accurate 
count for both platelets and PMPs could be obtained. 
 
Figure 3.3: Swarm detection 
A sample of A23187-stimulated platelets and PMPs was fixed by 1% PFA, diluted from 1/1 to 
1/8, and acquired by flow cytometry. Changes in the microparticle count and the platelet 
count were plotted against the dilution factor, highlighting differences between the 
theoretical trend and the real trend captured by flow cytometry. Both axes are set on 
logarithmic scales. Results are representative of data from 5 different donors. 
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3.5. Optimised method for detecting platelet-derived microparticles 
Microparticle release was triggered by stimulating washed platelets with the Ca2+ ionophore 
A23187. Following stimulation and staining, samples of platelets and PMPs were fixed by 1% 
PFA and diluted by half. Acquisition was triggered on anti-human CD41a PE-Cy7 fluorescence 
and the 1μm size was defined by FSC values of 1μm silicon dioxide beads. Platelets exposed 
PS and released PS-positive PMPs in response to increasing concentrations of A23187 (Figure 
3.4).  
 
In an unstimulated sample, the majority of events were larger than 1μm and negative for PS 
exposure. The positive range for Annexin V FITC fluorescence was determined separately for 
each experiment, so that around 2% of the resting platelets were positive on FL1-A. When 
platelets were stimulated with a low concentration of A23187 (0.625μM), there was a 
moderate yet statistically significant increase in the number of events smaller than 1μm and 
the percentage of platelets positive for Annexin V binding. When scaled on FSC-A vs. FL1-A, 
unstimulated platelets (>1μm, PS negative) are in the lower right quadrant (LR), activated 
platelets (>1μm, PS positive) in the upper right quadrant (UR), and PMPs (<1μm, PS positive) 
in the upper left quadrant (UL). Almost all platelets became activated and exposed PS on the 
surface when they were stimulated with a high concentration of A23187 (10μM), which was 
accompanied by a large increase in the number of PMPs released (Figure 3.4). 
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Figure 3.4: Optimised method for detecting platelet-derived microparticles 
Washed platelets (5 x 107 per ml) were added with 2mM CaCl2 and stimulated with the 
indicated concentration of A23187 for 10 minutes, after which samples were stained with 
anti-human CD41a PE-Cy7 and Annexin V FITC to detect PS exposure on channel FL1. PE-Cy7 
fluorescence on FL3 was used to trigger acquisition of CD41a positive events. (Upper row) 
Histograms show the percentage of platelets (CD41a +ve, >1μm) positive for Annexin V 
binding on FL1-A, where resting platelets were arbitrarily determined as 2% positive for each 
individual experiment. (Lower row) Density plots show events scaled on FSC-A and FL1-A. 
The vertical line separating left and right was defined by FSC-A values of 1μm silicon dioxide 
beads. The line separating top and bottom was defined by Annexin V FITC fluorescence. 
Unstimulated platelets have high FSC values and low Annexin V binding (lower right quadrant, 
LR). Stimulation with A23187 triggered PS exposure in platelets (upper right quadrant, UR) 
and release of Annexin V-positive PMPs (upper left quadrant, UL). These plots are 
representative of data from 5 different donors. 
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3.6. Microparticle release can be triggered from platelets by multiple stimuli 
Microparticle release can be triggered from human platelets in response to Ca2+ ionophore 
A23187 (Figure 3.4) or thrombin plus collagen-related peptide (CRP). These agonists mimic 
the pro-coagulant stimulation of platelets in vivo, which is associated with a large increase in 
the intracellular Ca2+ concentration and its downstream activation of calpain (Yano et al., 
1993). In this experimental system, A23187 triggered PMP release and PS exposure on the 
surface of platelets in a concentration-dependent manner (Figure 3.5A-B). For PMP release, 
the maximum response was 0.28 ± 0.04 PMP/PLT (Mean ± SEM; n = 5) and EC50 was 1.20μM. 
For PS exposure, the maximum response was almost 100% and EC50 was 1.54μM.  
 
Apart from pro-coagulant stimuli, the bacterial toxin streptolysin O (SL-O) triggers PMP 
release. SL-O is a subtype of streptolysin, which is a haemolytic exotoxin derived from 
Streptococcus. In its active reduced form, SL-O permeabilises platelets, allows influx of Ca2+ 
into the cytosol, and activates Ca2+- and calpain-dependent responses such as the release of 
α-granules (Flaumenhaft et al., 1999; Rozenvayn and Flaumenhaft, 2001). Similar to A23187, 
SL-O triggered PMP release and PS exposure in a concentration-dependent manner in the 
presence of extracellular Ca2+ (Figure 3.5A-B). For PMP release, the maximum response was 
0.16 ± 0.01 PMP/PLT (Mean ± SEM; n = 5), which was slightly lower than the maximum 
capacity of A23187. The EC50 was 89.4U/ml. For PS exposure, the maximum response was 
almost 100%, with its EC50 at 89.4U/ml. 
 
In addition to thrombin, collagen and bacterial toxins, platelets might encounter histones in 
the blood circulation. Normally bound to DNA molecules in the nucleus, histones are 
released from necrotic cells and activated immune cells during infection such as neutrophils 
(Beaulieu and Freedman, 2011). Histone H4 has been found to directly activate platelets 
leading to thrombosis (Fuchs et al., 2011), or indirectly increase pro-coagulant activities by 
interacting with platelet-derived polyphosphates (Semeraro et al., 2011). When platelets 
were treated with histone H4, there was a concentration-dependent increase in PS exposure 
on the surface, which confirmed the direct activating effect histone H4 had on platelets. The 
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maximum response was almost 100% and the EC50 was 15.9μg/ml (Figure 3.5B). On the 
other hand, histone H4 triggered the release of a huge number of EVs that were positive for 
CD41a, without reducing the platelet count (Figure 3.5C). On average, each platelet released 
5.27 ± 0.39 EVs in response to 40μg/ml Histone H4, and only 1.20 ± 0.26 of these EVs were 
positive for Annexin V (Figure 3.5A; Mean ± SEM; n = 5). It suggested that a majority of the 
EVs released from PS-positive platelets did not expose PS, so they were not classified as 
PMPs. The identity of these Annexin V-negative EVs remains unclear. 
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Figure 3.5: Microparticle release can be triggered from platelets by multiple stimuli 
Washed platelets (5 x 107 per ml) were added with 2mM CaCl2 and stimulated with A23187 
(up to 10μM), SL-O (up to 1000U/ml), or histone H4 (up to 40μg/ml) for 10 minutes, after 
which samples were stained with anti-human CD41a PE-Cy7 and Annexin V FITC. Prior to 
stimulation, concentrated SL-O stock at 10kU/ml was reduced by 5mM DTT. (A) Microparticle 
release in response to A23187, SL-O or histone H4 was measured as described in Figure 3.4 
(Mean ± SEM; n = 5). (B) PS exposure in response to A23187, SL-O or histone H4 was 
measured as described in Figure 3.4 (Mean ± SEM; n = 5). (C) Density plots of platelets 
stimulated with 10μM A23187, 1000U/ml SL-O and 40μg/ml histone H4. Quadrants are 
defined as in Figure 3.4, with Annexin V FITC fluorescence on FL1-A. These plots are 
representative of data from 5 different donors. 
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3.7. Various stimuli triggering microparticle release from platelets have differential effects 
on plasma membrane integrity 
Ca2+ ionophore A23187, bacterial toxin SL-O and histone H4 were tested for their effects on 
platelet viability. Calcein was used to detect cell viability by measuring integrity of the 
plasma membrane. In its acetoxymethyl (AM) ester form, non-fluorescent calcein AM readily 
penetrates the plasma membrane due to its hydrophobic nature. After hydrolysis of AM by 
intracellular esterases, calcein cannot penetrate the plasma membrane, so it is retained in 
the cytoplasm in its green fluorescent form, which can be detected on channel FL1 of flow 
cytometry. Loss of calcein fluorescence from the platelet population indicates leakage of 
calcein via the plasma membrane into the surroundings, and thus loss of plasma membrane 
integrity. 
 
After loading calcein into PRP for 10 minutes, excess calcein in the plasma was removed by 
discarding the supernatant after the second centrifugation spin during platelet isolation 
(Figure 2.1). Washed platelets loaded with calcein were stimulated with A23187, SL-O or 
histone H4 in the presence of Ca2+ at their respective concentrations that triggered maximal 
PMP release and PS exposure. Compared to unstimulated control (0.62 ± 0.06%; Mean ± 
SEM; n = 5), neither 10μM A23187 (1.29 ± 0.43%; Mean ± SEM; n = 5) nor 40μg/ml histone 
H4 (1.96 ± 0.35%; Mean ± SEM; n = 5) significantly increased the percentage of platelets 
negative for calcein fluorescence (Figure 3.6A-B), so A23187 and histone H4 did not affect 
platelet viability. By contrast, SL-O at 1000U/ml almost completely permeabilised the entire 
platelet population (94.2 ± 1.01%; Mean ± SEM; n = 5; Figure 3.6A-B). EC50 of this 
concentration-dependent effect was 268U/ml (Figure 3.6C). 
 
Based on the results, A23187 was the most suitable stimulus for PMP release for two reasons. 
Firstly, most of the EVs released in response to A23187 exposed PS, as they were positive for 
Annexin V binding. Secondly, treatment with A23187 did not affect platelet viability, since 
membrane integrity was not compromised. 
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Figure 3.6: Various stimuli triggering microparticle release from platelets have differential 
effects on plasma membrane integrity 
PRP was loaded with 1μM calcein for 10 minutes. Calcein-loaded washed platelets (5 x 107 
per ml) were treated as indicated and stained with anti-human CD41a PE-Cy7, fluorescence 
of which was used to trigger acquisition of CD41a positive events. All samples were acquired 
live on flow cytometry. (A) Histograms show the percentage of platelets (CD41a +ve, >1μm) 
negative for calcein on FL1-A. (B) Percentage of platelets negative for calcein following 
stimulation with 10μM A23187, 1000U/ml SL-O, or 40μg/ml histone H4 for 10 minutes 
(Mean ± SEM; n = 5; **** p < 0.0001, ns: not significant, compared to unstimulated control). 
(C) Percentage of platelets negative for calcein following stimulation with SL-O (up to 
1000U/ml) for 10 minutes (Mean ± SEM; n = 5). 
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3.8. Influx of sodium ions is not required for A23187-triggered microparticle release 
The optimised PMP detection and counting method was used to test whether influx of Na+ 
was involved in PMP release. When microparticles are released from platelets, outward 
blebbing of the plasma membrane requires calpain-dependent cleavage of the cytoskeleton 
(Yano et al., 1993). It was hypothesised that Na+ entry into platelets, possibly coupled to Cl- 
influx and then water entry, might provide the hydrostatic pressure, which could be 
mediated by an elevation in intracellular Ca2+ level. A23187 was used to cause this elevation 
without compromising membrane integrity. 
 
To study if Na+ influx is involved in PMP release, Na+ was replaced with alternative 
monovalent cations. The substitute ion needed to be significantly larger than Na+, so that it 
could not permeate most of the known Na+ channels on the plasma membrane. Several 
types of organic cations have been used to replace Na+ or K+ in platelet studies. These 
include N-methyl D-glucamine (NMDG) (Kimura et al., 1993; Harper et al., 2010), choline 
(Lingjaerde, 1969) and tetra-methyl ammonium (TMA) (Kashiwagi et al., 1997). 
  
The normal reference range of plasma Na+ concentration in human blood is between 
135mM and 145mM (Hoorn and Zietse, 2017). In this experimental system, 135mM 
extracellular Na+ was present in HEPES-buffered saline (HBS) in the form of NaCl. To replace 
NaCl, the alternative saline contained 135mM choline chloride, TMA chloride or NMDG 
chloride. As NMDG chloride was not commercially available, NMDG-based HBS was titrated 
with 135mM HCl to compensate for Cl-. In addition, phosphorous is present in the blood at a 
low concentration in the form of inorganic phosphates (Bansal, 1990). Phosphate was 
present in HBS as NaH2PO4. It was replaced by equimolar KH2PO4 in NMDG-, choline-, or 
TMA-based HBS (Table 3.1). 
 
Different forms of HBS were used throughout the experiment to ensure depletion of 
extracellular Na+. Reagents were reconstituted or diluted in specific forms of HBS for each 
monovalent cation, including CaCl2, A23187, the Annexin V FITC plus anti-human CD41a 
PE-Cy7 staining buffer, and PFA. The only exceptions were the anti-coagulant reagents 
65 
 
sodium citrate and ACD (Figure 2.1). Na+ present in whole blood was later removed by two 
centrifugation steps during isolation and preparation of washed platelets. Dilution of PRP 
and re-suspension of the platelet pellet were both conducted in Na+-free HBS.  
 
Platelets prepared and incubated in Na+-free HBS were stimulated with A23187 for 10 
minutes. PMP release, along with PS exposure, was almost completely abolished when Na+ 
was replaced by equimolar NMDG. However, there was no significant inhibition or 
enhancement for PMP release or PS exposure in platelets incubated in choline- or 
TMA-based HBS compared to the conventional Na+-based HBS (Figure 3.7A). Since 
substitution of Na+ by choline or TMA did not affect PMP release, it is most likely that 
membrane blebbing for PMP release does not require locally increased hydrostatic pressure 
driven by influx of Na+ and Cl-.  
 
NMDG-dependent inhibition of PMP release could be attributed to lower levels of PS 
exposure in the released EVs, rather than direct inhibition of EV release. When platelets in 
NMDG- or choline-based HBS were stimulated with the same concentration of A23187 
(10μM), the number of EVs released, regardless of Annexin V staining, was similar. However, 
Annexin V binding was much lower for both A23187-stimulated platelets and platelet- 
derived EVs when platelets were incubated in NMDG-based HBS compared to those 
incubated in choline-based HBS (Figure 3.7A).  
 
It was not clear why Annexin V binding was low in NMDG-based HBS. CaCl2 was added to 
platelets prior to activation, which was confirmed by the release of EVs upon A23187 
stimulation (Figure 3.7B). Na+ was not indispensable to Annexin V binding, as it was not 
affected in choline- or TMA-based HBS (Figure 3.7A). In addition, Annexin V binding to 
heat-killed platelets was not affected in NMDG-based HBS. After platelets were killed by two 
cycles of 5 minutes’ heating at 95ºC, membrane fluidity was increased, so Annexin V 
molecules could bind to PS distributed at the inner membrane leaflet of heat-killed platelets 
incubated in NMDG-based HBS (Figure 3.7C). However, Annexin V did not bind to surfaces of 
stimulated platelets or platelet-derived EVs that supposedly exposed PS. 
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Table 3.1: Na+ replacement. (A) Chemical Structures of NMDG, choline and TMA. (B) Recipe 
for different types of HBS. For every litre of NMDG-based HBS, 11.12 ml of HCl (37.5%) was 
added to compensate for Cl-. To reach final pH of 7.40, NaOH was used to titrate for 
Na+-based HBS, while KOH was used for Na+-free HBS. 
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Figure 3.7: Influx of sodium ions is not required for A23187-triggered microparticle release 
Washed platelets (5 x 107 per ml) were incubated in different types of HBS as indicated. (A) 
A23187-triggered PMP release and PS exposure were measured as described in Figure 3.4 
(Mean ± SEM; n = 5). (B) Platelets incubated in NMDG- or choline-HBS were stimulated with 
10μM A23187. Density plots are defined as in Figure 3.4, with Annexin V FITC fluorescence 
on FL1-A. These plots are representative of data from 5 different donors. (C) Platelets 
incubated in different types of HBS were heat-killed and stained with Annexin V FITC. 
Percentage of platelets positive for Annexin V binding was measured (Mean ± SEM; n = 3). 
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3.9. Discussion 
In this chapter, an optimised assay for detecting PMPs was established. Samples were 
stained with fluorescently-conjugated Annexin V to detect PS exposure and anti-human 
CD41a PE-Cy7 to detect platelet-derived events. The 1μm gate was set by silicon dioxide 
calibration beads. To differentiate events of interest from debris and machine noise, events 
were triggered on PE-Cy7 fluorescence of anti-human CD41a. Samples were diluted by half in 
HBS before analysis using a flow cytometer, so that swarm detection could be prevented. 
PMPs were defined as events that were smaller than 1μm and Annexin V-positive. 
 
It needs to be acknowledged that the number of events seen by this approach is likely to be 
an underestimate of the total number of PMPs. Microparticles are a heterogeneous 
population of EVs with their diameters ranging from 100nm to 1μm (Raposo and Stoorvogel, 
2013). Flow cytometry can struggle to resolve the smaller EVs as it cannot detect particles 
with diameters lower than 488nm, which is the wavelength of the blue laser used to define 
FSC (Robert et al., 2009; van der Pol and Harrison, 2017). The model of flow cytometer used 
for experiments in this thesis was BD Accuri C6, which has been shown by other groups to 
have a limited resolution capacity (Cointe et al., 2017). Only the largest EVs were 
predominantly acquired. On the other hand, flow cytometry cannot detect exosomes formed 
by endocytosis into secretory granules and released by subsequent exocytosis, which are 
believed to be smaller than 100nm (van der Pol et al., 2016). All following experiments in 
Chapters 4 to 6 focused only on microparticle release from platelets and it does not involve 
any mechanistic details about exosome release. 
 
PMP release can be triggered in vitro by a few different types of stimuli. Compared to SL-O or 
histone H4, A23187 was a more suitable choice in this experimental system. The population 
of EVs released from platelets in response to histone H4 was not homogeneous in terms of 
Annexin V binding (and thus PS exposure), so it was not definitive whether these EVs could 
be classified as PMPs. On the other hand, EVs released in response to SL-O were Annexin 
V-positive, with flow cytometry profiles identical to PMPs released in response to A23187. 
However, SL-O was not relevant to physiological pro-coagulant stimulation as it compromised 
69 
 
cell viability and caused leakage of calcein. This result is consistent with a previous report 
where SL-O was used to introduce antibodies into the platelet cytosol (Flaumenhaft, 2004). 
 
As an example, the optimised PMP detection method was used to test whether ion influx 
mediates membrane blebbing for PMP release. Extracellular Na+ was replaced by equimolar 
NMDG, choline or TMA. A23187 was used to rapidly trigger an elevation in intracellular Ca2+ 
concentration and its downstream calpain activity without compromising plasma membrane 
integrity. The physiological agonist, thrombin plus CRP, would not be suitable for this 
experiment because the catalytic activity of thrombin is dependent on Na+ (Huntington, 
2008). Substitution of Na+ by organic monovalent cations did not significantly affect PMP 
release or PS exposure in response to A23187. These results ruled out the involvement of 
Na+ influx-mediated membrane blebbing in the process of PMP release. 
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Chapter 4 Lipid rafts 
4.1. Aim of study 
Cholesterol-rich lipid rafts provide a platform for coordinating signalling events in platelets 
and other cells (Sezgin et al., 2017). Lipid rafts are involved in the release of PS-exposing 
extracellular vesicles from other cardiovascular cells including monocytes (Del Conde et al., 
2005), endothelial cells (Burger et al., 2011) and erythrocytes (Salzer et al., 2002, 2008). In 
this chapter, it was investigated whether lipid rafts are required in PMP release. 
 
4.2. Methyl-β-cyclodextrin depletes cholesterol from the platelet surface 
To test whether lipid rafts are required for microparticle release, lipid rafts were disrupted by 
treating platelets with methyl-β-cyclodextrin (MβCD) which depletes cholesterol from the 
plasma membrane. Following treatment with MβCD, platelets were stained with a 
fluorescent dye filipin that binds to cholesterol with high affinity (Schnitzer et al., 1994; 
Maekawa and Fairn, 2014), before images were taken by confocal microscopy.  
 
The intensity of filipin fluorescence has been used to measure the cholesterol content on cell 
surfaces (Kenworthy et al., 2004; Goodwin et al., 2005). Results generated by this semi- 
quantitative approach were comparable to those obtained by gas chromatography (Qin et al., 
2006; Borisova et al., 2011). Filipin was only added after cells were fixed by PFA to prevent 
any potential damage to lipid rafts (Herbert et al., 2015; Son et al., 2015), as filipin itself 
might modify the cholesterol content of cell membranes (Ferraro et al., 2004). The 
concentration of filipin was optimised and set at 50μg/ml, which has been used on other cell 
lines (Halliday et al., 2005; Liu et al., 2014). 
 
 
 
 
 
 
71 
 
In previous studies, MβCD has been added to either washed platelet suspensions (Maurice 
et al., 2006; Manne et al., 2015) or platelet-rich plasma (PRP) to deplete cholesterol prior to 
isolation of washed platelets (Quinton et al., 2005; Quinter et al., 2007). Effects of these two 
strategies have not been directly compared, so a preliminary study was conducted where 
MβCD (10mM and 25mM) was added separately to PRP or washed platelets. Images were 
obtained under identical conditions, and platelets treated with MβCD showed lower levels of 
fluorescence intensity compared to control. When MβCD was added into PRP, filipin 
fluorescence of platelets was reduced to 41.0 ± 6.7% of matched controls by 10mM MβCD 
and 20.0 ± 2.7% of matched controls by 25mM MβCD (Figure 4.1; Mean ± SEM; n = 3). When 
MβCD was added into washed platelets, fluorescence of filipin was reduced to 45.8 ± 7.1% of 
matched controls by 10mM MβCD and 21.2 ± 3.3% of matched controls by 25mM MβCD 
(Figure 4.1; Mean ± SEM; n = 3). Therefore, there was no additional benefit of adding MβCD 
into PRP rather than washed platelets in terms of cholesterol depletion. 
 
Figure 4.1: Preliminary study for treating platelets with MβCD 
MβCD was added into PRP or washed platelets as indicated. Platelets (5 x 107 per ml) were 
treated with MβCD (10mM or 25mM) or vehicle (HBS) as control for 30 minutes, fixed with 
PFA (1%), and stained with filipin (50μg/ml). Filipin fluorescence was determined by confocal 
microscopy, objective 63x oil, excitation at 405nm, and emission from 411 to 505nm. Adding 
MβCD into PRP or washed platelets achieved similar effects in terms of reducing filipin 
fluorescence of platelets (Mean ± SEM; n = 3; * p < 0.05; ** p < 0.01, compared to matched 
vehicle controls). 
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A further experiment was performed by adding MβCD to washed platelets and 
α-cyclodextrin (αCD) was included as an additional control. While MβCD binds to and 
sequesters cholesterol in its hydrophobic core (Christian et al., 1997), the cavity of αCD is too 
small to accommodate a cholesterol molecule yet it retains many other properties of MβCD 
(Ohtani et al., 1989). Filipin fluorescence of platelets decreased following MβCD treatment in 
a concentration-dependent manner, to 51.4 ± 8.0% of matched controls by 10mM MβCD and 
to 30.2 ± 4.5% of matched controls by 25mM MβCD (Figure 4.2A; Mean ± SEM; n = 5). In 
contrast, αCD did not remove cholesterol from the platelet surface, as filipin fluorescence 
was at 96.5 ± 5.1% of matched controls (Figure 4.2A; Mean ± SEM; n = 5). This suggested that 
MβCD was both effective and specific in depleting cholesterol from the platelet membrane. 
By comparing fluorescence images to their differential interference contrast (DIC) 
counterparts, it was confirmed that filipin specifically adhered to the surface of platelets 
(Figure 4.2B). 
 
Figure 4.2: MβCD depletes cholesterol from the platelet surface 
(A) MβCD (10mM or 25mM), αCD (10mM) or vehicle (HBS) was added into washed platelets 
suspension (5 x 107 per ml) for 30 minutes. MβCD-treated platelets were fixed with PFA (1%) 
and stained with filipin (50μg/ml). Fluorescence was determined by confocal microscopy as 
described in Figure 4.1 (Mean ± SEM; n = 5; ** p < 0.01; *** p < 0.001; ns, not significant, 
compared to matched vehicle controls). (B) Representative DIC and fluorescence images of 
filipin-stained platelets were taken under identical conditions. 
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4.3. Cholesterol depletion prevents microparticle release from platelets 
Platelets were stimulated with various concentrations of A23187 and dose-response curves 
were plotted for PMP release and PS exposure. When platelets treated with MβCD (10mM or 
25mM) were stimulated with A23187, few PS-exposing PMPs were detected (Figure 4.3A). 
On the contrary, PS exposure in these platelets (>1μm, CD41a +ve) was not inhibited (Figure 
4.3B), which suggested that platelet activation and exposure of negatively-charged 
phospholipids were not affected. Consistent with this, there was no increase in Annexin V- 
negative vesicles (<1μm, CD41a +ve) in MβCD-treated platelet samples following A23187 
stimulation (Figure 4.3D). It indicated that the lack of PS-exposing PMPs in these samples 
resulted directly from inhibition of vesicle release, rather than inhibition of PS exposure 
(hence not detected as Annexin V-positive events). Meanwhile, αCD (10mM) had no effect 
on PMP release or PS exposure (Figure 4.3A-B). Since αCD can be used as control for any 
effect of MβCD independent of cholesterol (Zidovetzki and Levitan, 2007), inhibition of PMP 
release caused by MβCD could be attributed to cholesterol depletion from the platelet 
membrane. The inhibitory effect of MβCD for PMP release was concentration-dependent 
(Figure 4.3C).  
 
Flow cytometry can only detect the largest microparticles (between 488nm and 1μm), so a 
more sensitive method for detecting particles was required to confirm the flow cytometry 
data. In transmission electron microscopy (TEM), an image is formed when a beam of 
electrons is transmitted through a thin specimen and then focused to create an image on a 
screen or a film (Momen-Heravi et al., 2012). It offers a spatial resolution three orders of 
magnitude shorter than the wavelength of visible light, at around 0.5nm (Pisitkun et al., 
2004). Moreover, TEM has been widely used to characterise EVs (Baran et al., 2010; Miranda 
et al., 2010), including microparticles released from human platelets stimulated by thrombin, 
CRP or A23187 (Aatonen et al., 2014). 
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Figure 4.3: Cholesterol depletion prevents microparticle release from platelets 
Washed platelets (5 x 107 per ml) were treated with MβCD (10mM or 25mM), αCD (10mM) 
or vehicle (HBS) as control for 30 minutes, prior to stimulation with A23187 for 10 minutes. 
(A) PMP release was measured as described in Figure 3.4 (Mean ± SEM; n = 5). (B) PS 
exposure was measured as described in Figure 3.4 (Mean ± SEM; n = 5). (C) Washed platelets 
(5 x 107 per ml) were treated with indicated concentrations of MβCD (1 to 10mM) or vehicle 
(HBS) for 30 minutes, prior to stimulation with 10μM A23187 for 10 minutes. PMP release 
was measured and normalised to matched vehicle controls (Mean ± SEM; n = 5). (D) Density 
plots of platelets treated as indicated. Quadrants are defined as in Figure 3.4, with Annexin V 
FITC fluorescence on FL1-A. These plots are representative of data from 5 different donors. 
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PMPs were isolated by centrifugation, absorbed onto glow-discharged copper grids, 
negatively-stained with uranyl acetate, and visualised by TEM. Small vesicles could be 
detected in large numbers in the supernatant of platelets stimulated with 10μM A23187 
(Figure 4.4). Consistent with flow cytometry data, few particles were observed in the 
supernatant of unstimulated platelets or 10mM MβCD-treated platelets stimulated with 
A23187 (Figure 4.4). Although of different sizes, the majority of these vesicles were smaller 
than 500nm in diameter, which is below the detection limit of light-based experimental 
approaches. It further suggested that the number of events counted by flow cytometry was 
an underestimate of the total number of microparticles. 
 
Figure 4.4: Transmission electron microscopy images 
TEM images confirm that cholesterol depletion prevents microparticle release from platelets. 
Washed platelets (5 x 107 per ml) were treated with 10mM MβCD or vehicle (HBS) for 30 
minutes, stimulated with 10μM A23187 for 10 minutes, and centrifuged at 600g for 10 
minutes to pellet platelets. The supernatant was collected and processed for microscopy. 
These images are representative of results from 4 different donors. 
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It was not clear whether platelet viability was maintained after cholesterol depletion. If 
platelets were killed, MβCD could have been configured as an unspecific inhibitor that led to 
production of fewer PMPs. The effect of MβCD treatment on plasma membrane integrity 
was assessed using a fluorescent fixable viability dye (FVD) eFluor 660. With a molecular 
weight of 1.6kDa, FVD cannot permeate intact plasma membranes. Only cells with 
compromised membrane integrity would be labelled positive for FVD fluorescence. FVD was 
chosen over calcein in this experiment, because FVD is retained by cells even after fixation 
with PFA, making the experimental design more convenient.  
 
Heat-killed platelets were used as positive control, while platelets in the resting state were 
used as negative control. After platelets had been killed by two cycles of 5 minutes of 
heating, membrane fluidity was increased. As they were permeable to FVD, heat-killed 
platelets showed strong FVD fluorescence. Heat-killed platelets were also positive for 
Annexin V FITC binding because Annexin V molecules could reach the cytoplasm and access 
PS distributed at the inner membrane leaflet. By contrast, resting platelets were negative for 
both FVD and Annexin V binding (Figure 4.5). 
 
Neither MβCD treatment, nor A23187 stimulation for 10 minutes, led to an increase in FVD 
fluorescence in platelets. The efficacy of A23187 in this experiment was validated as all 
stimulated platelets exposed PS (Figure 4.5). This suggested that cholesterol depletion by 
MβCD did not cause platelet death or reduced stimulation. Therefore, lipid raft disruption 
does not prevent PMP release by reducing platelet viability. 
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Figure 4.5: Cholesterol depletion does not affect platelet viability 
Platelets (5 x 107 per ml) were treated with MβCD (10mM and 25mM), αCD (10mM) or 
vehicle (HBS) for 30 minutes, prior to stimulation with 10μM A23187 for 10 minutes. After 
this, platelets were stained with anti-human CD41a PE-Cy7, Annexin V FITC, and FVD eFluor 
660. (A) Percentage of dead platelets (FVD +ve) in the entire platelet population (>1μm, 
CD41a +ve) (Mean ± SEM; n = 5; n.d.: not determined). (B) Density plots of platelets (>1μm, 
CD41a +ve) with Annexin V FITC on FL1-A and FVD fluorescence on FL4-A. Platelets were 
treated as indicated. These plots are representative of data from 5 different donors. 
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4.4. Cholesterol depletion inhibits microparticle release from platelets in response to 
physiological stimulation 
Although A23187 effectively stimulated PMP release, it is possible that the mechanism of 
PMP release in response to A23187 does not mimic the mechanism by which PMPs are 
released in response to physiological activators. Major physiological agonists for platelets 
include ADP, thrombin receptor-activating peptide (TRAP), thrombin and collagen-related 
peptide (CRP). ADP activates the purinergic P2Y1 and P2Y12 receptors. P2Y1 is a Gq-coupled 
GPCR that regulates shape change, aggregation and TXA2 generation (Yuan et al., 2016). 
P2Y12 is a Gi-coupled GPCR that potentiates platelet aggregation, procoagulant activities and 
dense granule secretion (Cattaneo, 2015). Thrombin activates platelets via PAR1 and PAR4 
(Brass, 2003), while the short peptide sequence SFLLRN (TRAP6 amide) specifically targets 
PAR1. PAR activation initiates platelets for aggregation, coagulation and haemostasis (De 
Candia, 2012). CRP mimics collagen that activates GPVI. CRP is a highly potent GPVI agonist 
only in its cross-linked form (CRP-XL), in which a specific quaternary protein structure is 
introduced (Achison et al., 1996).  
 
Platelets were stimulated with high concentrations of ADP, SFLLRN, thrombin, CRP-XL, and 
CRP-XL plus thrombin. Of all agonists, none could stimulate PMP release by itself and only 
thrombin was moderately effective for PS exposure. Dual stimulation with thrombin plus 
CRP-XL significantly promoted both PMP release and PS exposure (Figure 4.6A-B). 
 
Effects of cholesterol depletion were then measured in platelets activated with CRP-XL plus 
thrombin. Treatment with MβCD (10mM, 30 minutes) inhibited PMP release (Figure 4.6C), so 
lipid rafts might also be important in this process in platelets stimulated with physiological 
activators. However, MβCD treatment also significantly inhibited PS exposure (Figure 4.6D), 
which suggested that platelet receptors or Ca2+ channels might be affected by cholesterol 
depletion. For this reason, further lipid raft-associated studies were continued with A23187 
rather than physiological activators. 
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Figure 4.6: Cholesterol depletion inhibits microparticle release from platelets in response 
to physiological stimulation 
(A-B) Washed platelets (5 x 107 per ml) were stimulated for 10 minutes with 100μM ADP, 
10μM SFLLRN, 1U/ml thrombin, 10μg/ml CRP-XL (synthesised by Dr. J.D.M Malcor), and 
10μg/ml CRP-XL plus 1U/ml thrombin or vehicle (HBS) as control. PMP release and PS 
exposure were measured as described in Figure 3.4 (Mean ± SEM; n = 5). (C-D) Washed 
platelets (5 x 107 per ml) were treated with 10mM MβCD (+) or vehicle (HBS) as control (-) 
for 30 minutes, prior to stimulation with CRP-XL (10μg/ml) plus thrombin (1U/ml) or vehicle 
(HBS) for 10 minutes. PMP release and PS exposure were measured as described in Figure 
3.4 (Mean ± SEM; n = 5; * p < 0.05, compared to vehicle). (E) Density plots of MβCD- or 
vehicle (HBS)-treated platelets stimulated with CRP-XL (10μg/ml) plus thrombin (1U/ml). 
Quadrants are defined as described in Figure 3.4, with Annexin V FITC fluorescence on FL1-A. 
These plots are representative of data from 5 different donors. 
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4.5. Cholesterol depletion by an antifungal drug also prevents microparticle release from 
platelets 
Apart from cyclodextrin, some antifungal drugs can interact with membrane lipids including 
cholesterol. Filipin forms complexes with membrane cholesterol when applied to unfixed 
cells and disrupts lipid rafts (Bolard, 1986; Bang et al., 2005). Platelets treated with filipin 
released significantly fewer PMPs with no effect on PS exposure in response to A23187. The 
inhibitory effect of filipin on PMP release was concentration-dependent (Figure 4.7). 
 
Amphotericin B, a structurally-related polyene macrolide antibiotic, is used intravenously to 
treat deep fungal infections by disintegrating fungal membranes (Gallis et al., 1990). Found 
only in fungal cells, ergosterol changes the dynamic properties of and stabilises the lipid 
bilayer structure. Amphotericin B has a higher selectivity for ergosterol over its mammalian 
counterpart cholesterol (Kamiński, 2014). When used over the same range of concentrations 
as filipin, Amphotericin B had no significant effect on PMP release or PS exposure in 
response to A23187 (Figure 4.7). These data indicate that cholesterol depletion prevents the 
release of microparticles from human platelets. 
 
Figure 4.7: Cholesterol depletion by an antifungal drug also prevents microparticle release 
from platelets 
Washed platelets (5 x 107 per ml) were treated with the indicated concentrations of filipin or 
amphotericin B (4, 10, 40, 100μg/ml), or vehicle (DMSO) as control for 30 minutes, prior to 
stimulation with 10μM A23187 for 10 minutes. (A) PMP release was measured as in Figure 
3.4 and normalised to matched vehicle controls (Mean ± SEM; n = 5; ** p < 0.01, compared 
to control). (B) PS exposure was measured as described in Figure 3.4 (Mean ± SEM; n = 5). 
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4.6. Cholera toxin B, a lipid raft marker, binds to platelets and platelet-derived 
microparticles 
Experiments above studied the importance of lipid rafts in PMP release based on results 
from cholesterol depletion. An alternative method independent of cholesterol was used to 
probe lipid rafts in platelets. Cholera toxin subunit B (CTxB) from Vibrio cholerae, the 
membrane binding unit of cholera toxin, has been widely identified as a marker of lipid rafts. 
CTxB binds with high avidity to monosialo-tetrahexosyl ganglioside (GM1) on the host cell 
membrane and GM1 is itself confined to lipid rafts (Heyningen S Van, 1974). The B subunit 
alone is not toxic, so CTxB-treated cells do not become necrotic. Unlike the A subunit, CTxB 
itself possesses no intrinsic adenylyl cyclase (AC) activity, so it can be exogenously added to 
cells for lipid raft-associated studies (Day and Kenworthy, 2015). 
 
A FITC conjugate of CTxB has been used to stain GM1 in human cells and measured by flow 
cytometry (Zhang et al., 2014; Bhat et al., 2015). Unlike other conjugated antibodies, CTxB 
FITC was added to platelet samples after they had been fixed with PFA, because CTxB can 
cross-link membrane domains on live cells, forming large stabilised lipid rafts. In a purified 
model system, lipids reorganised into distinct, resolvable CTxB-enriched liquid-ordered (Lo) 
and CTxB-depleted liquid-disordered (Ld) domains following the addition of CTxB (Hammond 
et al., 2005). Similarly, in cytoskeleton-free membrane vesicles that were still attached to 
cells, addition of CTxB induced the emergence of a slower diffusing phase enriched in 
cholesterol, i.e. Lo or lipid raft, which then selectively reorganised the lateral distribution of 
membrane proteins (Lingwood et al., 2008). 
 
In addition, fixing cells before staining with CTxB prevents internalisation of CTxB FITC and 
thus intracellular staining. In a previous study on T cells, FITC fluorescence of CTxB increased 
upon cell activation when these cells were fixed before staining, yet significant uptake of 
CTxB FITC into cells occurred when non-fixed cells were stained (Blank et al., 2007). Similarly, 
platelets were negative for fluorescence on FL1 when they were stained with CTxB FITC prior 
to fixation. When platelets were stained with CTxB FITC after fixation with PFA, they were 
positive for the binding of CTxB (Figure 4.8A). 
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CTxB FITC bound to unstimulated platelets, as MFI on FL1-A increased significantly for CTxB 
FITC-stained platelets compared to unstained samples (Figure 4.8A), which confirmed the 
presence of lipid raft domains on the platelet membrane. PMPs also stained positive for CTxB 
FITC (Figure 4.8B). In this experiment, CTxB FITC fluorescence was recorded on channel FL1, 
so Annexin V FITC was omitted (however, as shown in Figure 3.4, the majority of platelet- 
derived EVs that could be detected were positive for Annexin V). Of all EVs detected, 74.7 ± 
0.8% (Mean ± SEM; n = 5) were positive for CTxB FITC binding (indicated by the gate in Figure 
4.8C).  
 
Following stimulation with A23187, MFI of CTxB FITC bound to intact platelets decreased, as 
its specific staining reduced to 78.4 ± 6.0% (Mean ± SEM; n=5) of matched controls (Figure 
4.8A). This suggests that GM1 is lost from platelets into PMPs and supports the hypothesis 
that PMPs are released from sites of lipid rafts. 
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Figure 4.8: Cholera toxin B, a marker of lipid rafts, binds to platelets and platelet-derived 
microparticles 
(A) Washed platelets (5 x 107 per ml), unstimulated (-) or stimulated with 10μM A23187 for 
10 minutes (+), were stained with anti-human CD41a PE-Cy7, fixed with 1% PFA, then stained 
with 10μg/ml cholera toxin subunit B FITC conjugate and measured by flow cytometry. Event 
acquisition was triggered by PE-Cy7 fluorescence on FL3. MFI on FL1-A for FTIC fluorescence 
is shown for stained and unstained platelets. Stimulation with A23187 led to a significant 
reduction in CTxB binding to platelets (Mean ± SEM; n = 5, * p < 0.05). (B) MFI on FL1-A for 
stained and unstained microparticles from platelets stimulated with A23187 in the same 
experiment. PMPs were positive for CTxB binding (Mean ± SEM; n = 5, *** p < 0.001). (C) 
Density plots of platelets stimulated with A23187, with CTxB FITC fluorescence on FL1-A. Left: 
an unstained sample; Right: the same sample stained with CTxB FITC. The black rectangular 
box gates for PMPs positive for CTxB binding. These plots are representative of data from 5 
different donors. 
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4.7. Cholesterol depletion does not affect calpain activity 
Calpain, an intracellular Ca2+-dependent protease, is important for microparticle release from 
human platelets (Fox et al., 1991; Yano et al., 1993). Inhibition of calpain reduces the degree 
of PMP release in response to thrombin and CRP (Shcherbina and Remold-O’Donnell, 1999). 
A rise in intracellular Ca2+ concentration leads to activation of calpain, which cleaves 
prominent cytoskeletal proteins such as filamin-1, talin and myosin (Morel et al., 2011). This 
may uncouple the plasma membrane from the cytoskeleton and result in cellular contraction 
and membrane blebbing. 
 
The role of calpain in PMP release was confirmed in this experimental system. Platelets were 
treated with calpeptin, a cell-penetrative inhibitor specific for calpain (Tsujinaka et al., 1988). 
Calpeptin (140μM) significantly inhibited PMP release in response to A23187 (Figure 4.9A). It 
also increased the proportion of platelets that bound Annexin V at lower concentrations of 
A23187 (Figure 4.9B; p = 0.0008). These results are consistent with a previous report where 
complete inhibition of calpain by calpeptin (100μM) enhanced PS exposure, measured by 
Annexin V binding, on platelet surface (Bachelot-Loza et al., 2006). 
 
Calpain activity in platelets can be measured by cleavage of talin, which is a cytosolic 
substrate of calpain highly expressed in platelets (Mattheij et al., 2013). In Western blot, a 
monoclonal anti-talin antibody recognised an epitope at 225kDa and a fragment at 190kDa 
obtained by protease cleavage (Soslau et al., 2014). In platelets in the resting state, both 
bands could be detected (Figure 4.9C). It might reflect baseline calpain activity, which has 
also been reported in platelets under storage (Cauwenberghs et al., 2006). Stimulation with 
A23187 led to complete cleavage of talin and the upper band at 225kDa disappeared (Figure 
4.9C), suggesting that calpain was activated upon influx of Ca2+. Cleavage of talin, including 
the baseline activity, was inhibited by prior treatment with calpeptin, either with or without 
A23187 stimulation, since no band could be detected at 190kDa (Figure 4.9C). These results 
confirmed that cleavage of talin could be used as a reliable indicator of calpain activity. 
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Cleavage of talin was then used to measure calpain activity in platelets where lipid rafts were 
disrupted. Incubation of platelets with MβCD (10mM and 25mM) or αCD (10mM) did not 
affect the baseline calpain activity in the resting state. Following stimulation with A23187, 
cleavage of talin was not affected by pre-treatment with MβCD or αCD either (Figure 4.9D). It 
suggests that cholesterol depletion does not affect influx of Ca2+ through the plasma 
membrane, Ca2+-dependent activation of calpain in the cytosol, or subsequent protease 
activities of calpain. This confirms that cytosolic activities of calpain in platelets are not 
localised to lipid raft domains on the membrane (Huang and Wang, 2001). The effects of lipid 
raft disruption on PMP release are more likely to be focused at the platelet membrane, 
downstream of the Ca2+-dependent signalling events. 
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Figure 4.9: Cholesterol depletion does not affect calpain activity 
(A-B) Washed platelets (5 x 107 per ml) were treated with calpeptin (140μM) or vehicle 
(DMSO) as control for 30 minutes, prior to stimulation with A23187 for 10 minutes. (A) PMP 
release was measured as described in Figure 3.4 (Mean ± SEM; n = 5). (B) PS exposure was 
measured as described in Figure 3.4 (Mean ± SEM; n = 5). (C) Washed platelets (5 x 108 per 
ml) were treated as indicated with 140μM calpeptin (+) or vehicle (-) for 30 minutes, prior to 
stimulation with 10μM A23187 for 10 minutes where indicated, and then lysed by RIPA 
buffer. Proteins (20μg) were separated by SDS-PAGE on a 6% poly-acrylamide gel. Talin was 
detected with anti-talin antibody (1 in 10000). Membranes were stripped and re-probed for 
CD41 with anti-CD41 antibody (1 in 2000) as a loading control. Calpain-mediated cleavage of 
talin was triggered by A23187 and inhibited by calpeptin. The blots are representative of 5 
independent experiments. (D) Washed platelets (5 x 108 per ml) were treated as indicated 
with 10mM αCD (α), 10mM MβCD (10β), 25mM MβCD (25β) or vehicle (-) as control for 30 
minutes, prior to stimulation with 10μM A23187 for 10 minutes where indicated. 
A23187-triggered talin cleavage was not affected by MβCD. These blots are representative of 
data from 5 different donors. 
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4.8. P2Y12 and thromboxane signalling are not required for A23187-triggered microparticle 
release in platelets 
The ADP receptor P2Y12 and the thromboxane receptor TPα have been reported to reside in 
lipid rafts on platelet surface (Quinton et al., 2005; Moscardó et al., 2014). To determine if 
disruption of these two pathways could account for the effect of cholesterol depletion, 
platelets were treated with the P2Y12 antagonist, cangrelor (AR-C 69931MX; 10μM), or the 
COX inhibitor, aspirin (100μM). Cangrelor was chosen over the pro-drug clopidogrel, because 
it has a rapid onset of action independent of metabolic conversion (Ferreiro et al., 2009). 
TXA2 is the primary end product of COX1-dependent metabolism of arachidonic acid via the 
intermediate product prostaglandin H2. By inhibiting COX enzymes, aspirin blocks TXA2 
biosynthesis, thereby removing the major TPα agonist (Davì et al., 2012). Neither drug had 
any significant effect on PMP release or PS exposure in response to A23187 (Figure 4.10). 
 
Figure 4.10: P2Y12 and thromboxane signalling are not required for A23187-triggered 
microparticle release in platelets 
Washed platelets (5 x 107 per ml) were treated for 30 minutes with the P2Y12 inhibitor 
cangrelor (10μM) or vehicle (HBS) as control in (A-B), or the COX inhibitor aspirin (100μM) or 
vehicle (DMSO) as control in (C-D), prior to stimulation with A23187 for 10 minutes. (A, C) 
PMP release was measured as described in Figure 3.4 (Mean ± SEM; n = 5). (B, D) PS 
exposure was measured as described in Figure 3.4 (Mean ± SEM; n = 5).  
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4.9. ESCRT-associated proteins are not expressed in human platelets 
The ESCRT complex comprises a system for membrane budding and severing membrane necks 
from their inner surface (Hurley, 2015). In a previous study, ESCRT-0 was found to bind to lipid 
rafts. Local membrane curvature in these domains further recruits other ESCRT-associated 
proteins, which helps to stabilise the membrane neck (Babst, 2011). Also, a raft-associated 
protein, flotillin-1, was found to be involved in recognition and sorting of cargoes by ESCRTs 
(Meister et al., 2017). On the other hand, microparticle release is topologically similar to viral 
budding and shedding of small wounds, both of which are mediated by ESCRT proteins 
(Jimenez and Perez, 2017). More importantly, ESCRT proteins have been reported to mediate 
EV release from erythrocytes (Prudent et al., 2015). Here, ESCRT-mediated scaffolding was 
studied as a potential lipid raft-associated mechanism that facilitates membrane scission.  
 
Since pharmacological modulators are not available for the ESCRT pathway, RNA interference 
has been the tool of choice in most ESCRT-associated studies (Hurley, 2015). For example, the 
sequence for ESCRT recruitment in wound repair was illustrated using siRNA for ALG2 and 
shRNA for ALIX in HeLa cells (Scheffer et al., 2014). However, RNA interference-based methods 
are not applicable for platelets as platelets do not possess a genome (Garraud and Cognasse, 
2015). The few options left include probing for ESCRT expression levels by Western blot and 
visualising ESCRT localisation in the cytoplasm by fluorescent microscopy. 
 
Three ESCRT-associated proteins apoptosis-linked gene 2 (ALG2; 21kDa), ALG2-interacting 
protein X (ALIX; 95kDa) and charged multiple vesicular protein 4B (CHMP4B; 25kDa) were 
selected to be probed by Western blot, because these proteins are crucial to the biogenesis of 
EVs in general (Akers et al., 2013). None of the three proteins were found to be expressed in 
human platelets, or their expression levels were too low to be detected. As control, all three 
ESCRT-associated proteins were detected in lysates from human umbilical vein endothelial 
cells (HUVECs) and HeLa cells (Figure 4.11). 
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Figure 4.11: ESCRT-associated proteins are not expressed in human platelets 
Washed platelets (5 x 108 per ml) were lysed in RIPA buffer. Proteins (20μg) were separated by 
SDS-PAGE and detected with (A) anti-ALG-2 antibody (1 in 1000; 14% poly-acrylamide gel), (B) 
anti-ALIX antibody (1 in 1000; 8% poly-acrylamide gel), and (C) anti-CHMP4B antibody (1 in 
500; 14% poly-acrylamide gel). Membranes were stripped and re-probed for GAPDH with 
anti-GAPDH antibody (1 in 2000) as a loading control. Lanes on the blots are: 1-4 for platelets 
from four individual blood donors, 5 for HUVECs and 6 for HeLa cells. HUVECs and HeLa cells 
acted as positive controls for the ESCRT-associated proteins. 
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4.10. Discussion 
In this chapter, it was shown that intact cholesterol-rich lipid rafts are required for PMP 
release. MβCD, a widely used lipid raft disruptor, depleted cholesterol from platelets and 
prevented PMP release. Filipin, which binds and sequesters membrane cholesterol, also 
prevented PMP release. In contrast, amphotericin B, a structurally-related polyene antibiotic, 
had no effect on PMP release. Cholera toxin B (CTxB) binds to the lipid raft marker, GM1 
ganglioside. CTxB readily bound to PMPs, whereas CTxB binding to platelets was reduced by 
stimulation with A23187, suggesting that GM1 ganglioside was lost from platelets during 
PMP release. Together, these data indicate that lipid rafts have an essential role in PMP 
release. This is consistent with a previous report that PMPs are enriched in cholesterol 
relative to the membrane fractions of unstimulated platelets (Biró et al., 2005). 
 
How lipid rafts contribute to PMP release is still unclear. Little is known beyond calpain 
activity and PS exposure. Lipid raft disruption did not disrupt PS exposure, since MβCD or 
filipin had no effect on Annexin V binding to stimulated platelets. Inhibition of PMP release 
was not due to a selective deficit of PS exposure in the released EVs either, since there was 
no increase in Annexin V-negative vesicles following stimulation of MβCD-treated platelets. 
In addition, lipid raft disruption did not affect intracellular calpain activity, since calpain- 
dependent cleavage of talin was not affected. 
 
Although it is not a physiological stimulus for platelets, A23187 was chosen over more 
physiological agonists such as thrombin and collagen for two reasons. Firstly, PS-positive 
microparticles are released from platelets that expose PS on their surface (Briedé et al., 
1999). Not all physiological activators, even in combination, are able to cause PS exposure in 
platelets (Harper and Poole, 2013; Harper et al., 2013), but PS exposure can be achieved in 
the entire platelet population by A23187 when used at high concentrations. Secondly, 
signalling pathways relevant to PMP release might be affected when lipid rafts are disrupted. 
Using a Ca2+ ionophore allows platelet stimulation to bypass receptor activation and its 
subsequent Ca2+ signalling mechanisms, such as SOCE (Brownlow et al., 2004). 
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Inhibition of PMP release by MβCD pre-treatment in response to thrombin plus CRP-XL 
might reflect inhibition of PS exposure, which is required for formation of PMPs on platelet 
surface. The PS scramblase TMEM16F itself does not appear to be affected by cholesterol 
depletion, as MβCD pre-treatment did not affect PS exposure in platelets activated by 
A23187. Rather, cholesterol depletion is more likely to affect the receptors, ion channels or 
signalling molecules required for triggering PS exposure upstream of TMEM16F in response 
to physiological agonists, including type I protein kinase A (Raslan et al., 2015) and TRPC6 
(Harper et al., 2013). Intact lipid rafts are also necessary for SOCE, which is another major 
route for Ca2+ entry leading to PS exposure (Harper and Poole, 2013).  
 
Although P2Y12 and TPα receptors have been found in platelet lipid rafts, neither inhibition of 
P2Y12 with cangrelor, nor inhibition of TXA2 synthesis with aspirin, significantly affected 
A23187-stimulated PMP release or PS exposure. In contrast, PMP release induced by SFLLRN 
or thrombin plus convulxin was inhibited by pre-treatment with cangrelor (Behan et al., 2005; 
Kahner et al., 2008). Similarly, arachidonic acid was found to induce PMP release, which was 
inhibited by aspirin (Giacomazzi et al., 2016). This indicates that activation of P2Y12 and TPα 
enhances signalling downstream of receptor stimulation, potentially by promoting Ca2+ 
mobilisation and signalling. They are not directly involved in the PMP release mechanism, 
since inhibition of these receptor activities could be circumvented by the use of A23187. 
 
Membrane scission in PMP release is not mediated by the ESCRT machinery, which has been 
implicated in lipid rafts. Absence of ESCRT-associated proteins in platelets does not contradict 
early studies. ALG2 was only reported in platelets when mass spectroscopy-derived peptide 
fragments were compared with a computational data base (Lewandrowski et al., 2009). ALIX 
and CHMP4B were reported in platelets when a combinatorial ligand library was used to 
specifically concentrate and capture low-abundance proteins (Guerrier et al., 2007). The 
expression levels of ALIX, ALG2 and CHMP4B in platelets, if any, would be too low to underlie 
PMP release, which is a rapidly-triggered process with high turnover rates. 
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Chapter 5 Apoptosis 
5.1. Aim of study 
In terms of apoptosis in human platelets, little is known beyond the intrinsic pathway 
regulated by Bcl-xL and PS exposure mediated by caspases. Activated PS-exposing platelets 
tend to release PS-positive PMPs (Morel et al., 2011). Release of EVs, including exosomes and 
microparticles, has been reported as a hallmark of cellular apoptosis in general (Caruso and 
Poon, 2018). In this chapter, it was investigated whether PMPs are released when platelets 
undergo apoptosis. If this is the case, other questions include how this process is regulated in 
platelets, and how apoptotic PMP release links to stimulatory PMP release from platelets. 
 
5.2. ABT-737 triggers Ca2+-dependent apoptosis and microparticle release in platelets 
To investigate platelet apoptosis in vitro, washed human platelets were treated with the 
BH3-mimetic drug ABT-737 (10μM) for up to 3 hours. PS exposure was detected by Annexin 
V FITC binding. ABT-737-treated platelets showed two levels of stimulated Annexin V binding, 
medium and high (Figure 5.1A). Two levels of positive Annexin V binding were consistent 
with a previous report (van Kruchten et al., 2013).  
 
Coincident with development of platelets with high Annexin V binding, Annexin V-positive 
PMPs were released (Figure 5.1C). PMPs were detected via flow cytometry as described in 
Figure 3.4, so PMPs detected here are likely an underestimate of the total number of EVs 
present. This result shows that PMPs are released from apoptotic platelets. 
 
ABT-737 also triggered a slow increase in intracellular Ca2+ concentration ([Ca2+]i), which was 
detected by loading platelets with Fluo-4 or Cal520 (Figure 5.1D). Fluo-4 fluorescence was 
measured live using flow cytometry in platelets (>1μm, CD41a +ve) discretely at the 
indicated time points. Since the earliest time analysed in this experiment was 10 minutes, 
the previously-reported transient (<1min) increase in [Ca2+]i was not detected in this assay 
(Harper and Poole, 2012). By comparison, Cal520 fluorescence was measured using a 
microplate reader continuously every minute throughout 3 hours of incubation. A rapid, 
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though not transient, increase in [Ca2+]i was detected, as the initial fluorescence intensity of 
ABT-737-treated platelets was 1.26 ± 0.07 times higher than that of vehicle control (Mean ± 
SEM; n = 5). Results from Fluo-4- and Cal520-based assays followed the same trend. Further 
experiments for [Ca2+]i measurement were conducted using Cal520 on a microplate reader 
because of its continuity and high throughput. 
 
The increase in [Ca2+]i was largely dependent on the presence of extracellular Ca2+ (Figure 
5.1D), which indicated that it was largely due to Ca2+ entry. Ca2+ entry was required for 
ABT-737-triggered PS exposure and PMP release, as both were significantly inhibited in the 
absence of extracellular Ca2+ (Figure 5.1B-C). Notably, CaCl2 was present in the Annexin V 
staining buffer, as is required for Annexin V binding to PS. In control experiments, Annexin V 
readily bound to heat-killed platelets when CaCl2 was absent during the treatment and only 
present in the staining buffer (see Figure 5.2A below, for an example). 
 
In contrast, chelation of intracellular Ca2+ by treating platelets with BAPTA AM (20μM) had 
less effect on PS exposure. The total percentage of Annexin V-positive platelets was not 
affected. Instead, the percentage of high Annexin V platelets was reduced (at 180 minutes, 
5.9 ± 0.8% showed high Annexin V binding in BAPTA-loaded platelets, compared to 42.7 ± 
6.3%; n = 5; p < 0.001) and the percentage of medium Annexin V platelets correspondingly 
increased (at 180 minutes, 50.3 ± 2.2% showed medium Annexin V binding in BAPTA-loaded 
platelets, compared to 38.8 ± 4.3%; n = 5; p < 0.01), so that the total percentage of Annexin 
V-positive platelets was only slightly reduced (at 180 minutes, 56.2 ± 2.3% were positive for 
Annexin V binding in BAPTA-loaded platelets, compared to 81.5 ± 2.4%; n = 5; p < 0.05). PMP 
release was abolished when ABT-737-treated platelets were co-incubated with BAPTA 
(Figure 5.1C). Chelation of intracellular Ca2+ by BAPTA was confirmed by [Ca2+]i assay (Figure 
5.1D). This suggested that PMP release was linked to the development of platelets with high 
Annexin V binding during apoptosis, rather than platelets with medium Annexin V binding. 
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Figure 5.1: ABT-737 triggers Ca2+-dependent apoptosis and microparticle release in 
platelets. 
Washed platelets (5 x 107 per ml) were stimulated with 10μM ABT-737 or vehicle (DMSO) for 
3 hours with or without 2mM extracellular CaCl2, or with 20μM BAPTA AM in the presence of 
2mM CaCl2, after which samples were stained with anti-human CD41a PE-Cy7 and Annexin V 
FITC to detect PS exposure. PE-Cy7 fluorescence on FL3 was used to trigger acquisition of 
CD41a positive events. (A) The panels show density plots of events from low density (blue) to 
high density (red) on FSC-A and FITC fluorescence on FL1-A. The vertical line separating left 
and right was defined by FSC-A values of 1μm silicon dioxide beads. Unstimulated platelets 
have high FSC-A and low Annexin V binding. Stimulation with ABT-737 triggers PS exposure 
at two levels, detected as medium and high Annexin V binding. These plots are 
representative of data from 5 different donors. (B) PS exposure in platelets treated with 
10μM ABT-737 at the indicated times was measured as described in Figure 3.4. Percentage 
of platelets positive for medium or high Annexin V binding was shown separately (Mean ± 
SEM; n = 5; ** p < 0.01, *** p < 0.001 for high Annexin V binding compared to platelets 
treated with 10μM ABT-737 plus 2mM CaCl2; †† p < 0.01, ††† p < 0.001 for medium Annexin 
V binding compared to platelets treated with 10μM ABT-737 plus 2mM CaCl2). (C) Number of 
Annexin V-positive PMPs released in platelets treated with 10μM ABT-737 at the indicated 
times (left) and only at the endpoint of 180 minutes (right), measured as described in Figure 
3.4 (Mean ± SEM; n = 5, ** p < 0.01). (D) Intracellular Ca2+ assay of platelets treated with 
10μM ABT-737, where PRP was loaded with 1μM Fluo-4 (upper) or 500nM Cal520 (lower) for 
10 minutes (Mean ± SEM; n = 5). Fluorescence was normalised to the initial fluorescence 
intensity of vehicle control prior to stimulation (F/F0). Area under curve (AUC) above basal 
was calculated for the Cal520-based Ca2+ trace (Mean ± SEM; n = 5; * p < 0.05, *** p < 0.001, 
ns: not significant, compared to unstimulated control; ††† p < 0.001 compared to platelets 
treated with 10μM ABT-737 plus 2mM CaCl2). 
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5.3. ABT-737 triggers secondary necrosis in platelets 
During the course of ABT-737 treatment, some platelets gradually lost plasma membrane 
integrity, as detected by loss of calcein fluorescence from the cytosol (Figure 5.2A). It was 
proposed that these platelets had progressed to secondary necrosis at later stages. Following 
3 hours of treatment with ABT-737 in the presence of 2mM CaCl2, 31.1 ± 1.3% (Figure 5.2B; 
Mean ± SEM; n = 5) of platelets had lost plasma membrane integrity. For positive control, 
almost all heat-killed platelets (97.8 ± 1.3%; Mean ± SEM; n = 5) lost plasma membrane 
integrity. Heat-killed platelets were positive for Annexin V fluorescence since Annexin V 
molecules had access to PS distributed at the inner leaflet of plasma membrane (Figure 
5.2A). In contrast, following 3 hours of treatment with vehicle (DMSO), only 1.4 ± 0.1% of 
platelets lost plasma membrane integrity (Mean ± SEM; n = 5).  
 
ABT-737 triggers secondary necrosis in a Ca2+-dependent manner. Absence of extracellular 
Ca2+ prevented secondary necrosis, with only 1.6 ± 0.2% (Figure 5.2B; Mean ± SEM; n = 5) of 
platelets losing plasma membrane integrity. BAPTA also prevented ABT-737-triggered 
secondary necrosis, with only 6.0 ± 0.4% (Figure 5.2B; Mean ± SEM; n = 5) of platelets losing 
plasma membrane integrity. This suggested that higher levels of PS exposure triggered by 
ABT-737, detected as high Annexin V binding, could at least be partially attributed to 
secondary necrosis. 
 
 
 
 
 
 
 
 
 
 
97 
 
 
Figure 5.2: ABT-737 triggers secondary necrosis in platelets 
PRP was loaded with 1μM calcein for 10 minutes. Calcein-loaded washed platelets (5 x 107 
per ml) were treated as indicated and stained with anti-human CD41a PE-Cy7 and Annexin V 
APC. Samples were acquired live with flow cytometry and triggered on PE-Cy7 fluorescence 
on FL3. (A) Density plots are gated on platelets (CD41a +ve, >1μm) after 180 minutes of 
ABT-737 incubation and scaled on FL1-A for calcein and FL4-A for Annexin V APC. These plots 
are representative of data from 5 different donors. Unstimulated platelets are a negative 
control and heat-killed platelets are a positive control for loss of calcein. (B) The percentage 
of platelets negative for calcein at the indicated time points (Mean ± SEM; n = 5; *** p < 
0.001 for ABT-737 + CaCl2 vs. ABT-737 no CaCl2; ††† p < 0.001 for ABT-737 + CaCl2 vs. 
ABT-737 + BAPTA). 
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5.4. ABT-737-triggered apoptosis and microparticle release are dependent on caspase and 
only partially dependent on calpain 
Cell death mechanisms often require intracellular proteases (Vanden Berghe et al., 2014). 
Two proteases, caspase and calpain, were examined for their roles in platelet apoptosis and 
its associated PMP release. Caspases have well-established roles in cell death through 
initiating and executing a cascade of protein cleavage and degradation (Elmore, 2007). On 
the other hand, calpain has been reported as a major effector of necrotic death. Its 
substrates include cytoskeletal proteins, ion channels and transporters, adhesion molecules, 
kinases, phosphatases and phospholipases (Liu et al., 2004; Zong and Thompson, 2006).  
 
Firstly, platelets were treated with a cell-permeable pan-caspase inhibitor Q-VD-OPh (50μM) 
prior to stimulation with ABT-737. When caspases were inhibited, PS exposure on the 
surface of platelets was almost completely abolished (Figure 5.3A). At 180 minutes, only 3.0 
± 0.5% of Q-VD-OPh-treated platelets were positive for Annexin V binding compared to 81.5 
± 2.4% of controls (Figure 5.3B; Mean ± SEM; n = 5; p < 0.001). Caspase inhibition also 
suppressed PMP release (Figure 5.3C) and Ca2+ entry throughout 180 minutes (Figure 5.3D). 
This suggests that caspase activities are upstream of Ca2+ mobilisation and phospholipid 
scramblase activation during platelet apoptosis, which includes both the Ca2+-dependent 
TMEM16F responsible for higher PS exposure and the unidentified caspase-dependent 
scramblase responsible for lower PS exposure. 
 
Compared to caspase, calpain has a relatively limited role in apoptosis and PMP release. 
Platelets were treated with calpeptin (140μM) prior to stimulation with ABT-737. Calpeptin 
partially inhibited high Annexin V binding, with a slight yet statistically insignificant increase 
in medium Annexin V binding (Figure 5.3B). At 180 minutes, 20.1 ± 4.3% showed high 
Annexin V binding in calpeptin-treated platelets, compared to 42.7 ± 6.3% in vehicle control 
(Figure 5.3B; Mean ± SEM; n = 5; p < 0.01), while 44.8 ± 4.5% showed medium Annexin V 
binding in calpeptin-treated platelets, compared to 38.8 ± 4.3% in vehicle control (Figure 
5.3B; Mean ± SEM; n = 5; not significant).  
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Although calpain was required for A23187-triggered PMP release (Figure 4.9), calpeptin had 
a statistically significant whilst small inhibitory effect on PMP release in response to ABT-737 
(Figure 5.3C). In addition, calpeptin-treated platelets showed significant, but not complete, 
suppression of the slow increase in intracellular Ca2+ concentration (Figure 5.3D). 
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Figure 5.3: ABT-737-triggered apoptosis and microparticle release are dependent on 
caspase and only partially dependent on calpain 
Washed platelets (5 x 107 per ml) were treated with the caspase inhibitor, Q-VD-OPh (50μM), 
or the calpain inhibitor, calpeptin (140μM), or vehicle control (DMSO) for 30 minutes, prior 
to stimulation with 10μM ABT-737 in the presence of 2mM extracellular CaCl2 for 3 hours. (A) 
Density plots of platelets treated as indicated after 180 minutes of ABT-737 incubation. 
Unstimulated control is included. Quadrants are defined as in Figure 5.1, with Annexin V FITC 
fluorescence on FL1-A. These plots are representative of data from 5 different donors. (B) PS 
exposure was measured as described in Figure 5.1. The panel shows percentage of platelets 
positive for medium and high Annexin V binding at the indicated time points (Mean ± SEM; n 
= 5; ** p < 0.01, *** p < 0.001 for high Annexin V binding compared to vehicle; ††† p < 0.001 
for medium Annexin V binding compared to vehicle). (C) PMP release was measured as 
described in Figure 5.1. The left panel shows the number of PMPs released in platelets 
treated as indicated at the indicated time points. The right panel shows the number of PMPs 
released in platelets treated as indicated after 180 minutes of ABT-737 incubation (n = 5, * p 
< 0.05, ** p < 0.01 compared to vehicle). (D) Intracellular Ca2+ assay of platelets treated with 
the indicated drugs, where PRP was loaded with 500nM Cal520 for 10 minutes. Fluorescence 
was normalised to initial fluorescence intensity of untreated platelets prior to stimulation 
(F/F0). AUC above basal was calculated (Mean ± SEM; n = 5; *** p < 0.001 compared to 
vehicle). 
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5.5. ABT-737-triggered secondary necrosis requires caspase and calpain 
Caspase and calpain were then examined for their roles in ABT-737-triggered secondary 
necrosis. Calcein-loaded platelets were pre-treated with Q-VD-OPh or calpeptin prior to 
stimulation with ABT-737. Caspase activities were required for secondary necrosis. Inhibition 
of caspases abolished this process, because only 1.7 ± 0.1% of Q-VD-OPh-treated platelets 
were negative for calcein fluorescence compared to 31.1 ± 1.3% of vehicle-treated controls 
at 180 minutes (Figure 5.4B; Mean ± SEM; n = 5; p < 0.001). 
 
Inhibition of calpain by calpeptin also significantly inhibited loss of calcein fluorescence in 
platelets treated with ABT-737 (at 180 minutes, 8.3 ± 1.9% of calpeptin-treated platelets 
were negative for calcein fluorescence compared to 31.1 ± 1.3% of vehicle-treated controls; 
Figure 5.4B; Mean ± SEM; n = 5; p < 0.001), so low levels of calpain activity in apoptotic 
platelets led to loss of plasma membrane integrity. This may account for the small apparent 
role of calpain in PMP release, high levels of PS exposure (high Annexin V binding) and Ca2+ 
entry. 
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Figure 5.4: ABT-737-triggered secondary necrosis requires caspase and calpain 
PRP was loaded with 1μM calcein for 10 minutes. Calcein-loaded washed platelets (5 x 107 
per ml) were treated with Q-VD-OPh (50μM), or calpeptin (140μM), or vehicle control 
(DMSO) for 30 minutes, prior to stimulation with 10μM ABT-737 in the presence of 2mM 
extracellular CaCl2 for 3 hours. Platelets were then stained with anti-human CD41a PE-Cy7 
and Annexin V APC. Samples were acquired live with flow cytometry and triggered on PE-Cy7 
fluorescence on FL3. (A) Density plots of platelets treated as indicated. Quadrants are 
defined as in Figure 5.2, with calcein fluorescence on FL1-A and Annexin V APC fluorescence 
on FL4-A. These plots are representative of data from 5 different donors. (B) The percentage 
of platelets negative for calcein fluorescence at 180 minutes (n = 5; *** p < 0.001 compared 
to vehicle).  
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5.6. ABT-737 triggers significant caspase activities and weak calpain activity 
Caspase and calpain activities were examined by Western blotting. ABT-737 induced self- 
cleavage of caspase 3 into its active effector fragment, which then cleaved its substrate 
gelsolin within 60 minutes. Caspase-dependent cleavage of gelsolin was inhibited in the 
presence of Q-VD-OPh (Figure 5.5A). The onset of caspase 3 cleavage activities was slightly 
earlier than that of Ca2+ entry, PS exposure, PMP release or loss of plasma membrane 
integrity. This confirms that these apoptotic and secondary necrotic features are dependent 
on and thus downstream of caspase activities. 
 
Cleavage of talin by calpain was weak, as its pattern in ABT-737-stimulated platelets was 
similar to untreated control (Figure 5.5B). By contrast, cleavage of another calpain substrate 
ATP8A1 was more prominent in platelets treated with ABT-737 (Jing et al., 2019). It may 
suggest that calpain activity is biased towards different substrates during platelet activation 
and apoptosis. 
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Figure 5.5: ABT-737 triggers significant caspase activities and weak calpain activity 
(A) Washed platelets (5 x 108 per ml) were treated with ABT-737 (10μM) with or without 
Q-VD-OPh (50μM), or vehicle (DMSO) as control for the indicated times, before being lysed 
with RIPA buffer. Proteins (20μg) were separated by SDS-PAGE on a 16% poly-acrylamide gel. 
Caspase 3 was detected with anti-caspase 3 antibody (1 in 500), stripped and re-probed for 
gelsolin with anti-gelsolin antibody (1 in 1000), again stripped and re-probed for GAPDH with 
anti-GAPDH antibody (1 in 2000) as a loading control. Asterisks (*) indicate cleavage 
products. (B) Washed platelets (5 x 108 per ml) were treated with A23187 (10μM), calpeptin 
(140μM) or ABT-737 (10μM) as indicated, and lysed with RIPA buffer. Talin and the loading 
control CD41 were probed as described in Figure 4.9. These blots are representative of data 
from 5 different donors. 
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5.7. ABT-737 triggers cytochrome c release from mitochondria and loss of mitochondrial 
membrane potential in platelets 
Effects of apoptosis on platelet mitochondria were studied. Mitochondrial outer membrane 
permeabilisation (MOMP) occurs in the early stages of apoptotic cell death. Activated 
pro-death BAK and BAX proteins perforate the outer mitochondrial membrane, which allows 
the release of cytochrome c from the mitochondrial intermembrane space into the cytosol 
(Nagata, 2018). To examine retention of cytochrome c, digitonin had been transiently 
applied to selectively permeabilise the plasma membrane without damaging the outer 
mitochondrial membrane. After washing digitonin-treated cells by centrifugation, the 
supernatant containing released cytochrome c was discarded (Campos et al., 2006).  
 
In this experiment, digitonin treatment was optimised to 0.05% (w/v) for 2 minutes for 
platelets at 5 x 108 per ml. After washing out released cytochrome c, the digitonin-resistant 
pellet showed loss of the cytosol marker extracellular signal-regulated kinases 1 and 2 (ERK 
1/2), but retained the mitochondrial marker cytochrome c oxidase or complex IV (COX IV). 
ABT-737 triggered cytochrome c release within 10 minutes, which is consistent with a 
previous report (Choo et al., 2017). Release of cytochrome c was not delayed or inhibited in 
the presence of Q-VD-OPh or BAPTA (Figure 5.6A). This confirmed that MOMP is 
independent of intracellular Ca2+ levels and it occurs upstream of caspase activation.  
 
To monitor the loss of mitochondrial membrane potential, platelets were treated with 
tetra-methyl-rhodamine methyl-ester (TMRM). After penetrating the plasma membrane, 
TMRM is readily sequestered by active mitochondria. Loss of TMRM from cells is linked to 
disruption of the inner mitochondrial membrane (IMM) (Jobe et al., 2008). Slower than 
cytochrome c release, loss of TMRM from the mitochondria was temporally coincident with 
Ca2+ entry, PS exposure and PMP release. It was abolished by Q-VD-OPh, partially inhibited 
by BAPTA, but not affected by calpeptin (Figure 5.6B). This showed that IMM disruption and 
loss of mitochondrial membrane potential were regulated by Ca2+ entry and caspases, and 
largely independent of calpain. 
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Figure 5.6: ABT-737 triggers cytochrome c release from mitochondria and loss of 
mitochondrial membrane potential in platelets 
(A) Washed platelets (5 x 108 per ml) were treated with 50μM Q-VD-OPh or 20μM BAPTA 
AM where indicated, before treatment with 10μM ABT-737 for 10 to 30 minutes. Platelets 
were briefly permeabilised with 0.05% (w/v) digitonin for 2 minutes and the cytosol-rich 
fraction removed by centrifugation (600g, 10 minutes), after which digitonin-resistant pellets 
were lysed with RIPA buffer. Proteins (20μg) were separated by SDS-PAGE on a 16% 
poly-acrylamide gel. Cytochrome c was detected with anti-cytochrome c antibody (1 in 250), 
stripped and re-probed for ERK 1/2 with anti-ERK 1/2 antibody (1 in 1000), again stripped 
and re-probed for COX IV with anti-COX IV antibody (1 in 1000). Whole cell lysate was 
included as a control. These blots are representative of data from 5 different donors. (B) 
Washed platelets (5 x 107 per ml) were loaded with 500nM TMRM for 30 minutes and 
treated with 50μM Q-VD-OPh, 20μM BAPTA AM or 140μM calpeptin where indicated, prior 
to treatment with 10μM ABT-737 for the time indicated. Platelets were stained with 
anti-human CD41a PE-Cy7. Percentage of platelets (CD41a +ve, >1μm) positive for TMRM 
fluorescence on FL2 was shown (Mean ± SEM; n = 5). 
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5.8. Calpain-dependent release of microparticles is downregulated during apoptosis 
It was surprising that calpain was only weakly involved in ABT-737-triggered PMP release, 
since calpain is required for PMP release in response to A23187 (Figure 4.9) or procoagulant 
stimuli (Yano et al., 1993). It was hypothesised that ABT-737 treatment might somehow 
reduce the ability of calpain to promote PMP release. To investigate this hypothesis, 
platelets were treated with ABT-737 for 3 hours without extracellular Ca2+, as very few PMPs 
were released under this condition (Figure 5.1). These platelets were then stimulated with 
A23187 for 10 minutes in the presence of extracellular Ca2+ to trigger a large increase in 
intracellular Ca2+ concentration (Figure 5.7A). A23187 was used rather than physiological 
agonists, such as thrombin and CRP-XL, since ABT-737 disrupts responses to these agonists 
through shedding of GPVI and GPIb (Schoenwaelder et al., 2011; Vogler et al., 2011), yet 
A23187 can bypass these disruptions. 
 
As control, A23187 rapidly triggered PMP release in the presence of 2mM CaCl2 in untreated 
platelets. ABT-737 treatment significantly inhibited PMP release in response to subsequent 
stimulation with A23187 plus CaCl2 (Figure 5.7B). PS exposure in response to A23187 was 
not affected (Figure 5.7C). Caspase activation inhibited the ability of platelets to release 
PMPs in response to A23187. The importance of this process was seen when apoptosis was 
triggered by ABT-737 yet caspases were inhibited by Q-VD-OPh. Compared to control, these 
platelets released more PMPs in response to A23187 (Figure 5.7B), yet PS exposure was at 
similar levels (Figure 5.7C). Therefore, ABT-737 makes platelets more sensitive to A23187 
stimulation if caspases are not activated. 
 
Caspase and calpain activities in this experiment were confirmed by Western blot. Although 
A23187 triggered calpain-dependent self-cleavage of caspase 3, it did not activate the cell 
death-related effector cascade, as indicated by cleavage of gelsolin (Figure 5.7E). ABT-737 
still triggered caspase 3 activity in the absence of extracellular Ca2+, which was inhibited by 
Q-VD-OPh (Figure 5.7E). A23187-triggered calpain activity was not affected by activation of 
caspases. A23187, in the presence of CaCl2, was still able to activate calpain regardless of 
treatment with ABT-737 and Q-VD-OPh, as shown by cleavage talin (Figure 5.7E). 
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Figure 5.7: Calpain-dependent microparticle release is downregulated during apoptosis 
(A) Scheme of the experiment. Washed platelets (5 x 107 per ml) were treated with 50μM 
Q-VD-OPh or vehicle (DMSO) for 30 minutes, prior to 10μM ABT-737 or vehicle (DMSO) in 
the absence of extracellular CaCl2. After 3 hours of ABT-737, platelets were stimulated with 
A23187 for 10 minutes in the presence of 2mM CaCl2. (B-C) A23187-stimulated platelets 
were stained with anti-human CD41a PE-Cy7 and Annexin V FITC. PMP release and PS 
exposure were measured as described in Figure 3.4 (Mean ± SEM; n = 5). (D) Density plots of 
platelets treated as indicated. Quadrants are defined as described in Figure 3.4, with 
Annexin V FITC fluorescence on FL1-A. These plots are representative of data from 5 
different donors. (E) Washed platelets (5 x 108 per ml) were treated with 10μM ABT-737 (or 
DMSO), with or without 50μM Q-VD-OPh in the absence of extracellular Ca2+ for 10 or 180 
minutes as indicated, prior to stimulation with 10μM A23187 (or DMSO) in the presence of 
2mM CaCl2 for 10 minutes as indicated and lysed with RIPA buffer. (Top) Proteins (20μg) 
were separated with SDS-PAGE on a 16% poly-acrylamide gel. Caspase 3, gelsolin and the 
loading control GAPDH were probed as described in Figure 5.5. Asterisks (*) indicate 
cleavage products. (Bottom) Proteins (20μg) were separated with SDS-PAGE on a 6% 
poly-acrylamide gel. Talin and the loading control CD41 were probed as described in Figure 
4.9. These blots are representative of data from 5 different donors. 
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5.9. ABT-737 is the most suitable drug for studying platelet apoptosis and necrosis in vitro 
Multiple drugs can trigger apoptosis in cells. Similar to ABT-737, clinically used BH3-mimetics 
ABT-199 (venetoclax) and ABT-263 (navitoclax) inhibit Bcl-2 proteins (Wilson et al., 2010; 
Souers et al., 2013). BAM7 selectively binds and activates BAX, independently of BAK or Bcl-2 
proteins (Gavathiotis et al., 2012). AT-101 inhibits Mcl-1, Bcl-2 and Bcl-xL with high affinity, 
and it induces caspase-dependent apoptosis in various cancer cell lines both in vivo and in 
vitro (Paoluzzi et al., 2008; Zerp et al., 2009). HA14-1, a non-peptide ligand of a Bcl-2 surface 
pocket, showed cytotoxic effects in vitro (Skommer et al., 2006), yet it did not directly affect 
growth of tumour cells in vivo (Manero et al., 2006). The pan-Bcl-2 inhibitor sabutoclax 
suppresses tumour cell growth through activation of BAK and BAX both in vivo and in vitro 
(Wei et al., 2010; Dash et al., 2011). TW-37 was shown to inhibit proliferation and induce 
apoptosis in lymphoma cells without any significant effect on normal peripheral blood 
lymphocytes. However, its affinity has only been determined in vitro for recombinant Bcl-2, 
Bcl-xL and Mcl-1 proteins in cell-free assays (Mohammad et al., 2007). Of these pro-death 
drugs, only ABT-199, ABT-263 and ABT-737 have been applied to platelets. 
 
To investigate their effects in vitro, pro-death drugs were added to platelets for 3 hours. At a 
low concentration (100nM), none of the drugs triggered PS exposure or PMP release. At a 
medium concentration (1μM), ABT-737 was the only drug that triggered apoptosis (64.5 ± 
2.9% of platelets were AnxV +ve and PMP/PLT = 0.09 ± 0.02; n=5). At a high concentration 
(10μM), ABT-263, ABT-737, AT-101, HA14-1 and sabutoclax triggered PMP release and PS 
exposure. By contrast, ABT-199, BAM7 and TW-7 did not lead to any significant increase in 
PMP release or PS exposure, which corresponds to the specificities of these drugs on Bcl-xL 
(Figure 5.8A-B). ABT-263 and sabutoclax were less potent than ABT-737 for triggering PMP 
release, while AT-101 and HA14-1 were at least equally potent (for PMP/PLT: ABT-263 = 0.05 
± 0.02, ABT-737 = 0.23 ± 0.03, AT-101 = 0.23 ± 0.05, HA14-1 = 0.29 ± 0.03, sabutoclax = 0.11 
± 0.03; n = 5). ABT-263 was weaker than ABT-737 for triggering PS exposure, while the rest 
were equally potent (for % of AnxV +ve: ABT-263 = 49.4 ± 4.9%, ABT-737 = 76.0 ± 3.7%, 
AT-101 = 60.6 ± 12.8%, HA14-1 = 80.6 ± 6.2%, sabutoclax = 71.6 ± 8.5%; n = 5). 
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To understand their pro-death effects, platelets were treated with ABT-263, AT-101, HA14-1 
or sabutoclax (10μM) in the presence of Q-VD-OPh or calpeptin, or in the absence of 
extracellular CaCl2. Responses to all drugs were dependent on Ca2+ entry, as PMP release 
and PS exposure were abolished in the absence of extracellular CaCl2. Apoptosis triggered by 
ABT-263 was similar to that triggered by ABT-737, as it was dependent on caspases and 
largely independent of calpain. By contrast, platelet death in response to AT-101, HA14-1 or 
sabutoclax was mechanistically distinct. Caspase inhibition by Q-VD-OPh did not abolish PMP 
release or suppress PS exposure; whereas calpain inhibition by calpeptin was largely 
insignificant at least in terms of PS exposure (Figure 5.8C-D). 
 
ABT-263, AT-101, HA14-1 and sabutoclax were further examined for their capacity in 
inducing necrosis, again measured by loss of cytosolic calcein. Apoptosis in ABT-263-treated 
platelets did not progress to secondary necrosis, as only 2.5 ± 0.7% of the platelets were 
negative for calcein (Figure 5.8F). By comparison, treatment with AT-101, HA14-1 or 
sabutoclax produced variable results. These drugs were more potent than ABT-737 in 
triggering necrosis in platelets from some blood donors, yet they did not cause necrosis in 
platelets from other donors (Figure 5.8F). 
  
Based on the results above, ABT-737 is the most suitable drug for studying platelet apoptosis 
and necrosis in vitro. ABT-199, BAM7 and TW-37 did not trigger apoptosis in platelets, as 
suggested by little increase in PMP release or PS exposure. ABT-263 was similar to ABT-737 
in terms of mechanistic details, but it was less potent and did not lead to secondary necrosis 
in platelets. Rather than inhibiting Bcl-xL and thus leading to activation of effector caspases, 
AT-101, HA14-1 and sabutoclax triggered PMP release and PS exposure in platelets 
potentially through off-target effects that are yet to be resolved. Whether these drugs 
trigger secondary necrosis might be subject to individual differences between blood donors. 
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Figure 5.8: ABT-737 is the most suitable drug for studying platelet apoptosis and necrosis in 
vitro 
(A-B) Washed platelets (5 x 107 per ml) were treated with 0.1μM, 1μM or 10μM of ABT-199, 
ABT-263, ABT-737, AT-101, BAM7, HA14-1, sabutoclax or TW-37 in the presence of 
extracellular CaCl2 for 3 hours. PMP release and PS exposure were measured as described in 
Figure 5.1 (Mean ± SEM; n = 5; * p < 0.05, ** p < 0.01, *** p < 0.001, compared to vehicle). 
(C-D) Washed platelets (5 x 107 per ml) were treated with calpeptin (140μM), Q-VD-OPh 
(50μM) or vehicle control (DMSO) for 30 minutes, prior to stimulation with 10μM ABT-263, 
AT-101, HA14-1 or sabutoclax in the presence of extracellular CaCl2 for 3 hours. Platelets 
were also stimulated in the absence of CaCl2 with each drug for 3 hours. PMP release and PS 
exposure were measured as described in Figure 5.1 (Mean ± SEM; n = 5; * p < 0.05, ** p < 
0.01, *** p < 0.001, ns: not significant, compared to vehicle of each drug). (E) Density plots 
of platelets treated for 3 hours with 10μM of the pro-apoptotic drugs, as indicated. 
Quadrants are defined as in Figure 5.1, with Annexin V FITC fluorescence on FL1-A. These 
plots are representative of data from 5 different donors. (F) PRP was loaded with 1μM 
calcein for 10 minutes. Calcein-loaded washed platelets (5 x 107 per ml) were treated with 
10μM ABT-263, ABT-737, AT-101, HA14-1 or sabutoclax in the presence of 2mM 
extracellular CaCl2 for 3 hours. Loss of calcein fluorescence was measured as described in 
Figure 3.6 (n = 10).  
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5.10. Discussion 
In this chapter, it was shown that PMPs were released from platelets during apoptosis, 
which progressed to secondary necrosis in vitro as they were not cleared. This PMP release 
was dependent on Ca2+ entry and caspases, but largely independent of calpain. Intracellular 
signalling events involved in stages of apoptosis and secondary necrosis were differentially 
regulated by Ca2+ entry, caspases and calpain activity. During platelet apoptosis, caspases 
downregulate calpain-dependent PMP release in response to pro-coagulant stimuli (Figure 
5.9). 
 
Two levels of Annexin V binding were detected in platelets in response to ABT-737. This is 
consistent with a previous report where apoptosis was induced in platelets from healthy 
donors (van Kruchten et al., 2013). When platelets from a Scott Syndrome patient were 
treated with ABT-737, most Annexin V-positive platelets showed medium Annexin V binding 
(van Kruchten et al., 2013). Similarly, medium Annexin V binding was detected when 
platelets from TMEM16F-/- mice were treated with ABT-737 (Mattheij et al., 2016). This 
suggests that high level of PS exposure (high Annexin V binding) is mediated by the 
Ca2+-dependent phospholipid scramblase TMEM16F, which is defective in Scott Syndrome 
(Suzuki et al., 2010). PMPs also appear to derive from platelets of high Annexin V binding. On 
the other hand, medium levels of PS exposure (medium Annexin V binding) might be 
mediated by the caspase-activated scramblase XKR8 (Suzuki et al., 2016), though it has not 
been reported in platelets so far. 
 
Apoptosis was largely dependent on Ca2+ entry, as it was substantially reduced in the 
absence of extracellular Ca2+. Interestingly, chelation of intracellular Ca2+ had less effect. 
Intracellular BAPTA significantly inhibited the large rise in [Ca2+]i, which was required to 
activate TMEM16F for high PS exposure. By contrast, BAPTA had little effect on the 
TMEM16F-independent medium PS exposure. It is possible that there is an additional role 
for extracellular Ca2+. This may be to support Ca2+ entry, or there might be an extracellular 
site of action for an unidentified platelet scramblase (Hampton et al., 1996). The precise 
roles that Ca2+ plays in these two pathways for PS exposure are worth further investigations. 
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After prolonged treatment with ABT-737, some platelets lost plasma membrane integrity, 
suggesting that these platelets had entered secondary necrosis. The progression to necrosis 
required caspases, extracellular and intracellular Ca2+, and calpain. This has important 
implications for interpreting results from in vitro studies. Many ABT-737-triggered signalling 
events were attributed to apoptosis (Rukoyatkina et al., 2013; Zhang et al., 2013; Chatterjee 
et al., 2014), but they may instead be associated with secondary necrosis.  
 
It is unlikely that platelets normally reach secondary necrosis in vivo, but rapid induction of 
apoptosis (e.g. chemotherapy) in many platelets could temporarily overwhelm the capacity 
for clearance. Circulating PS-positive platelets were readily detectable following ABT-737 
administration in mice, with a 90% reduction in platelet count (Schoenwaelder et al., 2011). 
Impaired clearance and accumulation of secondary necrotic cells have been associated with 
activation of the adaptive immune system and chronic inflammation (Sachet et al., 2017). 
Necrotic cells were found to release damage-associated molecular patterns (DAMPs) that 
activate innate immune cells via receptors including toll-like receptors (Chen and Nuñez, 
2010; Krysko et al., 2011). Some DAMPs are associated with thrombosis (Wang et al., 2014; 
Vogel et al., 2015). Impaired clearance of apoptotic cells is also associated with development 
of auto-antibodies against intracellular antigens and subsequently chronic inflammation 
(Mahajan et al., 2016; Sachet et al., 2017). Although consequences of platelet secondary 
necrosis are yet to be determined, a large number of circulating secondary necrotic cells 
would have the potential to promote acute and chronic inflammation. 
 
Responses from secondary necrotic platelets may have been modified by prior activation of 
caspases. It was found that caspases downregulated calpain-dependent PMP release in 
response to A23187 and an acute rise in [Ca2+]i, which may provide a period of reduced 
capacity to activate platelets. When apoptosis was triggered yet caspases were inhibited, 
platelets became more sensitive to pro-coagulant stimuli, as they released more PMPs in 
response to A23187. This might be linked to disruption of mitochondrial functions during 
apoptosis (Tait and Green, 2013). ABT-737 triggered caspase-independent MOMP within 10 
minutes (cytochrome c release), which then gradually led to IMM disruption (loss of TMRM). 
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Figure 5.9: Apoptosis and microparticle release in human platelets 
ABT-737-triggered responses in platelets in vitro are not a single apoptotic event, but a 
temporal sequence of stages that can be distinguished by their sensitivity to different 
inhibitors. Medium levels of PS exposure (medium Annexin V binding; AnxVmed) is triggered 
in a caspase-dependent manner. There is a slow progression to high levels of PS exposure 
(high Annexin V binding; AnxVhigh), which is blocked by chelation of intracellular Ca2+. PMPs 
are released in a calpain-independent manner from platelets with high levels of PS exposure, 
but absent from platelets with medium levels of PS exposure. Platelets slowly become 
secondary necrotic and feature loss of plasma membrane integrity (measured by loss of 
calcein), which is partially dependent on calpain. Caspase activation is required for all 
apoptotic responses, including PS exposure, PMP release, Ca2+ entry and loss of membrane 
integrity. Caspase activation also downregulates the rapid release of PMPs in response to 
A23187 and the acute increase in intracellular Ca2+ that follows. 
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Chapter 6 2-Aminoethoxydiphenyl borate as an inhibitor for 
microparticle release from platelets 
6.1. Aim of study 
Initially developed as a cheap and fast-acting antagonist for intracellular phosphoinositide 
signalling, 2-aminoethoxydiphenyl borate (2-APB) has now been established as a non-specific 
blocker of numerous ion channels, particularly Ca2+ channels. In preliminary experiments, 
2-APB was found to significantly inhibit microparticle release from platelets in response to 
either pro-coagulant stimulation (A23187) or apoptosis (ABT-737). Neither of these two 
microparticle release pathways has been fully understood. In this chapter, the effects of 
2-APB were characterised in an effort to better understand their inhibition. 
  
6.2. 2-APB inhibits A23187-triggered microparticle release from platelets 
When platelets were treated with 2-APB (100μM), PMP release was significantly inhibited 
compared to platelets treated with vehicle (DMSO) at all concentrations of A23187 tested 
(Figure 6.1A). PS exposure was only weakly affected (Figure 6.1B). When 10μM A23187 was 
used, the inhibitory effect of 2-APB on PMP release was concentration-dependent (pIC50 = 
4.45 ± 0.09; IC50 approximately 35μM; Mean ± SEM; n = 5; Figure 6.1C), again with little 
effect on PS exposure (Figure 6.1D). 
 
To assess the reversibility of 2-APB-mediated inhibition on PMP release, platelets were 
treated with 2-APB (100μM) or vehicle (DMSO) and then washed by centrifugation. This 
procedure of washing platelets resulted in slightly greater sensitivity to A23187 (for PMP 
release, pEC50 = 5.77 ± 0.20 prior to washing, pEC50 = 6.16 ± 0.12 after washing; Mean ± SEM; 
n = 5). After washing, platelets treated with 2-APB still released significantly fewer PMPs in 
response to A23187 (Figure 6.1F). Notably, there was no difference in PS exposure between 
2-APB-treated platelets and vehicle control at any concentration of A23187 used (Figure 
6.1G). Therefore, 2-APB inhibits A23187-triggered PMP release and this inhibition is not 
related to the weak inhibition of PS exposure. 
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Figure 6.1: 2-APB inhibits A23187-triggered microparticle release from platelets  
(A-B) Washed platelets (5 x 107 per ml) were treated with 100μM 2-APB or vehicle control 
(DMSO) for 30 minutes, prior to stimulation with A23187 for 10 minutes. PMP release and PS 
exposure were measured as described in Figure 3.4 (Mean ± SEM; n = 5). (C-D) Washed 
platelets (5 x 107 per ml) were treated with indicated concentrations of 2-APB (1 to 100μM), 
prior to stimulation with 10μM A23187 for 10 minutes. PMP release and PS exposure were 
measured as described in Figure 3.4 (Mean ± SEM; n = 5). (E) Density plots of platelets 
treated as indicated. Quadrants are defined as in Figure 3.4, with Annexin V FITC 
fluorescence on FL1-A. These plots are representative of data from 5 different donors. (F-G) 
Washed platelets (5 x 107 per ml) were treated with 100μM 2-APB or vehicle control (DMSO) 
for 30 minutes, followed by a second washing step by centrifugation (600g, 10 minutes) in 
the presence of apyrase (0.02U/ml) and PGE1 (100nM). Resuspended platelets (5 x 107 per 
ml) were stimulated with A23187 for 10 minutes. PMP release and PS exposure were 
measured as described in Figure 3.4 (Mean ± SEM; n = 5). 
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6.3. DPBA and DP3A, two 2-APB analogues, inhibit A23187-triggered microparticle release 
A small panel of compounds structurally related to 2-APB were used to investigate inhibition 
of A23187-triggered PMP release. Compounds used in this study include phenylborinic acid 
(PBA), dimesitylborinic acid (DMBA), diphenhydramine (DPHD), 2, 2-diphenyl 
tetrahydrofuran (DPTHF), diphenylborinic anhydride (DPBA) and 3-(diphenylphosphino)-1- 
propylamine (DP3A). For chemical structures of these compounds, please refer to Figure 1.5. 
Each of these compounds was applied to platelets in the same way as 2-APB (100μM, 30 
minutes). PBA, DMBA, DPHD and DPTHF did not affect PMP release or PS exposure in 
response to A23187 (Figure 6.2A-B). 
 
DPBA significantly inhibited PMP release in response to A23187 (Figure 6.2A). PS exposure 
was also inhibited, but the level of inhibition was not to the same extent as PMP release 
(Figure 6.2B). When 10μM A23187 was used, the inhibitory effect of DPBA on PMP release 
was concentration-dependent (pIC50 = 4.55 ± 0.32; IC50 approximately 28μM; Mean ± SEM; n 
= 5; Figure 6.2C). The small inhibitory effect of DPBA on A23187-triggered PS exposure was 
ambiguous (Figure 6.2D), as its predicted IC50 value (565.5μM) exceeded the range of 
concentrations used (1 to 100μM). It was therefore considered ineffective. 
 
DP3A also significantly inhibited PMP release in response to A23187 (Figure 6.2A), yet PS 
exposure was not affected (Figure 6.2B). When 10μM A23187 was used, the inhibitory effect 
of DP3A on PMP release was also concentration-dependent (pIC50 = 4.38 ± 0.14; IC50 
approximately 42μM; Mean ± SEM; n = 5; Figure 6.2C), again without any effect on PS 
exposure (Figure 6.2D). 
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Figure 6.2: DPBA and DP3A inhibit A23187-triggered microparticle release 
(A-B) Washed platelets (5 x 107 per ml) were treated as indicated with 100μM PBA, DMBA, 
DPHD, DPTHF, DPBA, DP3A or vehicle control (DMSO) for 30 minutes, prior to stimulation 
with A23187 for 10 minutes. PMP release and PS exposure were measured as described in 
Figure 3.4 (Mean ± SEM; n = 5). (C-D) Washed platelets (5 x 107 per ml) were treated with 
indicated concentrations of DPBA or DP3A (1 to 100μM), prior to stimulation with 10μM 
A23187 for 10 minutes. PMP release and PS exposure were measured as described in Figure 
3.4 (Mean ± SEM; n = 5). (E) Density plots of platelets treated as indicated. Quadrants are 
defined as in Figure 3.4, with Annexin V FITC fluorescence on FL1-A. These plots are 
representative of data from 5 different donors. 
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6.4. 2-APB and DPBA, but not DP3A, inhibit A23187-triggered Ca2+ entry 
2-APB and its analogues were tested for their effects on A23187-triggered Ca2+ entry by the 
Cal520-based intracellular [Ca2+]i assay on a microplate reader as described previously. 
Treatment with A23187 (10μM) immediately triggered a large increase in fluorescence 
intensities of Cal520-loaded platelets, which indicated Ca2+ entry into the platelet cytosol 
(Figure 6.3A). Results were compared by area under curve for the Ca2+ trace throughout 10 
minutes of A23187 stimulation (Figure 6.3B). 
 
As control, platelets were treated with specific inhibitors of Ca2+ entry pathways, including 
SN-6 that blocks NCX (Harper and Sage, 2007), SAR7334 that blocks TRPC6 and thus NCCE 
(Hou et al., 2018; Zhou et al., 2018), Synta66 that blocks Orai1 and thus SOCE (van Kruchten 
et al., 2012; Tian et al., 2016) and a combination of SN-6, SAR7334 and Synta66. TRPC and 
Orai1 channels are known targets of 2-APB. Functions of TPRC channels are sometimes 
coupled to NCX (see introduction chapter 1.7). These inhibitors of calcium entry pathways, 
singly or combined, did not significantly affect Ca2+ entry in response to A23187 (Figure 6.3A, 
B; 1st row). As expected, inhibition of these pathways did not inhibit PMP release or PS 
exposure in response to A23187 (Figure 6.3C-D). These data confirmed that A23187 could 
bypass any contribution of plasma membrane Ca2+ entry pathways. 
 
Treating platelets with 2-APB or DPBA, but not DP3A, inhibited A23187-triggered Ca2+ entry 
in a concentration-dependent manner (Figure 6.3A-B; 2nd, 4th and 5th rows). This suggested 
that there is no direct link between the inhibition of Cal520 fluorescence and inhibition of 
PMP release. Analogues that did not inhibit PMP release (PBA, DMBA, DPHD and DPTHF) had 
no effect on A23187-triggered Ca2+ entry into platelets (Figure 6.3A-B, 3rd row). 
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Figure 6.3: 2-APB and DPBA, but not DP3A, inhibit A23187-triggered Ca2+ entry 
PRP was loaded with 500nM Cal520 for 10 minutes. Cal520-loaded washed platelets (5 x 107 
per ml) were treated for 30 minutes with SN-6 (50μM), SAR7334 (1μM), Synta66 (10μM), 
SN-6 plus SAR7334 plus Synta66 (S+S+S), 2-APB (12.5 to 100μM), DPBA (12.5 to 100μM), 
DP3A (12.5 to 100μM), PBA (100μM), DMBA (100μM), DPTHF (100μM), DPHD (100μM) or 
vehicle control (DMSO), prior to stimulation with 10μM A23187 for 10 minutes. Cal520 
fluorescence values were recorded every 15 seconds and normalised to the initial 
fluorescence intensity of vehicle-treated control prior to stimulation (F/F0). (A) 
Representative Ca2+ trace. A23187 was added into platelets at minute 0. (B) AUC above basal 
was calculated (Mean ± SEM; n = 5; * p < 0.05, ** p < 0.01, ns: not significant, compared to 
vehicle). (C-D) Washed platelets (5 x 107 per ml) were treated with SAR7334 (1μM), SN6 
(50μM), Synta66 (10μM), SAR7334 plus SN6 plus Synta66 (S+S+S), or vehicle control (DMSO) 
for 30 minutes, prior to stimulation with 10μM A23187 for 10 minutes. PMP release and PS 
exposure were measured as described in Figure 3.4 (n = 5; ns: not significant, compared to 
vehicle). 
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6.5. Mild changes in intracellular pH do not affect A23187-triggered microparticle release 
It was investigated whether the effect of 2-APB on Cal520 fluorescence might be an artefact 
due to a change in cytosolic pH. Addition of NH4Cl to unstimulated Cal520-loaded platelets, 
which was expected to result in rapid intracellular alkalinisation, gave a rapid increase in 
fluorescence. Similarly, addition of extracellular NaOH also increased the signals. By contrast, 
extracellular HCl had little effect on the Cal520 signals in unstimulated platelets (Figure 6.4A). 
Although A23187 rapidly increased Cal520 fluorescence to a plateau (which was expected as 
the dye was likely to be saturated with Ca2+ under these conditions), this fluorescence signal 
could be further increased by extracellular NH4Cl or NaOH. It could also be decreased by 
extracellular HCl, suggesting that H+ had entered stimulated platelets (Figure 6.4B). Together, 
these data showed that Cal520 fluorescence is highly sensitive to pH, consistent with a 
previous report that signals of intracellular Ca2+ indicators are subject to pH changes 
(Paredes et al., 2008). 
 
To determine whether 2-APB affects cytosolic pH, platelets were loaded with the 
cell-permeable pH-sensitive carboxyfluorescein dye BCECF (Han and Burgess, 2010). As 
control, BCECF-loaded platelets were treated with HCl and NH4Cl. NH4Cl (100mM) 
immediately increased the BCECF signal to 1.27 ± 0.02 times that of vehicle-treated control 
(F/F0; Mean ± SEM; n = 5; Figure 6.4C), indicating cytosolic alkalinisation, which slowly 
reversed. HCl (1mM) immediately decreased the BCECF signal to 0.90 ± 0.01 times that of 
vehicle (F/F0; Mean ± SEM; n = 5; Figure 6.4C), indicating cytosolic acidification. By 
comparison, changes in BCECF signals induced by 2-APB or any of the analogues over 30 
minutes of incubation were all within the range of 0.95 to 1.12 (F/F0; n = 5; Figure 6.4D). This 
suggested that 2-APB did not significantly affect cytosolic pH. Moreover, the effect of 2-APB 
and DPBA on Cal520 fluorescence was not an artefact of decreased cytosolic pH. 
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Furthermore, it was tested if PMP release could be affected by intracellular pH. Platelets 
were treated with HCl (1mM) or NH4Cl (100mM), followed by immediate stimulation with 
A23187 to temporally match the rapid induction of pH changes. PMP release and PS 
exposure in response to A23187 was not significantly affected by modulation of pH in either 
direction (Figure 6.4E-F). This suggested that a change in cytosolic pH does not account for 
the inhibitory effect of 2-APB on PMP release. 
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Figure 6.4: Mild changes in intracellular pH do not affect A23187-triggered microparticle 
release 
(A-B) PRP was loaded with 500nM Cal520 for 10 minutes. (A) Cal520-loaded washed 
platelets (5 x 107 per ml) were treated with HCl (10mM), NaOH (10mM) or NH4Cl (100mM) at 
the time point indicated by the dashed line. (B) Cal520-loaded washed platelets (5 x 107 per 
ml) were stimulated with 10μM A23187 at minute 0, followed by HCl (10mM), NaOH (10mM) 
or NH4Cl (100mM) at the time point indicated by the dashed line. These traces are 
representative of data from 5 different donors. (C-D) PRP was loaded with 1μg/ml BCECF for 
30 minutes. BCECF-loaded washed platelets (5 x 107 per ml) were treated as indicated. 
Fluorescence was recorded for 30 minutes and normalised to the initial fluorescence 
intensity of vehicle control (DMSO) prior to stimulation (F/F0). (C) Platelets were treated with 
acid (1mM HCl) or base (100mM NH4Cl) at minute 0 (Mean ± SEM; n = 5). (D) Platelets were 
manually added with 2-APB or its analogues (all 100μM), immediately before the recording 
started (Mean ± SEM; n = 5). (E-F) Washed platelets (5 x 107 per ml) were treated with 1mM 
HCl, 100mM NH4Cl or vehicle control (HBS), immediately followed by stimulation with 
A23187 for 10 minutes. PMP release and PS exposure were measured as described in Figure 
3.4 (Mean ± SEM; n = 5). 
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6.6. 2-APB does not inhibit microparticle release by blocking Ca2+-activated K+ channels 
2-APB has been reported to inhibit Ca2+-activated K+ channels (KCa) following activation of 
SOCE in human erythroleukemia cells (Littlechild et al., 2015). These channels might be 
required for PS exposure and PMP release (Wolfs et al., 2006). Experiments were performed 
to test if PMP release was associated with KCa channels, the presence of which has been 
recorded in platelets (Mahaut-Smith, 2012). 
 
Quinine and tetra-ethyl ammonium (TEA), two non-selective blockers (Fatherazi and Cook, 
1991), were used to block KCa channels. They have not been applied to platelets before. The 
concentrations used were slightly higher than the saturated effective dose previously 
reported in other cell lines (Kozak et al., 1998). Neither quinine nor TEA significantly affected 
PMP release or PS exposure in response to A23187 (Figure 6.5).  
 
 
Figure 6.5: 2-APB does not inhibit microparticle release by blocking Ca2+-activated K+ 
channels 
Washed platelets (5 x 107 per ml) were treated with 500μM quinine, 30mM TEA or vehicle 
control (HBS) for 30 minutes, prior to stimulation with A23187 for 10 minutes. PMP release 
and PS exposure were measured as described in Figure 3.4 (Mean ± SEM; n = 5). 
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6.7. 2-APB, DPBA and DP3A inhibit streptolysin O-triggered microparticle release 
Similar to A23187, streptolysin O (SL-O) triggers PMP release in the presence of extracellular 
Ca2+ in a concentration-dependent manner (Figure 3.5). Perforation of platelet membrane by 
SL-O bypasses all channels on the plasma membrane, not limited to Ca2+ channels, and 
enables Ca2+ to reach its intracellular target calpain (Figure 3.6). To test if any membrane 
channel is involved in 2-APB-mediated inhibition of PMP release, SL-O (1000U/ml) was 
applied to platelets treated with 2-APB and its analogues.  
 
Treatment with calpeptin inhibited SL-O-triggered PMP release (Figure 6.6A), which 
confirmed its dependence on calpain activity. 2-APB, DPBA and DP3A significantly inhibited 
PMP release in response to SL-O, while PBA, DMBA, DPHD and DPTHF did not (Figure 6.6A). 
PS exposure in response to SL-O was not prevented by any of these drugs (Figure 6.6B). 
2-APB, DPBA and DP3A did not inhibit efficacy of SL-O in terms of membrane perforation, as 
calcein leakage from SL-O-treated platelets was not significantly prevented by these drugs 
(Figure 6.6D). 
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Figure 6.6: 2-APB, DPBA and DP3A inhibit streptolysin O-triggered microparticle release  
(A-B) Washed platelets (5 x 107 per ml) were treated with calpeptin (140μM), 2-APB or its 
analogues (100μM), or vehicle control (DMSO) for 30 minutes, prior to stimulation with 
1000U/ml SL-O in the presence of 2mM CaCl2 for 10 minutes. PMP release and PS exposure 
were measured as described in Figure 3.4 (n = 5; *** p < 0.001, ns: not significant, compared 
to vehicle). (C) Density plots of platelets stimulated with 1000U/ml SL-O. Quadrants are 
defined as in Figure 3.4, with Annexin V FITC fluorescence on FL1-A. These plots are 
representative of data from 5 different donors. (D) PRP was loaded with 1μM calcein for 10 
minutes. Calcein-loaded washed platelets (5 x 107 per ml) were treated with 100μM 2-APB, 
DPBA or DP3A, or vehicle control (DMSO) for 30 minutes, prior to stimulation with 1000U/ml 
SL-O in the presence of 2mM CaCl2 for 10 minutes. Loss of calcein fluorescence was 
measured as described in Figure 3.6 (n = 5; ns: not significant, compared to vehicle). 
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6.8. 2-APB and DPBA, but not DP3A, partially inhibit A23187-triggered calpain activity 
Calpain is required for the Ca2+-dependent PMP release following stimulation with either 
A23187 or SL-O (Figures 4.9 & 6.6). Calpain inhibition by 2-APB was reported in HeLa cells 
(Splettstoesser et al., 2007). Therefore, it was tested whether 2-APB and its analogues 
affected calpain activity in platelets. Intracellular targets of calpain in platelets include talin 
(Figure 4.9), phospholipid flippase ATP8A1 (Jing et al., 2019), caspase 3 (Figure 5.7), and 
protein tyrosine phosphatase 1C (PTP1C) (Falet et al., 1998).  
 
Calpain activity was measured by the extent of cleavage of these proteins via Western blot. 
As control, A23187 stimulation and its subsequent Ca2+ influx led to cleavage of talin, 
ATP8A1, caspase 3 and PTP1C, which was inhibited in the presence of calpeptin (Figure 6.7A). 
At a high concentration of 100μM, 2-APB and DPBA partially inhibited calpain-dependent 
cleavage of all four proteins (Figure 6.7A), which was not observed following treatment with 
DP3A, PBA, DMBA, DPHD or DPTHF (Figure 6.7A). Inhibitory effects of 2-APB and DPBA on 
calpain activity were concentration-dependent (Figure 6.7B). Cleavage of talin and caspase 3 
by calpain was quantified (Figure 6.7C). 
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Figure 6.7: 2-APB and DPBA, but not DP3A, partially inhibit A23187-triggered calpain 
activity 
Washed platelets (5 x 108 per ml) were treated with the indicated drugs for 30 minutes, prior 
to stimulation with A23187 (+) or vehicle (-) for 10 minutes and lysed with RIPA buffer. 
Proteins (20μg) were separated with SDS-PAGE on a 6% poly-acrylamide gel, probed for talin 
as described in Figure 4.9 and ATP8A1 with anti-ATP8A1 antibody (1 in 1000), stripped and 
re-probed for CD41 as a loading control. Also, proteins (20μg) were separated with 
SDS-PAGE on a 12% poly-acrylamide gel, probed for caspase 3 as described in Figure 5.5 and 
PTP1C with anti-PTP1C antibody (1 in 1000), stripped and re-probed for GAPDH as a loading 
control. (A) Platelets were treated with calpeptin (140μM), 2-APB ,DPBA, DP3A, PBA, DMBA, 
DPHD, DPTHF (100μM), or vehicle control (DMSO). (B) Platelets were treated with 2-APB 
(12.5μM to 200μM), DPBA (12.5μM to 200μM), or vehicle control (DMSO; NA). Asterisks (*) 
indicate the cleaved protein fragment to be quantified. (C) Intensity of cleaved protein 
fragment was divided by intensity of the loading control, which was then normalised to that 
of matched vehicle controls. Dose-response inhibition curves were plotted (Mean ± SEM; n = 
5; ** p < 0.01, *** p < 0.001, ns: not significant, compared to matched vehicle controls).  
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6.9. 2-APB inhibits ABT-737-triggered microparticle release and Ca2+ entry 
To investigate whether 2-APB also affects PMP release during apoptosis in vitro, platelets 
treated with 2-APB (100μM) were stimulated with ABT-737 in the presence of extracellular 
CaCl2. Although PS exposure was not affected (Figure 6.8A-B), platelets treated with 2-APB 
showed lower levels of PMP release (Figure 6.8C). Ca2+ entry in response to ABT-737 was 
inhibited (Figure 6.8D). Secondary necrosis, measured by loss of calcein, was not affected 
(Figure 6.8E).  
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Figure 6.8: 2-APB inhibits ABT-737-triggered microparticle release and Ca2+ entry 
Washed platelets (5 x 107 per ml) were treated with 2-APB (100μM) or vehicle control 
(DMSO) for 30 minutes, prior to stimulation with 10μM ABT-737 in the presence of 2mM 
CaCl2 for 3 hours. (A) Density plots of platelets treated as indicated after 3 hours of ABT-737 
treatment. Quadrants are defined as in Figure 5.1, with Annexin V FITC fluorescence on 
FL1-A. These plots are representative of data from 5 different donors. (B) PS exposure, 
detected as medium and high Annexin V binding, was measured as described in Figure 5.1 
(Mean ± SEM; n = 5). (C) PMP release at the indicated time points was measured as 
described in Figure 3.4 (Mean ± SEM; n = 5; * p < 0.05, ** p < 0.01, compared to vehicle at 
the same time point). (D) PRP was loaded with 500nM Cal520. Cal520-loaded washed 
platelets (5 x 107 per ml) were treated as indicated. Calcium trace was recorded as described 
in Figure 5.1 and AUC above basal was calculated (Mean ± SEM; n = 5; * p < 0.05 compared 
to vehicle). (E) PRP was loaded with 1μM calcein. Calcein-loaded washed platelets (5 x 107 
per ml) were treated as indicated. Loss of calcein fluorescence was measured as described in 
Figure 3.6 at the indicated time points (Mean ± SEM; n = 5; ns: not significant, compared to 
vehicle). 
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6.10. ABT-737-triggered microparticle release is independent of Ca2+ entry pathways on 
the plasma membrane 
Inhibition of ABT-737-triggered PMP release by 2-APB was associated with reduced Ca2+ 
entry (Figure 6.8D), so inhibitors of calcium entry pathways SN6, SAR7334 and Synta66 were 
screened. These inhibitors, singly or combined, did not significantly affect PS exposure, PMP 
release or Ca2+ entry in response to ABT-737 (Figure 6.9). Therefore, NCX, TRPC6 and Orai1 
are not involved in Ca2+ entry or PMP release during apoptosis. Inhibition of Ca2+ entry 
pathways by 2-APB does not explain its effect on ABT-737-triggered PMP release. 
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Figure 6.9: ABT-737-triggered microparticle release is independent of Ca2+ entry pathways 
on the plasma membrane 
Washed platelets (5 x 107 per ml) were treated with SAR7334 (1μM) or vehicle (HBS), SN-6 
(50μM), Synta66 (10μM), SAR7334 plus SN-6 plus Synta66 (S+S+S), or vehicle control (DMSO) 
for 30 minutes, prior to stimulation with 10μM ABT-737 in the presence of 2mM CaCl2 for 3 
hours. (A-B) PS exposure and PMP release were measured as described in Figure 5.1 (Mean ± 
SEM; n = 5). (C) Calcium trace in Cal520-loaded platelets was recorded for 180 minutes as 
described in Figure 5.1. AUC above basal was calculated (Mean ± SEM; n = 5; ns: not 
significant, compared to vehicle). 
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6.11. ABT-737-triggered microparticle release may be dependent on gap junction channels 
Apart from selective Ca2+ channels, 2-APB also inhibits gap junctions that potentially act as 
routes for Ca2+ flow into cells (Griffith et al., 2005; Neijssen et al., 2005). Connexins and 
pannexins, two types of gap junction subunits, were reported in platelets (Taylor et al., 2014; 
Vaiyapuri et al., 2015). To investigate whether gap junctions are the effective target of 2-APB 
in terms of ABT-737-triggered PMP release, platelets were treated with carbenoxolone and 
probenecid, two non-specific gap junction inhibitors. Concentrations of these drugs used 
were similar to those in previous studies (Packham et al., 1996; Ye et al., 2009). 
 
Carbenoxolone and probenecid had divergent effects on ABT-737-triggered responses in 
platelets. PS exposure, at medium but not high levels, was inhibited by carbenoxolone, yet 
PMP release and secondary necrosis were not affected. On the other hand, PS exposure, at 
high but not medium levels, PMP release and secondary necrosis were inhibited by 
probenecid (Figure 6.10A-C). This suggested that ABT-737-triggered PMP release was 
associated with platelets that showed high levels of PS exposure and loss of plasma 
membrane integrity, consistent with previous findings derived from chelating intracellular 
Ca2+ by BAPTA (Figures 5.1 & 5.2). However, Ca2+ entry was reduced when platelets were 
treated with either carbenoxolone or probenecid (Figure 6.10D), so the exact link between 
PMP release and Ca2+ entry during apoptosis in vitro remains unclear. 
 
To further understand how gap junctions may contribute to PMP release and Ca2+ entry, 
platelets were treated with more selective inhibitors. Gap27, a peptide derived from Cx43, 
has high specificities for connexin subtypes Cx40 and Cx43 (Vaiyapuri et al., 2013). On the 
other hand, 10Panx, a Panx1 mimetic peptide, specifically blocks the pannexin subtype Panx1 
(Pelegrin and Surprenant, 2006). Concentrations of these drugs used were similar to those in 
previous studies (Manohar et al., 2012; Vaiyapuri et al., 2012). Neither peptide had any 
effect on A23187-triggered PS exposure, PMP release or Ca2+ entry (Figure 6.10E-G). 
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Figure 6.10: ABT-737-triggered microparticle release and Ca2+ entry might be dependent on 
gap junction channels 
(A-D) Washed platelets (5 x 107 per ml) were treated with carbenoxolone (CBX; 30μM), 
probenecid (2mM), or vehicle control (HBS) prior to stimulation with 10μM ABT-737 in the 
presence of 2mM CaCl2 for 3 hours. (A) PS exposure was measured as described in Figure 5.1 
(Mean ± SEM; n = 5; ** p < 0.01, compared to high Annexin V binding of vehicle; †† p < 0.01, 
compared to medium Annexin V binding of vehicle). Density plots are representative of data 
from 5 different donors. (B) PMP release was measured as described in Figure 5.1 (Mean ± 
SEM; n = 5; ** p < 0.01, compared to vehicle). (C) Loss of calcein fluorescence in 
calcein-loaded platelets after 180 minutes was measured as described in Figure 3.6 (n = 5; ** 
p < 0.01, ns: not significant, compared to vehicle). (D) Calcium trace in Cal520-loaded 
platelets was recorded as described in Figure 5.1. AUC above basal was calculated (Mean ± 
SEM; n = 5; ** p < 0.01, *** p < 0.001, compared to vehicle). (E-G) Washed platelets (5 x 107 
per ml) were treated with Gap27 (100μg/ml), 10Panx (200μM) or vehicle control (HBS), prior 
to stimulation with 10μM ABT-737 in the presence of 2mM CaCl2 for 3 hours. (E) PS exposure 
was measured as described in Figure 5.1 (Mean ± SEM; n = 5). (F) PMP release was measured 
as described in Figure 5.1 (Mean ± SEM; n = 5). (G) Calcium trace was record in 
Cal520-loaded platelets as described in Figure 5.1. AUC above basal was calculated (Mean ± 
SEM; n = 5; ns: not significant, compared to vehicle). 
142 
 
6.12. Discussion 
In this chapter, it was found that 2-aminoethoxydiphenyl borate (2-APB), a cell-permeable 
modulator of numerous ion channels, inhibited PMP release in response to A23187. It was 
surprising since A23187 was expected to bypass any contribution of plasma membrane Ca2+ 
channels. It is not likely that 2-APB directly inhibits scramblase TMEM16F that leads to PS 
exposure, because platelet Annexin V binding was largely unaffected under conditions 
where PMP release was almost completely inhibited. Although a small inhibition of platelet 
Annexin V binding was observed when 2-APB was present, this was fully reversed by 
washing the platelets, whereas inhibition of PMP release was not readily reversed. 
 
To understand this effect, a panel of structurally related compounds was used, which 
included DPBA, DP3A, DMBA, DPHD, DPTHF and PBA. Of these compounds, DPBA and DP3A 
inhibited PMP release with similar potency to 2-APB, so neither the amine group nor the 
boron-oxygen core is essential for inhibition. Interestingly, the pattern of active and inactive 
analogues was similar to that reported for inhibiting interleukin (Il)-1β release from murine 
macrophages (Baldwin et al., 2017). In that study, the effect was attributed to inhibition of 
NLRP3 inflammasome. Since Il-1β may be released in microparticles (MacKenzie et al., 2001), 
inhibition of microparticle release could potentially contribute to inhibition of Il-1β release. 
 
PMP release in response to streptolysin O (SL-O) was also inhibited by 2-APB, DPBA and 
DP3A. This showed that 2-APB-mediated inhibition of Ca2+-induced PMP release could not be 
attributed to inhibition of plasma membrane ion channels, because these channels were 
effectively bypassed by the use of SL-O. Consistent with this, blockers of Orai1, TRPC6, NCX 
or KCa channels had no effect on A23187-triggered PMP release. On the other hand, PBA, 
DMBA, DPHD and DPTHF did not inhibit PMP release when they could access intracellular 
proteins in response to stimulation with SL-O. Therefore, lack of inhibition by these 2-APB 
analogues was not due to insufficient penetration of membrane. It is likely that 2-APB, DPBA 
and DP3A have an intracellular target in PMP release separate to plasma membrane ion 
channels, for which the inactive analogues have low affinities. 
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At first sight, the observation that 2-APB inhibited A23187-induced increase in Cal520 signals 
leads to the opposite conclusion, as it suggested that 2-APB inhibited the rise in [Ca2+]i. It is 
unclear whether this is a real inhibition of [Ca2+]i, or an artefact on Cal520 signals. It was 
tested whether 2-APB induced cytosolic acidification, as 2-APB has been reported to acidify 
the cytoplasm of Jurkat T lymphocytes (Chokshi et al., 2012), although this effect might be 
specific to certain cell types. Cal520 signals were also shown to be pH-sensitive. However, 
2-APB did not significantly affect intracellular pH, as measured by BCECF fluorescence, 
suggesting that cytosolic acidification does not explain the reduced Cal520 signals. In 
addition, extracellular addition of NH4Cl and HCl did alter intracellular pH without affecting 
PMP release. Therefore, 2-APB does not inhibit PMP release by altering intracellular pH. 
 
It is possible that 2-APB does inhibit the A23187-triggered increase in [Ca2+]I rather than 
artefactually decrease Cal520 signals, although the mechanism is unclear. Data showed that 
it did not involve Orai1 or TRPC6, the major channels for Ca2+ entry into platelets. Inhibition 
of Ca2+ signalling could account for the weak inhibition of PS exposure and calpain activity by 
2-APB and DPBA. However, it cannot fully explain inhibition of PMP release, because DP3A 
did not have any effect on Ca2+ signalling, PS exposure or calpain activity. Together, these 
data suggest that there is a target of 2-APB, independent of plasma membrane ion channels 
or Ca2+ signalling, that is required for PMP release (Figure 6.11). DP3A is likely to inhibit the 
same target without these other effects. DP3A may be a better scaffold from which to 
develop a more selective inhibitor of PMP release.  
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Figure 6.11: Summary of the targets of 2-APB 
2-APB, along with its analogues DPBA and DP3A, inhibits PMP release in response to A23187 
or SL-O. 2-APB and DPBA also inhibit A23187-triggered rise in Cal520 fluorescence signals, 
which may indicate inhibition of Ca2+ signalling or may be an artefact. Inhibition of Ca2+ 
signalling by 2-APB and DPBA may explain weak inhibition of TMEM16F and calpain. In 
contrast, DP3A does not inhibit Ca2+ signalling, TMEM16F or calpain. 2-APB, DPBA and DP3A 
have a common intracellular target required for PMP release that is yet to be resolved (as 
indicated by “X”).  
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In addition to that triggered by A23187, PMP release triggered by ABT-737 was also found to 
be inhibited by 2-APB. Unlike BAPTA, calpeptin or Q-VD-OPh, 2-APB did not inhibit cell death. 
PS exposure and loss of calcein were not affected in platelets treated with 2-APB. Rather, this 
inhibitory effect might be linked to reduced Ca2+ entry. Ca2+ entry during ABT-737-triggered 
apoptosis was independent of NCX, SOCE and NCCE at the plasma membrane, as it was not 
affected by inhibitors of Ca2+ entry pathways including SN-6, Synta66 or SAR7334. 
 
Inhibition of ABT-737-triggered PMP release by 2-APB might potentially result from inhibition 
of gap junctions, which, although they are often associated with anion movement, could act 
as bi-directional conduits for Ca2+ flow (Fiori et al., 2012). Two non-specific gap junction 
blockers, carbenoxolone and probenecid, were used. Whilst carbenoxolone only inhibited 
medium levels of PS exposure but not PMP release, probenecid was shown to attenuate 
most of the apoptotic features, including PS exposure (high levels), PMP release, Ca2+ entry 
and secondary necrosis. Divergence of effects between the two blockers might be explained 
by their off-target effects related to apoptosis in platelets. 
 
In chapter 5, it was found that secondary necrosis was dependent on Ca2+, as loss of calcein 
was inhibited in the absence of extracellular Ca2+ or in the presence of BAPTA. However, 
both 2-APB and carbenoxolone significantly, though not completely, inhibited Ca2+ entry, yet 
secondary necrosis was not affected by either drug. This suggested that secondary necrosis 
might be regulated by localised, rather than global, Ca2+ signalling events within the cytosol. 
 
Amongst various subunits that constitute gap junctions, pannexin 1 (Panx1) has been found 
to be activated by caspase cleavage (Sandilos et al., 2012). Truncated Panx1 mediates signal 
release and plasma membrane permeability during apoptosis (Chekeni et al., 2010). Also, 
connexin 43 (Cx43) has been implicated in apoptotic transformation of HeLa cells (Kalvelyte 
et al., 2003; Kameritsch et al., 2013). However, subtype-specific mimetic peptides, 10Panx (for 
Panx1) and Gap27 (for Cx40 and Cx43), did not inhibit PS exposure, PMP release or Ca2+ entry 
in response to ABT-737. 
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It is still unclear how 2-APB inhibits ABT-737-triggered PMP release. It might be linked to 
reduced Ca2+ entry via an unknown route, or it could be attributed to the same unidentified 
intracellular target underlying A23187-triggered PMP release. Future studies into 2-APB and 
its target might provide a scaffold for developing a pharmacological inhibitor of 
microparticle release from platelets in response to both activation and apoptosis. 
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Chapter 7 General discussion and future directions 
7.1. Detection of platelet-derived microparticles 
This thesis aims to understand how microparticles are released from human platelets. An 
assay was developed for the detection of PMPs by flow cytometry. A sample of platelets and 
PMPs was stained with fluorescently-conjugated Annexin V molecules to detect PS exposure 
and anti-human CD41a PE-Cy7 to detect events that were derived from platelets. The 1μm 
gate was set by silicon dioxide calibration beads. To differentiate events of interest from 
debris and machine noise, events were triggered on PE-Cy7 fluorescence of anti-human 
CD41a. Samples were diluted by half in HBS before analysis using a flow cytometer, so that 
swarm detection could be prevented. PMPs were defined as events smaller than 1μm and 
positive for Annexin V binding. It needs to be acknowledged that the number of events seen 
by this approach is likely an underestimate of the total number of PMPs, since flow 
cytometry can struggle to resolve the smaller EVs. However, this assay has proved useful for 
investigating the pharmacology of PMP release. 
 
A few types of stimuli can be used to trigger PMP release. These include physiological 
agonists thrombin plus CRP-XL, a Ca2+ ionophore A23187, a bacterial toxin SL-O, and histone 
H4. Compared to thrombin plus CRP-XL, A23187 allowed platelet stimulation to bypass 
receptor activation and its subsequent Ca2+ signalling mechanisms. Compared to SL-O, 
A23187 did not cause perforation of plasma membrane. In addition, the population of EVs 
released from platelets in response to histone H4 was not homogeneous in terms of PS 
exposure, so it was not definitive whether these EVs could be classified as PMPs. Therefore, 
A23187 was the most suitable stimulus for further investigations into the mechanisms of 
PMP release. 
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7.2. Lipid rafts, membrane blebbing and scission 
It was shown that cholesterol-rich lipid rafts are required for PMP release in response to 
A23187. A23187-triggered PMP release was prevented by MβCD that depletes cholesterol 
from membranes. It was also inhibited by filipin that sequesters membrane cholesterol, but 
not by amphotericin B, a structurally-related polyene antifungal that does not disrupt 
cholesterol. The importance of lipid rafts in PMP release was supported by data from using 
cholera toxin B (CTxB) that binds to GM1 ganglioside, an alternative marker of lipid rafts. 
CTxB bound to PMPs, whereas CTxB binding to platelets was reduced by A23187 stimulation. 
 
How lipid rafts contribute to PMP release is still unclear. Lipid raft disruption did not affect 
PS exposure, since MβCD or filipin had no effect on Annexin V binding to A23187-stimulated 
platelets. Lipid raft disruption did not affect intracellular calpain activity, since MβCD had no 
effect on calpain-dependent cleavage of talin. Inhibition of either P2Y12 or TPα, both of 
which have been found in lipid rafts, did not affect A23187-triggered PMP release, so these 
receptors are not directly involved in the PMP release mechanism. One future approach 
would be to compare the proteomes of platelet lipid rafts and of PMPs to identify novel 
regulators of PMP release. 
 
In the lipid raft domains, membrane curvature may be generated by protein crowding. Even 
in a cell-free lamellar vesicle system, lateral pressure created by protein-protein interactions 
was shown to cause membrane bending (Stachowiak et al., 2012). Enrichment of regulatory 
proteins and budding microparticles in lipid rafts could alone be sufficient to drive outward 
blebbing, which is independent of Na+ influx-mediated increases in hydrostatic pressure.  
 
After blebs are formed on the platelet surface, they are pinched off to form PMPs. 
Membrane scission is independent of the ESCRT system, because ESCRT-associated proteins 
are not expressed in human platelets. It is possible that scission during PMP release occurs 
spontaneously when lipid raft-facilitated protein crowding creates a curvature force beyond 
the threshold for constriction. 
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7.3. Apoptosis 
In addition to stimulated platelets, platelets undergoing apoptosis also release PMPs. In this 
thesis, apoptosis was triggered in platelets primarily by a BH3-mimetic drug ABT-737 that 
inhibits Bcl-xL and initiates the intrinsic apoptotic pathway. Two levels of PS exposure were 
detected in platelets in response to ABT-737. While high PS exposure is mediated by the 
Ca2+-dependent TMEM16F, medium PS exposure is likely to be mediated by an unknown 
caspase-dependent scramblase. PMPs are released from platelets with high PS exposure, but 
absent from platelets with medium PS exposure. Contrary to that triggered by A23187, PMP 
release triggered by ABT-737 is dependent on caspases and largely independent of calpain. 
 
Apoptotic platelets would progress to secondary necrosis if they are not cleared, including 
under in vitro conditions due to lack of scavenger cells. Mediated by caspases and partially 
calpain, secondary necrosis in platelets shows loss of plasma integrity and high PS exposure. 
This has important implications for in vitro studies, because some of the signalling events 
that were associated with apoptosis may rather reflect secondary necrosis. 
 
Two pathways of PMP release are linked with each other, one being stimulation-related and 
the other cell death-related. It was found that ABT-737-triggered activation of caspases 
downregulated calpain-dependent PMP release in response to A23187 and an acute rise in 
[Ca2+]i. However, when apoptosis was triggered yet caspases were inhibited, platelets 
released more PMPs in response to A23187. Therefore, during the early apoptotic phase, 
caspases may protect platelets from potential immunogenic effects of pro-thrombotic stimuli 
by down-regulating the capacity for rapid PMP release. 
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7.4. 2-aminoethoxydiphenyl borate as an inhibitor of microparticle release 
2-APB, a cell-permeable modulator of numerous ion channels, was found to inhibit A23187- 
triggered PMP release. DPBA and DP3A, two structurally-related compounds, also inhibit 
A23187-triggered PMP release with similar potency to 2-APB. 
 
It is not clear how 2-APB and its analogues lead to inhibition of A23187-triggered PMP 
release. A few hypotheses were tested and ruled out. These include Ca2+ entry into cytosol, 
ion channels or transporters on the plasma membrane, and calpain activity. The inhibitory 
effects of 2-APB might be attributed to an unidentified intracellular target. 
 
2-APB was also found to inhibit ABT-737-triggered PMP release. Rather than PS exposure 
and secondary necrosis, Ca2+ entry into platelets was inhibited by 2-APB during ABT-737- 
triggered apoptosis. NCX, SOCE and NCCE were ruled out as the route for Ca2+ entry. Results 
from inhibiting gap junctions, with drugs of varying specificities, were difficult to interpret. 
 
Therefore, 2-APB’s inhibitory effect on ABT-737-triggered PMP release might be linked to 
reduced Ca2+ entry via an unknown route, or to the same intracellular target underlying 
A23187-triggered PMP release. Future studies in identifying the target of 2-APB, followed by 
in silico docking of 2-APB and its analogues, might provide new insights into how 
microparticles are released from both activated and apoptotic platelets. 
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7.5. Future direction: other pro-death stimuli that trigger microparticle release  
In section 5.9, it was found that PMP release could be triggered by a few pro-death drugs in 
addition to ABT-737, including ABT-263, AT-101, HA14-1 and sabutoclax. AT-101, HA14-1 
and sabutoclax triggered PMP release largely independently of caspases, as PMP release and 
PS exposure in response to these drugs were not abolished in the presence of Q-VD-OPh 
(Figure 5.8C-D). Also, loss of plasma membrane integrity in response to these drugs was 
highly variable depending on specific donors (Figure 5.8F). These data suggest that AT-101, 
HA14-1 and sabutoclax might trigger PMP release via a third pathway, independent of 
calpain (e.g. in response to A23187 or thrombin plus CRP-XL) or caspases (e.g. in response to 
ABT-737 or ABT-263). 
 
Experiments can be performed in the future to characterise this unidentified pathway 
leading to PMP release. A few hypotheses for the intracellular targets of AT-101, HA14-1 and 
sabutoclax include Ca2+-dependent protease family cathepsin, mitochondria permeability 
transition pore (MPTP) and Rho-associated protein kinase (ROCK). Since the effects of these 
drugs were all dependent on extracellular Ca2+, the routes for Ca2+ entry into platelets in 
response to AT-101, HA14-1 and sabutoclax are also worth further investigations. 
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7.6. Limitations of studies in this thesis 
PMP detection in this thesis relied primarily on flow cytometry, but flow cytometry is limited 
by its resolution in detecting small vesicles. For example, PMPs with diameters below 488nm 
could not be detected. Although some results were confirmed by the use of transmission 
electron microscopy, a more objective and efficient method could be used to detect PMPs in 
parallel to flow cytometry. This include nanoparticle tracking analysis, which has been used 
for counting microparticles derived from platelets, endothelial cells and macrophages 
(Aatonen et al., 2014; Abbasian et al., 2015; Marchini et al., 2016). 
 
Platelet functions were mostly studied by flow cytometry, Western blotting and microplate 
assays. These include PS exposure, PMP release, cell viability, [Ca2+]i assay, pH measurement 
and protein expression. Some experiments in this thesis focused on the platelet membrane 
(e.g. lipid rafts, membrane leakage). It would be interesting to visualise these results by 
scanning electron microscopy, which has been used on platelets before (Schoenwaelder et 
al., 2011; Vasina et al., 2011). These include the topology of membranes from pro-coagulant, 
apoptotic and secondary necrotic platelets treated with various inhibitors such as 2-APB. 
 
Studies in this thesis relied heavily on pharmacology. Platelets were applied with specific 
activators, inhibitors or disruptors. If conditions allowed, some of the studies could be 
performed with platelets from knockout or knockdown mice. Some existing and viable 
targets for gene modification that might be useful include TMEM16F (Mattheij et al., 2016), 
Bcl-xL (Kodama et al., 2011), Cx37 and Cx40 (Vaiyapuri et al., 2012, 2013). 
 
Finally, the scope of this thesis is limited to platelets. Some experiments could be extended 
to other cardiovascular cells. For example, 2-APB and its structural analogues can be applied 
to endothelial cells, testing if the release of endothelial cell-derived microparticles is 
inhibited in response to A23187 or ABT-737. These results could help reveal commonalities 
and differences in pathways of microparticle release from different cells, which in turn might 
bring insights into the mechanisms of PMP release. 
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7.7. Concluding remarks 
Taken together, this thesis has made some contributions in understanding the mechanisms 
of microparticle release from human platelets.  
 
It was found that cholesterol-rich lipid rafts are required for the calpain-dependent release 
of microparticles from platelets in response to pro-coagulant stimuli. Membrane blebbing in 
this process is not mediated by local influx of Na+. Membrane scission in this process is not 
mediated by the endosomal sorting complex required for transport. It was also found that 
microparticles are released from platelets in response to pro-apoptotic triggers, which is 
dependent on caspases but largely independent of calpain. Microparticle release from 
apoptotic platelets is associated with high levels of phosphatidylserine exposure and 
secondary necrosis. Caspase activity during platelet apoptosis downregulates the 
calpain-dependent microparticle release in response to pro-coagulant stimuli. 
2-Aminoethoxydiphenyl borate (2-APB) was found to inhibit microparticle release from 
platelets under both stimulatory and apoptotic conditions. The effects of 2-APB have been 
characterised, although the intracellular target of 2-APB remains unknown. 
 
There are a few avenues for future studies into the subject. These include identifying novel 
regulators of microparticle release from platelets, using nanoparticle tracking analysis and 
platelets from knockout mice in parallel with flow cytometry and pharmacology, and 
extending these experiments to other cells in the cardiovascular system. 
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